

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number  
**WO 02/31134 A2**

- (51) International Patent Classification<sup>7</sup>: C12N 9/64
- (21) International Application Number: PCT/US01/31874
- (22) International Filing Date: 12 October 2001 (12.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/240,117 12 October 2000 (12.10.2000) US
- (71) Applicant (*for all designated States except US*): **FERRING BV** [US/US]; Polaris Avenue 144, NL-2132 JX Hoofddorp (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **QI, Steve** [GB/US]; 11034 West Ocean Air Drive, Apt. 24B, San Diego, CA 92130 (US). **AKINSANYA, Karen, O.** [GB/US]; 7675 Palmilla Drive, Apt. 642B, San Diego, CA 92122-5094 (US). **RIVIERE, Pierre, J.-M.** [FR/US]; 3993 Via Can-grejo, San Diego, CA 92130 (US). **JUNIEN, Jean-Louis** [FR/FR]; Ferring SAS, F-75507 Paris (FR).
- (74) Agents: **SAMPLES, Kenneth, H.** et al.; Fitch, Even, Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

BEST AVAILABLE COPY

WO 02/31134 A2

(54) Title: NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

(57) Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.

## Novel Serine Protease Genes Related to DPPIV

### Field of the Invention

The present invention relates to novel serine proteases related to dipeptidyl peptidase IV (DPPIV), and to isolated nucleic acids coding for these proteases, all of which are useful for the discovery of new therapeutic agents, for measuring protease activity, and for determining the inhibitory activity of compounds against these proteases.

### Background of the Invention

Proteases and peptidases are enzymes that catalyse the hydrolysis of peptidic amide bonds. Proteases play an important role in the regulation of biological processes in almost every life-form from bacteria to virus to mammals. They perform critical functions in, for example, digestion, blood clotting, apoptosis, activation of immune responses, zymogen activation, viral maturation, protein secretion and protein trafficking. They can be classified according to a number of criteria, such as site of action, substrate preference, and mechanism. So, for example, aminopeptidases act preferentially at the N-terminal residues of a peptide, while carboxypeptidases act preferentially at the C-terminus and endopeptidases act at sites removed from the two termini. Among the carboxy- and aminopeptidases, peptidyl peptidases cleave a single amino acid residue from the substrate, dipeptidyl peptidases cleave a dipeptide unit (two amino acids) from the substrate, and tripeptidases cleave three amino acids from the substrate. Substrate preference is frequently expressed in terms of the amino acid residue immediately N-terminal to the cleavage site. For example, trypsin-like peptidases will preferentially cleave a peptide next to a basic amino acid (arginine or lysine), i.e. where the bond hydrolysed is the Arg/Lys-Xaa bond. As another example, the chymotrypsin-like family of peptidases preferentially hydrolyse peptides adjacent to an aromatic residue. Mechanistically, peptidases are classified as being serine-dependent, cysteine-dependent, aspartic acid-dependent or zinc-dependent.

Because peptidases and proteases are involved in the regulation of many physiological processes, they are attractive targets for the development of therapeutic agents. Protease and peptidase inhibitors are, for example, used in the treatment of hypertension, coagulation disorders, and viral infection.

Proteolytic enzymes that exploit serine in their catalytic activity are ubiquitous, being found in viruses, bacteria and eukaryotes. Over 20 families (denoted S1 - S27) of serine protease have been identified; these are grouped into 6 clans (SA, SB, SC, SE, SF

and SG) on the basis of structural similarity and other functional evidence. Structures are known for four of the clans (SA, SB, SC and SE); these appear to be totally unrelated, suggesting at least four evolutionary origins of serine peptidases and possibly many more, Rawlings and Barrett, Meth. Enzymol. 244: 19-61 (1994).

- 5       The prolyl oligopeptidase family consists of a number of evolutionarily related peptidases whose catalytic activity seems to be provided by a charge relay system similar to that of the trypsin family of serine proteases, but which evolved by independent convergent evolution. A conserved serine residue has been shown experimentally (in *E. coli* protease II as well as in pig and bacterial PE) to be necessary for the catalytic  
10 mechanism. This serine, which is part of the catalytic triad (Ser, His, Asp), is generally located about 150 residues away from the C-terminal extremity of these enzymes (which are all proteins that contains about 700 to 800 amino acids).

- One of the most intensively studied prolyl oligopeptidases is dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5), a type II glycoprotein, which is the only well characterised  
15 dipeptidyl aminopeptidase known to be located on the outer side of plasma membranes. As indicated above, dipeptidyl aminopeptidases are characterised by their ability to cleave N-terminal dipeptides from a variety of small peptides. Dipeptidyl aminopeptidases show different substrate specificities and cellular localisation, suggesting different functions of each activity in peptide processing. DPPIV is characterised by its capacity to cleave N-  
20 terminal dipeptides containing proline or alanine as the penultimate residue. The DPPIV gene spans approximately 70 kb and contains 26 exons, ranging in size from 45 bp to 1.4 kb. The nucleotide sequence (3,465 bp) of the cDNA contains an open reading frame encoding a polypeptide comprising 766 amino acids. The nucleotides that encode the active site sequence (G-W-S-Y-G) are split between 2 exons. This clearly distinguishes  
25 the genomic organisation of the prolyl oligopeptidase family from that of the classic serine protease family.

- DPPIV is widely distributed in mammalian tissues and is found in great abundance in the kidney, intestinal epithelium and placenta (Yaron, A. and Naider, F., Critical Reviews in Biochem. Mol. Biol. 1993 [1], 31). In the human immune system,  
30 the enzyme is expressed almost exclusively by activated T-lymphocytes of the CD4<sup>+</sup> type where the enzyme has been shown to be synonymous with the cell-surface antigen CD26. Although the exact role of DP-IV in human physiology is still not completely understood, recent research has shown that the enzyme clearly has a major role in human physiology and pathophysiology.

On human T cells, DPPIV expression appears late in thymic differentiation and is preferentially restricted to the CD4<sup>+</sup> helper/memory population, and CD26 can deliver a potent co-stimulatory T-cell activation signal. DPPIV, also known as T-cell activation antigen CD26, therefore plays an important role in the immune response via association with CD45 tyrosine phosphatase and, through its ability to bind adenosine deaminase (ADA) to the T-cell surface, protects the T-cell from adenosine-mediated inhibition of proliferation. Furthermore, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains. DPPIV has been associated with numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells, Pethiyagoda et al., Clin. Exp. Metastasis 2000;18(5):391-400. DPPIV is also implicated in the endocrine regulation and metabolic physiology. More particularly, DPPIV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Glucagon-like peptide-1 (GLP-1), an incretin that induces glucose-dependent insulin secretion, is rapidly degraded by DPPIV, and since the half-life for DPPIV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10- fold) is anticipated from DPP-IV inhibition. Inhibitors of DPPIV are currently being studied in the clinic as potential therapeutic agents for type 2 diabetes and impaired glucose tolerance.

Various different inhibitors of DPPIV were known in 1993. One of these is a suicide inhibitor N-Ala-Pro-O-(nitrobenzoyl-) hydroxylamine. Another is a competitive inhibitor: e-(4-nitro) benzoxycarbonyl-Lys-Pro, and another is a polyclonal rabbit anti-porcine kidney DPPIV immunoglobulin. Others have since been developed and are described in detail in U.S. Patents Nos. 5,939,560, 6,110,949m 6,011,155 and 5,462,928.

In addition to, but independent of, its serine type catalytic activity, DPPIV binds closely to the soluble extracellular enzyme adenosine deaminase (ADA), acting as a receptor and is thought to mediate signal transduction. DPPIV structure is characterized by two extracellular domains, an  $\alpha/\beta$  fold hydrolase domain and a 7-blade beta-propeller domain consisting of repeated beta sheets of about 50 amino acids. Recently it has been shown that, besides selecting substrates by size, the beta-propeller domain, containing 10 of the 12 highly conserved cysteine residues, contributes to catalysis of the peptidase domain. In addition, the cysteine-rich domain is responsible for DPPIV-binding to collagen I and to extracellular ADA. DPPIV is also reported to play a role in fibronectin-



mediated interactions of cells with extracellular matrix. Recent studies show that the protease activity of DPPIV is not required for its anti-invasive activity because mutants of DPPIV that lack the extracellular serine protease activity maintain such activity.

A number of proteins that share similarities with DPPIV have been reported in the literature. Several of these proteins have been cloned including DPP-I, DPP-II, DPP-III, DPP-X and fibroblast activation protein (FAP). These have been identified and characterised either by molecular cloning and functional studies of expressed proteins or as biochemical activities in tissue extracts. DPPIV-beta and other novel peptidases with functional similarities to DPPIV are not yet cloned. The identification, characterization and/or appropriate classification of further members of the family of prolyl oligopeptidases, the elucidation of their physiological (and particularly pathophysiological) role, and the application of that knowledge to the development of new therapeutic agents are significant challenges.

#### **Summary of the Invention**

The present invention provides proteins with prolyl oligopeptidase (post-proline cleaving) activities that constitute three novel members of a family of proteins related to DPPIV, including the full-length proteins, alternative splice forms, subunits, and mutants, as well as nucleotide sequences encoding the same. The present invention also provides methods of screening for substrates, interacting proteins, agonists, antagonists or inhibitors of the above proteins, and furthermore to pharmaceutical compositions comprising the proteins and/or mutants, derivatives and/or analogues thereof and/or ligands thereto.

These novel proteins having significant sequence homology to DPPIV are termed dipeptidyl peptidase IV-related protein-1, 2 & 3 (DPRP-1, DPRP-2 and DPRP-3). The amino acid sequences of DPRP-1, DPRP-2 and DPRP-3 are given in SEQ. ID NOS:1, 3 and 5 respectively. Further disclosed are nucleic acid sequences coding for these proteins (SEQ. ID NOS:2, 4 and 6). Table 1 illustrates the homology (i.e. similarity) between the novel proteins DPRP-1, DPRP-2 and DPRP-3 and other known serine proteases.

**Table 1 – Comparison of the sequences of these three novel proteins with DPPIV and other Clan SC, Family S9 members and Subfamily B members**

	Protease Family	Protease name	No. of a.a.	Homology with DPPIV	TM region	Ser-Asp-His Triad	Gene location	Optimal pH
5	Clan CA, Family C1	DPPI	463	N	N	N	11q14.1-q14.3	-
	Clan SC, Family S28	DPPII	500	N	Y	N	-	4.5-6.0
		QPP	492	N	N	N	-	4.5-7.5
		PCP	496	N	N	N	-	-
	Unassigned	DPPIII	737	N	N	N	-	-
	10 Clan SC, Family S9, Subfamily B	DPPIV	766	100	Y	Y	2q24.3	7.5-8.0
		DPPVI	865	52	Y	Mutation	7	-
		FAP	760	70	Y	Y	2q23	7.5-8.0
		DPRP-1	882	41	N	Y	15q22.1-15q22.2	7.5-8.0
		DPRP-2	864	39	N	Y	19p13.3	7.5-8.0
		DPRP-3	796	54	Y	Mutation	2q12.3-2q14.1	-

The greatest homology between DPRP-1, DPRP-2 and DPPIV is seen in the C-terminal sequences. On the basis of sequence homology with DPPIV (see Figure 1), one might predict that these DPRP proteins would have functions that include, but are not limited to, roles as enzymes. Cloning, expression, biochemical and molecular characterization have confirmed this hypothesis.

The expression pattern of DPRPs and the localization to specialized epithelial cells and plasma cells (Leydig cells, prostate epithelial cells, lymphocytes, B cells) is consistent with a role in differentiation, proliferation and inflammation. The localization of the DPRP-1 gene in hormone sensitive cancers (breast, prostate, testicular), tissues regulated by testosterone and the abundant expression in poorly differentiated cancers, demonstrate that DPRP-activating or inhibiting molecules will have numerous therapeutic applications in the treatment of disorders characterized by dysregulated growth, differentiation and steroid or polypeptide hormone synthesis and degradation. Data disclosed herein supports the hypothesis that DPRP-1 and DPRP-2 are involved in the regulation of proliferation of *in vitro* models of prostate and testis cancer well known to those skilled in the art.

DPRP-1 and DPRP-2 activities described herein and their expression patterns are compatible with their having functional roles as physiological regulators of the immune and neuroendocrine systems through the enzymatic modification of biochemical mediators like peptides and chemokines. The numerous functions previously described

for DPPIV based upon the use of inhibitors may be due in part to its action and that of similar proteins, like the DPRPs. Therefore, the discovery of selective and potent inhibitors of DPPIV, of the DPRPs and of other related proteases like FAP is considered central to achieving effective and safe pharmaceutical use of these and any newly  
5 identified serine protease inhibitors, as well as other active compounds that modify the function(s) of such proteins.

The invention thus provides novel proteins or polypeptides, the nucleic acids coding therefor, cells which have been modified with the nucleic acid so as to express these proteins, antibodies to these proteins, a screening method for the discovery of new  
10 therapeutic agents which are inhibitors of the activity of these proteins (or which are inhibitors of DPPIV and not of the proteins), and therapeutic agents discovered by such screening methods. The novel proteins and the nucleic acids coding therefor can be used to discover new therapeutic agents for the treatment of certain diseases, such as for example, reproductive, inflammatory and metabolic disorders and also in the preparation  
15 of antibodies with therapeutic or diagnostic value.

In accordance with one aspect of the present invention, there are provided novel, mature, biologically active proteins, principally of human origin. Such proteins may be isolated in small quantities from suitable animal (including human) tissue or biological fluids by standard techniques; however, larger quantities are more conveniently prepared  
20 in cultures of cells genetically modified so as to express the protein.

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding polypeptides of the present invention including mRNAs, DNAs, cDNAs, genomic DNAs thereof.

In accordance with a further aspect of the present invention, nucleic acid probes  
25 are also provided comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.

In accordance with a still further aspect of the present invention, processes utilizing recombinant techniques are provided for producing such polypeptides useful for *in vitro* scientific research, for example, synthesis of DNA and manufacture of DNA  
30 vectors. Processes for producing such polypeptides include culturing recombinant prokaryotic and/or eukaryotic host cells that have been transfected with DNA vectors containing a nucleic acid sequence encoding such a polypeptide and/or the mature protein under conditions promoting expression of such protein and subsequent recovery of such protein or a fragment of the expressed product.

In accordance with still another aspect, the invention provides methods for using DPRP polypeptides and polynucleotides, including the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2, pain, diabetes, precocious puberty, infertility, obesity, anorexia, bulimia, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, asthma, allergies, benign prostatic hypertrophy, cancers including hormone-sensitive and androgen-independent cancers, migraines, vomiting, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, dementia, and severe mental retardation, and dyskinesias, hereinafter collectively referred to as "the Diseases".

In accordance with yet another aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for the discovery of compounds that inhibit the biological activity of the mature proteins thereof, e.g. by cleaving an N-terminal dipeptide, and such inhibitors are thus also provided.

In accordance with a more specific aspect, the invention provides isolated nucleic acid which encodes (a) a polypeptide which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function, or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6, or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b), or which is complementary to any one of the foregoing.

In accordance with another specific aspect, the invention provides a polypeptide which may be optionally glycosylated, and which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

In accordance with still another specific aspect, the invention provides a method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of the invention, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of a test

compound, and selecting the test compound or compounds that reduce the enzymatic activity, and it also provides a method for screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one mature protein and a suitable substrate in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

These and other aspects of the present invention should be apparent to those skilled in the art from the detailed description which follows.

#### **Brief Description of the Drawings**

FIGS. 1A and 1B show the co-linear alignment of DPRP-1, DPRP-2, DPRP-3 and DPPIV, with shading being supplied to indicate the same (black) or similar (gray) amino acid residues at a particular location.

FIG. 2 is similar to FIG. 1 and shows co-linear alignment of human and mouse DPRP-2.

FIG. 3 is a graph which shows the effects of various tetrapeptide amide inhibitors on dipeptidyl peptidase enzyme activity.

FIGS. 4A-4C show the effects of three inhibitor compounds on the proliferation of PC3 prostate cancer cell lines at various doses.

#### **Detailed Description of the Preferred Embodiments**

In accordance with an aspect of the present invention, there are provided isolated nucleic acid sequences (polynucleotides), which encode the mature polypeptides having the deduced amino acid sequences of the three DPRP's (SEQ ID NOS:1, 3 and 5).

The polynucleotides of this invention were discovered using a human testis cDNA library (DPRP-1), a human colon library (DPRP-2) and a human hypothalamus cDNA library (DPRP-3). Isolated nucleic acid for DPRP-1 contains an open reading frame encoding a protein of approximately 882 amino acids in length which is structurally related to human DPPIV, showing 26% identity, and 41% similarity over the entire human DPPIV protein sequence. Isolated nucleic acid for DPRP-2 contains an open reading frame encoding for a protein of approximately 864 amino acids, which is 39% similar to the entire DPPIV amino acid sequence. Analysis of DPRP-1 and DPRP-2 primary amino acid sequence using hydrophobicity plots predicts that these two proteins do not have a transmembrane domain. Despite this fact, it is possible that these intracellular serine proteases are secreted upon cellular activation. Quiescent cell proline

dipeptidase (QPP) is a serine protease that is targeted to intracellular vesicles that are distinct from lysosomes (Chiravuri M, et al., J. Immunol. 2000 Nov 15;165(10):5695-702 ). This hypothesis expands the potential site(s) and scope of DPRP-1 and DPRP-2 involvement in mechanisms for post-translational regulation of chemokines, cytokines, peptides and polypeptides. The full length DPRP-3 sequence contains 796 amino acids, a signal peptide from 1 to 48, and a transmembrane domain between 34 and 56. The mature protein is predicted to be a type II membrane protein and may be cleaved to produce a soluble form. The amino acid sequence is set forth in SEQ ID NO:5 , which was deduced from SEQ ID NO:6 and has 54% similarity with DPPIV.

Amino acid sequence alignments of these polypeptides with members of the prolyloligopeptidase enzyme subfamily S9B show that all three DPRP proteins have overall sequence and structural homology to DPPIV and FAP. DPRPs are predicted to be a members of the enzyme Clan SC (Serine nucleophile) with catalytic residues in the order Ser, Asp, His and the active site sequence (G-W-S-Y-G).

**Table 2.** Homology (i.e. similarity) between DPRP-1, DPRP-2, DPRP-3 and members of the prolyl oligopeptidase family S9B enzymes.

DPPIV					
41	DPRP-1				
39	74	DPRP-2			
54	39	40	DPRP-3		
70	41	39	52	FAP	
52	40	42	68	54	DPPVI

DPRP-1, DPRP-2 and DPRP-3 do not exhibit sequence similarity with any members of the classical serine protease families, chymotrypsin and subtilisin. The order of the catalytic triad residues is different in the three main related SC clan families: His-Asp-Ser in chymotrypsin, Asp-His-Ser in subtilisin and Ser-Asp-His in the prolyl oligopeptidases.

As shown in Table 2, DPRP-3 has the highest homology with DPPVI (68% homology and 51% identity). Wada et al isolated cDNA clones for DPPVI, a DPPIV-related protein, from bovine, rat (Wada et al., *Proc. Nat. Acad. Sci.* 89: 197-201. (1992)) and human (Yokotani et al., *Hum. Molec. Genet.* 2:1037-1039 (1993)) brain libraries. They demonstrated that, unlike DPPIV, the catalytic triad in DPPVI does not have the first serine residue. In DPRP-3 two of the amino acids in the catalytic triad

characteristic of the serine protease family are conserved. However, the serine residue itself is replaced by glycine. While the absence of the serine residue is likely to prevent protease activity at this site, it is possible that multiple other functions mediated by other functional domains of the protein remain intact.

5 As briefly described above, DPPIV is a multifunctional molecule that exerts important functions depending on the expressed cells and tissues, in addition to its catalytic activity as a peptidase. DPRP-3 and DPPVI are also likely to maintain multiple functions despite the absence of an intact catalytic triad. For example, DPPVI has been implicated in the regulation of neuronal plasticity. DPPVI is highly expressed in the  
10 hippocampus, thalamus, hypothalamus and striatum. In addition, developmental arrest and embryonic lethality of *rump white* *Rw/Rw* embryos is thought to be due to disruption of the DPPIV gene. *Rw* mutation is associated with a chromosomal inversion spanning 30 cM of the proximal portion of mouse chromosome 5. Genomic analysis of the DPPVI gene on the *Rw* chromosome places the inversion breakpoint in the coding region  
15 resulting in loss of a significant fraction of the C-terminal region, Hough R.B. et al., Proc. Nat. Acad. Sci., 95, 13800-13805 (1998).

The human DPRP-1 gene, predicted to be 32668bp in length, has at least 22 exons and eight transcripts. It maps to chromosome 15 (NT\_010265) at position 15q21.1 – 15q22.1. The lengths of predicted alternative splice variant transcripts vary  
20 between 602bp and 4523bp (see SEQ ID NOS: 7-22). This is in agreement with the multiple transcripts observed by Northern blot analysis (See Example 2). ESTs representing the transcripts were found in numerous tissues including senescent fibroblasts, T-lymphocytes, germinal center B-cells, germ cell seminoma, testis, melanocytes, uterus, ovary breast, multiple sclerosis lesions, pancreas and placenta.

25 Human DPRP-2 belongs to a gene with at least 27 exons and nine splice variants (see SEQ ID NOS:23-40). One SNP was observed in the 3' UTR. (88% (37) C vs. 12% (5) T). The DPRP-2 gene maps to region 19p13.3 of chromosome 19. This location is host to a number of disease markers and is associated with various disorders including hypocalciuric hypercalcemia, type II cerebellar ataxia, muscular dystrophy, convulsions,  
30 susceptibility to atherosclerosis, psoriasis, ectodermal dysplasia, and acute myeloid leukemia. In agreement with the ubiquitous distribution of the mRNA observed by Northern blot analysis (see Example 2), DPRP-2 was expressed in a wide variety of tissues upon examination of EST's coverage (e.g. over 64 EST's expressed in liver, spleen, muscle, melanocytes, heart, lung, placenta, skin, pancreas, stomach, brain  
35 parathyroid gland).

Human DPRP-3 belongs to a gene with at least 23 exons and two splice variants (see SEQ ID NOS:41-44). The gene maps to chromosome 2 (NT\_005445) at position 2q12.3-2q14.1. Transcripts for DPRP-3 did not show as wide a distribution as DPRP-1 and DPRP-2. As shown by Northern blot in Example 2, DPRP-3 expression is restricted to brain and pancreas. ESTs representing the DPRP-3 mRNA were abundant in tissue derived from multiple sclerosis lesions, hypothalamus, whole brain and nerves, with a few transcripts being found in uterus and colon.

The relationships among human and rodent proteases in clan SC, including DPRP-1 DPRP-2 and DPRP-3, were analyzed using Neighbor Joining method (NJ), see Saitou and Nei, Mol. Biol. Evol., 4, 406-525 (1987). Phylogenetic analysis shows that among the S9 proteases, DPRP-1 and DPRP-2, both lacking a transmembrane domain, are distinguished from DPPIV and its closely related proteins like FAP. Similarity is shown however between DPPIV and FAP and between DPRP-3 and DPPVI, which are all type II membrane proteins.

A database search for additional DPRP-related genes revealed the presence of a murine sequence related to DPRP-1. Alignment of this mouse sequence with the novel human proteases shows that the mDPRP-1 displays considerable homology with its human counterpart (FIG. 2). One skilled in the art will readily recognize that the novel mouse protease gene can be isolated using the sequence information disclosed herein and can be readily incorporated into one of the routinely used expression constructs which are well known in the art. Use of this disclosed sequence by those skilled in the art to generate a transgenic mouse model will employ development of gene-targeting vectors, for example, that result in homologous recombination in mouse embryonic stem cells. The use of knockout mice in further analysis of the function of DPRP genes is a valuable tool.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA; DNA should be understood to include cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded and, if single-stranded, may be the coding strand or non-coding (antisense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in SEQ ID NOS:2, 4 and 6 respectively, or it may be a different coding sequence encoding the same mature polypeptide, as a result of the redundancy or degeneracy of the genetic code or a single nucleotide polymorphism. For example, it may also be an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.



The polynucleotides which encode the mature proteins of SEQ ID NOS:1, 3, 5, respectively, may include but are not limited to the coding sequence for the mature protein alone; the coding sequence for the mature polypeptide plus additional coding sequence, such as a leader or secretory sequence or a proprotein sequence; and the  
5 coding sequence for the mature protein (and optionally additional coding sequence) plus non-coding sequence, such as introns or a non-coding sequence 5' and/or 3' of the coding sequence for the mature protein.

Thus, the term "polynucleotide encoding a polypeptide" or the term "nucleic acid encoding a polypeptide" should be understood to encompass a polynucleotide or nucleic  
10 acid which includes only coding sequence for the mature protein as well as one which includes additional coding and/or non-coding sequence. The terms polynucleotides and nucleic acid are used interchangeably.

The present invention also includes polynucleotides where the coding sequence for the mature protein may be fused in the same reading frame to a polynucleotide  
15 sequence which aids in expression and secretion of a polypeptide from a host cell; for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell may be so fused. The polypeptide having such a leader sequence is termed a preprotein or a proprotein and may have the leader sequence cleaved, by the host cell to form the mature form of the protein. These  
20 polynucleotides may have a 5' extended region so that it encodes a proprotein, which is the mature protein plus additional amino acid residues at the N-terminus. The expression product having such a prosequence is termed a proprotein, which is an inactive form of the mature protein; however, once the prosequence is cleaved an active mature protein remains. Thus, for example, the polynucleotides of the present invention  
25 may encode mature proteins, or proteins having a prosequence, or proteins having both a prosequence and a presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention. The marker sequence may be a polyhistidine tag, a hemagglutinin  
30 (HA) tag, a c-myc tag or a V5 tag when a mammalian host, e.g. COS-1 cells, is used. The HA tag would correspond to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., *Cell*, 37:767 (1984)), and the c-myc tag may be an epitope from human Myc protein (Evans, G.I. et al., *Mol. Cell. Biol.* 5: 3610-3616 (1985)).

The term "gene" means the segment of DNA involved in producing a polypeptide  
35 chain; it includes regions preceding and following the coding region (leader and trailer)

as well as intervening sequences (introns) between individual coding segments (exons). The term "significant sequence homology" is intended to denote that at least 25%, preferably at least 40%, of the amino acid residues are conserved, and that, of the non-conserved residues, at least 40% are conservative substitutions.

5           Fragments of the full-length genes of the present invention may be used as a hybridization probe for a cDNA library to isolate full-length cDNA as well as to isolate other cDNAs which have significant sequence homology to the gene and will encode proteins or polypeptides having similar biological activity or function. By similar biological activity or function, for purposes of this application, is meant the ability to  
10   cleave an N-terminal dipeptide having Ala or Pro as the penultimate residue or other amino acids. Such a probe of this type has at least 14 bases (at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 or 6), preferably at least 30 bases, and such may contain, for example, 50 or more bases. Such probe may also be used to identify a cDNA clone corresponding to a full-length transcript and/or a genomic clone or clones  
15   that contains the complete gene, including regulatory and promoter regions, exons, and introns. Labelled oligonucleotides having a sequence complementary to that of the gene of the present invention are useful to screen a library of human cDNA, genomic DNA or mRNA to locate members of the library to which the probe hybridizes. As an example, a known DNA sequence may be used to synthesize an oligonucleotide probe which is then  
20   used in screening a library to isolate the coding region of a gene of interest.

          The present invention is considered to further provide polynucleotides which hybridize to the hereinabove-described sequences wherein there is at least 70%, preferably at least 90%, and more preferably at least 95% identity or similarity between the sequences, and thus encode proteins having similar biological activity. Moreover, as  
25   known in the art, there is "similarity" between two polypeptides when the amino acid sequences contain the same or conserved amino acid substitutes for each individual residue in the sequence. Identity and similarity may be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue,  
30   Madison, WI 53705). The present invention particularly provides such polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means conditions which permit hybridization between polynucleotides sequences and the polynucleotide sequences of SEQ ID NOS:2, 4 and 6 where there is at least about 70% identity.  
35   Suitably stringent conditions can be defined by, e.g., the concentrations of salt or

formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, by increasing the concentration of formamide, and/or by raising the hybridization temperature.

5 For example, hybridization under high stringency conditions may employ about 50% formamide at about 37°C to 42°C, whereas hybridization under reduced stringency conditions might employ about 35% to 25% formamide at about 30°C to 35°C. One particular set of conditions for hybridization under high stringency conditions employs 42°C, 50% formamide, 5x. SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured  
10 salmon sperm DNA. For hybridization under reduced stringency, similar conditions as described above may be used in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions  
15 are well known in the art. Preferably, hybridization should occur only if there is at least 95%, and more preferably at least 97%, identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which exhibit substantially the same biological function or activity as the mature protein encoded by one of the cDNAs of  
20 SEQ ID NOS:2, 4 and 6.

As mentioned, a suitable polynucleotide probe may have at least 14 bases, preferably 30 bases, and more preferably at least 50 bases, and will hybridize to a polynucleotide of the present invention which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides  
25 may be employed as a probe for hybridizing to the polynucleotides of SEQ ID NOS:2, 4 and 6 respectively, for example, for recovery of such a polynucleotide, or as a diagnostic probe, or as a PCR primer. Thus, the present invention includes polynucleotides having at least a 70% identity, preferably at least a 90% identity, and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptides of SEQ ID NOS:1, 3  
30 and 5 respectively, as well as fragments thereof, which fragments preferably have at least 30 bases and more preferably at least 50 bases, and to polypeptides encoded by such polynucleotides.

As is well known in the art, the genetic code is redundant in that certain amino acids are coded for by more than one nucleotide triplet (codon), and the invention  
35 includes those polynucleotide sequences which encode the same amino acids using a

different codon from that specifically exemplified in the sequences herein. Such a polynucleotide sequence is referred to herein as an "equivalent" polynucleotide sequence. The present invention further includes variants of the hereinabove described polynucleotides which encode for fragments, such as part or all of the mature protein, analogs and derivatives of one of the polypeptides having the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5 respectively. The variant forms of the polynucleotides may be a naturally occurring allelic variant of the polynucleotides or a non-naturally occurring variant of the polynucleotides. For example, the variant in the nucleic acid may simply be a difference in codon sequence for the amino acid resulting from the degeneracy of the genetic code, or there may be deletion variants, substitution variants and addition or insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides that does not substantially alter the biological function of the encoded polypeptide.

The present invention further includes polypeptides which have the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5, as well as fragments, analogs and derivatives of such polypeptides. The terms "fragment," "derivative" and "analog", when referring to the polypeptides of SEQ ID NOS:1, 3 and 5, means polypeptides that retain essentially the same biological function or activity as such polypeptides. An analog might, for example, include a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature protein. The polypeptides of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptide; however, they are preferably recombinant polypeptides, glycosylated or unglycosylated.

The fragment, derivative or analog of a polypeptide of SEQ ID NOS:1, 3 and 5 respectively, may be (i) one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which additional amino acids are fused to the mature protein, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art to provide upon the basis of the teachings herein.

The polypeptides and polynucleotides of the present invention should be in an isolated form, and preferably they are purified to substantial homogeneity or purity. By substantial homogeneity is meant a purity of at least about 85%.

The term "isolated" is used to mean that the material has been removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not considered to be isolated, but the same polynucleotide or polypeptide, when separated from substantially all of the coexisting materials in the natural system, is considered isolated. For DNA, the term includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Further included is recombinant DNA which includes a portion of the nucleotides shown in one of SEQ ID NO:2,4 or 6 which encodes an alternative splice variant of the DPRP. Various alternative splice variants are exemplified in SEQ ID NOS:8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 and 46.

The polypeptides of the present invention include any one of the polypeptide of SEQ ID NOS:1, 3 and 5 (in particular the mature protein), as well as polypeptides which have at least 70% similarity (e.g. preferably at least 60% and more preferably at least 70% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, more preferably at least 90% similarity (e.g. preferably at least 90% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, and most preferably at least 95% similarity (e.g. preferably at least 95% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5. Moreover, they should preferably include exact portions of such polypeptides containing a sequence of at least 30 amino acids, and more preferably at least 50 amino acids.

Fragments or portions of the polypeptides of the present invention may be employed as intermediates for producing the corresponding full-length polypeptides by peptide synthesis. Fragments or portions of the polynucleotides of the present invention may also be used to synthesize full-length polynucleotides of the present invention.

The present invention also includes vectors which include such polynucleotides, host cells which are genetically engineered with such vectors and the production of polypeptides by recombinant techniques using the foregoing. Host cells are genetically

engineered (transduced or transformed or transfected) with such vectors which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those commonly used with the host cell selected for expression, as well known to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotides may be included in any one of a variety of expression vectors for expressing polypeptides. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by any of a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures well known in the art, which procedures are deemed to be within the scope of those skilled in this art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli* lac or trp, the phage lambda P.sub.L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector should also contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin-resistance for eukaryotic cell culture, or such as tetracycline- or ampicillin-resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells, such as

Drosophila S2 and Spodoptera Sf9; animal cells, such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

Synthetic production of nucleic acid sequences is well known in the art as is  
5 apparent from CLONTECH 95/96 Catalogue, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, Calif. 94303. Thus, the present invention also includes expression vectors useful for the production of the proteins of the present invention

The present invention further includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs may comprise a  
10 vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The  
15 following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540 and pRIT5 (Pharmacia); and Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other suitable plasmid or  
20 vector may be used as long as it is replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol acetyl transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P.sub.R, P.sub.L and trp. Eukaryotic  
25 promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

Components of the expression vector may generally include: 1) a neomycin phosphotransferase (G418), or hygromycin B phosphotransferase (hyg) gene as a  
30 selection marker, 2) an E. coli origin of replication, 3) a T7 and SP6 phage promoter sequence, 4) lac operator sequences, 5) the lactose operon repressor gene (lacIq) and 6) a multiple cloning site linker region. Such an origin of replication (oriC) may be derived from pUC19 (LTI, Gaithersburg, Md.).

A nucleotide sequence encoding one of the polypeptides SEQ ID NOS:2,4 and 6  
35 having the appropriate restriction sites is generated, for example, according to the PCR

protocol described in Example 1 hereinafter, using PCR primers having restriction sites for KpnI (as the 5' primer) and NotI or SacI (as the 3' primer) for DPRP-1, or sites for HindIII (as the 5' primer) and NotI or BamHI (as the 3' primer) for DPRP-2. The PCR inserts are gel-purified and digested with compatible restriction enzymes. The insert and  
5 vector are ligated according to standard protocols.

In a further embodiment, the present invention provides host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell  
10 can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

Such constructs in host cells are preferably used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the  
15 polypeptides of the invention can be synthetically produced by conventional peptide synthesizers or by chemical ligation of suitable fragments thus prepared.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of  
20 the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector.  
25 Enhancers include cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin-resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes, such as 3-  
35 phosphoglycerate kinase (PGK), alpha-factor, acid phosphatase, or heat shock proteins,



among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.

10 The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desired, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of

15 choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example,

20 pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis., U.S.A.). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g.,

25 temperature shift or chemical induction), and cells are cultured for an additional period. Cells are typically harvested by centrifugation and then disrupted by physical or chemical means, with the resulting crude extract being retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption and use of

30 cell-lysing agents; such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express a recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell*, 23:175 (1981). Other cell lines capable of expressing a compatible vector include, for example, the C127, 3T3,

35 CHO, HeLa and BHK cell lines. Mammalian expression vectors will generally comprise

an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to  
5 provide required nontranscribed genetic elements.

The polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography  
10 and lectin chromatography. Recovery can be facilitated if the polypeptide is expressed at the surface of the cells, but such is not a prerequisite. Recovery may also be desirable of cleavage products that are cleaved following expression of a longer form of the polypeptide. Protein refolding steps as known in this art can be used, as necessary, to complete configuration of the mature protein. High performance liquid chromatography  
15 (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be purified natural products, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect or mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the  
20 present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

In a preferred embodiment, the proteins of the invention are isolated and purified so as to be substantially free of contamination from other proteins. For example, the proteins of the invention should constitute at least 80% by weight of the total protein  
25 present in a sample, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% by weight of the total protein.

These proteins may be in the form of a solution in water, another suitable solvent, such as dimethyl sulphoxide (DMSO) or ethanol, or a mixture of suitable solvents. Examples of mixtures of solvents include 10% (by weight) ethanol in water and 2% (by  
30 weight) DMSO in water. A solution may further comprise salts, buffering agents, chaotropic agents, detergents, preservatives and the like. Alternatively, the proteins may be in the form of a solid, such as a lyophilised powder or a crystalline solid, which may also comprise a residual solvent, a salt or the like.

As used herein, the term "antibodies" includes polyclonal antibodies,  
35 affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding

fragments, such as F(ab')<sub>2</sub> and Fab' proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans should be reduced.

Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to human prohormone DPRP protein or a peptide therefrom, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled human DPRP protein or peptide). Genes encoding polypeptides having potential human DPRP polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding such polypeptides can be obtained in a number of ways well known in this art.

As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice and rats, with a human DPRP polypeptide or a fragment thereof. The immunogenicity of a human prohormone DPRP polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant, or surface active substances, such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH or dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of DPRP or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid, for immunization. Antibodies to DPRP may also be generated using methods that are well known in the art. Such antibodies may

include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which block or modify interactions at the active sites) are especially preferred for therapeutic use.

5 For the production of antibodies, binding proteins, or peptides which bind specifically to DPRP, libraries of single chain antibodies, Fab fragments, other antibody fragments, non-antibody protein domains, or peptides may be screened. The libraries could be generated using phage display, other recombinant DNA methods, or peptide synthesis (Vaughan, T. J. et al. Nature Biotechnology 14: 309-314 (1996)). Such  
10 libraries would commonly be screened using methods which are well known in the art to identify sequences which demonstrate specific binding to DPRP.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DPRP have an amino acid sequence consisting of at least about 5 amino acids and, more preferably, of at least about 10 amino acids. It is also preferable that  
15 these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DPRP amino acids may also be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to DPRP may be prepared using any well known  
20 technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique, although monoclonal antibodies produced by hybridoma cells may be preferred.

In addition, techniques developed for the production of "chimeric antibodies",  
25 such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used, see Neuberger, M.S. et al. Nature 312: 604-608 (1984). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DPRP-specific single chain antibodies. Antibodies with related  
30 specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (Burton D. R. Proc. Natl. Acad. Sci. 88: 11120-11123 (1991)).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly

specific binding reagents as disclosed in the literature. (Orlandi, R. et al. Proc. Natl. Acad. Sci. 86: 3833-3837 (1989)).

Antibody fragments which contain specific binding sites for DPRP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse, W. D. et al. Science 254: 1275-1281 (1989)).

10 Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DPRP and its specific antibody. A two-site, monoclonal-based  
15 immunoassay utilizing monoclonal antibodies reactive to two non-interfering DPRP epitopes is preferred, but a competitive binding assay may also be employed.

As earlier mentioned, the DPRPs can be used in treatment of the Diseases. Pharmaceutical compositions suitable for use in this aspect of the invention include compositions wherein the active ingredients are contained in an effective amount to  
20 achieve the intended purpose relating to one of the Diseases. The determination of a therapeutically effective dose is well within the capability of those skilled in the art and can be estimated initially either in cell culture assays, e.g. of neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration, which  
25 information is then commonly used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, e.g. a DPRP or fragment thereof, antibodies of DPRP, or an agonist, antagonist or inhibitor of DPRP, which ameliorates particular symptoms or conditions of the Disease. For  
30 example, the amount to be administered may be effective to cleave a desired target substrate upon contact therewith. Therapeutic efficacy and toxicity may likewise be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose  
35 ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the

LD50/ED50 ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the  
5 ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

An exact dosage will normally be determined by the medical practitioner in light of factors related to the subject requiring treatment, with dosage and administration being adjusted to provide a sufficient level of the active moiety or to maintain a desired  
10 effect. Factors to be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or even once every two weeks, depending  
15 on the half-life and clearance rate of the particular formulation.

Yet another aspect of the invention provides polynucleotide molecules having sequences that are antisense to mRNA transcripts of DPRP1, DPRP2 and DPRP-3 polynucleotides. Administration of an antisense polynucleotide molecule can block the production of the protein encoded by DPRP-1, DPRP2 or DPRP-3. The techniques for  
20 preparing antisense polynucleotide molecules and administering such molecules are known in the art. For example, antisense polynucleotide molecules can be encapsulated into liposomes for fusion with cells.

In particular, the expression of DPRP-1, DPRP-2 and DPRP-3 in specialized epithelial cells, immune cells (lymphocytes and B cells), astrocytic tumors, and in  
25 various hormone sensitive cancers provides evidence of a potential role in the pathophysiology of cancer, metaplasia and metastasis. Therefore in a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate DPRP activity or expression levels. Antibodies that specifically bind DPRP may be used for the diagnosis of disorders characterized by expression of DPRP, or in assays to  
30 monitor patients being treated with DPRP or with agonists or antagonists (inhibitors) of DPRP. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for DPRP include methods that utilize the antibody and a label to detect DPRP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and they  
35 may be labeled by covalent or non-covalent joining with a reporter molecule. A wide

variety of reporter molecules are known in the art. Recombinant DPRP proteins that have been modified so as to be catalytically inactive can also be used as dominant negative inhibitors. Such modifications include, for example, mutation of the active site.

A variety of protocols for measuring DPRP, including ELISAs, RIAs and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DPRP expression. Normal or standard values for DPRP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to DPRP under conditions suitable for complex formation. The method for detecting DPRP in a biological sample would comprise the steps of: a) providing a biological sample; b) combining the biological sample and an anti-DPRP antibody under conditions which are suitable for complex formation to occur between DPRP and the antibody; and c) detecting complex formation between DPRP and the antibody, thereby establishing the presence of DPRP in the biological sample. The amount of complex formation then may be quantified by various methods, preferably by photometric means. Quantities of DPRP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding DPRP are used for diagnostic purposes, which polynucleotides may include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. These polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of DPRP may be correlated with one of the Diseases. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of DPRP and to monitor regulation of DPRP levels during therapeutic intervention. Moreover, pharmacogenomic, single nucleotide polymorphisms (SNP) analysis of the DPRP genes can be used as a method to screen for mutations that indicate predisposition to disease or modified response to drugs.

DPRP polynucleotide and polypeptide sequences, fragments thereof, antibodies of DPRPs, and agonists, antagonists or inhibitors of DPRPs can be used to as discovery tools to identify molecular recognition events and therefore proteins, polypeptides and peptides that interact with DPRP proteins. A specific example is phage display peptide libraries where greater than 10<sup>8</sup> peptide sequences can be screened in a single round of panning. Such methods as well as others are known within the art and can be utilized to identify compounds that inhibit or enhance DPRP-1, DPRP-2 or DPRP-3 activity. Coupled links represent functional interactions such as complexes or pathways, and

proteins that interact with DPRPs can be identified by a yeast two-hybrid system, proteomics (differential 2D gel analysis and mass spectrometry) and genomics (differential gene expression by microarray or serial analysis of gene expression SAGE). Proteins identified as functionally linked to DPRPs and the process of interaction form  
5 the basis of methods of screening for inhibitors, agonists and antagonists and modulators of these DPRP-protein interactions.

The term "antagonist," as it is used herein, refers to an inhibitor molecule which, when bound to DPRP, decreases the amount or the duration of the effect of the biological or immunological activity of DPRP, e.g. decreasing the enzymatic activity of  
10 the peptidase to cleave the N-terminal dipeptide. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of DPRP; for example, they may include small molecules and organic compounds that bind to and inactivate DPRPs by a competitive or non-competitive type mechanism. Specific examples of DPRP tetrapeptide peptidic enzyme activity inhibitors are  
15 described in Example 6 and 7. Inhibitors can be, for example, inhibitors of the DPRP protease activity, or alternatively inhibitors of the binding activity of the DPRP to proteins with which they interact. Specific examples of such inhibitors can include, for example, anti-DPRP antibodies, peptides, protein fragments, or small peptidyl protease inhibitors, or small non-peptide, organic molecule inhibitors which are formulated in a  
20 medium that allows introduction into the desired cell type. Alternatively, such inhibitors can be attached to targeting ligands for introduction by cell-mediated endocytosis and other receptor mediated events. Such methods are described further below and can be practiced by those skilled in the art given the DPRP nucleotide and amino acid sequences described herein.

25 A further use for DPRPs is for the screening of potential antagonists for use as therapeutic agents, for example, for inhibiting binding to DPRP, as well as for screening for agonists. DPRP, its immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds which are prospective agonists or antagonists in any of a variety of drug screening techniques. The fragment employed in such screening  
30 may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DPRP and the agent being tested is then measured. Other assays to discover antagonists that will inhibit DPRP are apparent from the disclosures of U.S. Patents Nos. 6,011,155, 6,107,317, 6,110,949, 6,124,305 and 6,166,063, which describe inhibitors of DPPIV. Another worthwhile use



of these DPRPs is the screening of inhibitors of DPPIV to show that they will not have undesired side effects by also inhibiting one or more of the DPRPs.

A method provided for screening a library of small molecules to identify a molecule which binds DPRP generally comprises: a) providing a library of small  
5 molecules; b) combining the library of small molecules with the polypeptide of either SEQ ID NOS:1, 3 or 5, or with a fragment thereof, under conditions which are suitable for complex formation; and c) detecting complex formation, wherein the presence of such a complex identifies a small molecule which binds DPRP.

One method for identifying an antagonist comprises delivering a small molecule  
10 which binds DPRP into extracts from cells transformed with a vector expressing DPRP along with a chromogenic substrate (e.g. Ala-Pro-AFC or Ala-Pro-AMC) under conditions where cleavage would normally occur, and then assaying for inhibition of cleavage by the enzyme by monitoring changes in fluorescence, or UV light absorption, by spectrophotometry to identify molecules that inhibit cleavage. A reduced rate of  
15 reaction or total amount of fluorescence or UV light absorption, in the presence of the molecule, establishes that the small molecule is an antagonist which reduces DPRP catalytic/enzymatic activity. Once such molecules are identified, they may be administered to reduce or inhibit cleaving by a DPRP.

The term "agonist," as used herein, refers to a molecule which, when bound to  
20 DPRP, increases or prolongs the duration of the effect of DPRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules that bind to and modulate the effect of DPRP. Although it is less likely that small molecules will prove to be effective DPRP agonists, a method for identifying such a small molecule, which binds DPRP as an agonist, comprises delivering a chromogenic form of a small molecule that  
25 binds DPRP into cells transformed with a vector expressing DPRP and assaying for fluorescence or UV light absorption changes by spectrophotometry. An increased amount of UV absorption or fluorescence would establish that the small molecule is an agonist that increases DPRP activity.

Another technique for drug screening which may be used provides for high  
30 throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with DPRP, or with fragments thereof, and then washed. Bound DPRP is then detected by methods well  
35 known in the art. Purified DPRP can also be coated directly onto plates for use in the

aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DPRP specifically compete with a test  
5 compound for binding DPRP. In this manner, antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with DPRP.

As indicated above, by investigating the binding sites, ligands may be designed that, for example, have more interactions with DPRP than do its natural ligands. Such antagonist ligands will bind to DPRP with higher affinity and so function as competitive  
10 ligands. Alternatively, synthetic or recombinant proteins homologous or analogous to the ligand binding site of native DPRP may be designed, as may other molecules having high affinity for DPRP. Such molecules should also be capable of displacing DPRP and provide a protective effect.

As indicated above, the knowledge of the structures of DPRP enables synthetic  
15 binding site homologues and analogues to be designed. Such molecules will facilitate greatly the use of the binding properties to target potential therapeutic agents, and they may also be used to screen potential therapeutic agents. Furthermore, they may be used as immunogens in the production of monoclonal antibodies, which antibodies may themselves be used in diagnosis and/or therapy as described hereinbefore.

20 Given the ubiquitous expression of several members of the prolyl oligopeptidase S9B family, cell lines in which targeted gene disruption of DPPIV, DPRP-1, DPRP-2, DPRP-3, FAP and DPPVI to establish the null phenotype will be of great value to assist screening for selective and potent compounds. Accordingly, the invention provides such cell lines engineered with Lox-Neo IRES tk cassette and GFP-IRES-Neo Knock-in/out  
25 cassette DNA element for constructing somatic gene targeting vectors.

### Example 1

#### Cloning and Expression of DPRP genes Using the Mammalian Expression System

DNA fragments encoding the full-length polypeptide DPRP-1 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene,  
30 i.e. SEQ ID NO:45 and NO:46. In addition, DNA fragments encoding the full length polypeptide DPRP-2 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ ID NO:50 and NO:51. Furthermore, DNA fragments encoding the full length polypeptide DPRP-3 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ  
35 ID NO:55 and NO:56.

The three amplified sequences were respectively isolated from a 0.7% agarose gel using commercially available kit (GFX PCR DNA and Gel Band Purification Kit, Amersham Pharmacia Biotech Inc., Piscataway NJ, USA). The fragments were then ligated into cloning vector, pGEM-7Zf(-) (Promega Corporation, Madison WI, USA) and sequenced. The corresponding cloning constructs were respectively designated pGEM7-DPRP1, pGEM7-DPRP2 and pGEM7-DPRP3. The DNA sequences encoding the truncated DPRP-1 or DPRP-2 or DPRP-3 were amplified using pGEM7-DPRP1 or pGEM7-DPRP2 or pGEM7-DPRP3 as a template and PCR oligonucleotide primers. SEQ ID NO:45 and NO:47 were used for DPRP-1; SEQ ID NO:50 and NO:52 were used for DPRP-2; and SEQ ID NO:57 and NO:58 for DPRP-3. The amplified sequences were again isolated from a 0.7% agarose gel using the same purification kits and sub-cloned into pGEM-7Zf(-). The resulting constructs were designated pGEM7-DPRP1f, pGEM7-DPRP2f and pGEM7-DPRP3f.

To make the DPRP-1 mammalian expression construct, pGEM7-DPRP1 was digested with the restriction enzymes KpnI and NotI to release the full length DPRP-1 gene. The DNA fragment carrying the DPRP-1 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-1 expression construct, which was designated pcDNA-DPRP1. pGEM7-DPRP1f was digested with the restriction enzymes XbaI and HindIII to release the truncated DPRP-1f gene. The DNA fragment carrying the DPRP-1f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His A (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-1 expression construct pcDNA-MycHis-DPRP1.

To make the DPRP-2 mammalian expression construct, pGEM7-DPRP2 was digested with the restriction enzymes HindIII and BamHI to release the full length DPRP-2 gene. The DNA fragment carrying the DPRP-2 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-2 expression construct, which was designated pcDNA-DPRP2. pGEM7-DPRP2f was digested with the restriction enzymes EcoRI and BamHI to release the truncated DPRP-2f gene. The DNA fragment carrying the DPRP-2f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-2 expression construct designated pcDNA-MycHis-DPRP2.

To make the DPRP-3 mammalian expression construct, pGEM7-DPRP3 was digested with the restriction enzymes EcoRI and XhoI to release the full length DPRP-3

gene. The DNA fragment carrying the DPRP-3 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-3 expression construct designated pcDNA-DPRP3. pGEM7-DPRP3f was digested with the restriction enzymes NheI and ApaI to release the truncated DPRP-3f gene. The DNA fragment carrying the DPRP-3f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-3 expression construct pcDNA-MycHis-DPRP3.

### Example 2

#### 10 Expression Pattern of DPRP genes in human tissues

Quantitative PCR analysis was carried out to examine the levels of expression of the mRNAs for the polypeptides of the present invention in human tissues. RT PCR was also carried out on a number of human cell lines including but not limited to prostate cancer cells (LNCaP, PC3, DU145), the MLTC-1 line (mouse testis), and MDA-MB231 cells (breast cancer). Bands of the expected sizes for DPRP-1, DPRP-2 and DPPIV were all expressed in the various cancer cells lines, with FAP also being expressed at very low levels.

#### Northern Blot Analysis

Northern blot analysis was performed with 2µg poly(A)<sup>+</sup> RNA isolated from eight different tissues using DPRP probes. Specifically, a human Multiple Tissue Northern (MTN) blot (Clontech, Palo Alto, Calif.) was probed with a 1 kb N-terminal fragment that had been radioactively labeled by random priming in the presence of a <sup>32</sup>PdCTP (A. P. Feinberg et al., Anal. Biochem., 132, 6 (1983)). Hybridization was performed at 68°C overnight in ExpressHyb™ hybridization solution (Clontech, Palo Alto, Calif.). The blots were first washed at room temperature in 2 times SSC and 0.05% SDS, and then washed at 60°C (DPRP-1 & DPRP-2) and 50°C (DPRP-3) in 0.1 times SSC and 0.1% SDS.

Northern analysis showed expression of DPRP-1 in several tissues with the most abundant signal being in testis, prostate, muscle and brain. Testis showed 3 transcripts approximately 7.5, 4.5 and 2.5 kb in length. The shorter mRNA species was very abundant in testis but negligible in the other tissues tested. DPRP-2 was ubiquitously expressed in every tissue with highest levels in liver and muscle and a predominant transcript at 5kb. DPRP-3 expression was limited to brain and pancreas. Further analysis was conducted for the three proteases in specific brain regions (cerebellum, cortex, medulla, spinal cord, occipital lobe, frontal lobe temporal lobe and putamen).

DPRP-1 was expressed in all regions with low levels present in the spinal cord, while DPRP-2 was expressed in all brain regions tested.

Oligonucleotide primers SEQ ID NO:48 and NO:49 were used for DPRP-1 quantitative PCR, whereas oligonucleotide primers SEQ ID NO:53 and NO:54 were used for DPRP-2 quantitative PCR. Human Multiple Tissue cDNA (MTC™) Panel I and Panel II (Clontech, Palo Alto CA, USA) were used as normalized cDNA templates. 0.5 ng of each cDNA were used in a 25 µl PCR reaction, with each primer at a final concentration of 300 nM. The PCR reaction was performed using a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City CA, USA) and detected with an Applied Biosystems GeneAmp 5700 sequence detection system. Manufacturer's recommended thermal cycling parameter, e.g. 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min was used. Data obtained shows relatively high rates of expression for both DPRP-1 and DPRP-2 in the pancreas, ovary and testis, and a particularly high rate for DPRP-2 in the liver.

**Example 3 – Production of DPRP Polyclonal Antibodies and Western Blotting**

The amino acid sequence deduced from the cDNA encoding DPRP-1 was analyzed using DNASTAR software (DNASTAR, Inc.) to determine regions of high immunogenicity, and a corresponding oligopeptide was synthesized and used to raise anti-DPRP-1 antibodies. The procedure was repeated for DPRP-2 and DPRP-3. The selection of appropriate peptide sequences and the techniques for antibody production are methods well known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is well known in this art.

Typically, oligopeptides that are about 15 to 20 residues in length, e.g. SEQ ID NO:59 for DPRP-1, SEQ ID NO:60 for DPRP-2 and SEQ ID NO:61 for DPRP-3, were synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A. Fmoc-chemistry was used and the 19- or 15-residue peptides were respectively coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). Rabbits were immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera were tested for antipeptide activity, e.g., by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Western blotting was performed using normal human protein samples (Protein Medley) obtained from Clontech (about 36 µg of total proteins). Proteins were fractionated through 10% SDS-polyacrylamide gels, and transferred to 0.45 mm

nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) with 0.05% Tween 20 and 1% BSA. Anti DPRP-1 or DPRP-2 specific antibodies were used as primary antibodies and were diluted 1:5,000 in Tris-buffered saline with 0.05% Tween 20 (TBST) and the Alkaline Phosphatase (AP) conjugated goat anti-Rabbit IgG (Promega) was diluted 1: 5,000 in the same buffer before use. The positive reaction was visualized by incubating the membrane in Western Blue Stabilized Substrate (Promega) for AP until the bands of interest have reached the desired intensity. DPRP-1 and DPRP-2 proteins were detected in brain, muscles, kidney, prostate, testis and ovary tissues. DPRP-1 and DPRP-2 were synthesized as approximately 101kDa and 100kDa forms, respectively, which are in good agreement with the molecular masses estimated from their primary structure as shown in Table 3.

**Table 3.** Predicted Molecular Weight, Number of potential N-linked glycosylation sites (Asn residues) and predicted pI values of DPRP-1, DPRP-2 and DPRP-3, based on sequence analysis using the method developed by Hopp and Woods, Proc. Nat. Acad. Sci. 78:3824-3828 (1981).

	M.W. (Da.)	No. of Asn	pI
DPRP1	101422	26	5.39
DPRP2	98263	27	6.01
DPRP3	90914	33	6.11

Several additional bands of similar molecular weight were observed. These are thought to be due to the presence of post-translational glycosylation of the proteins. Table 3 also shows the number of potential N-glycosylation sites for the DPRP proteins. The presence of glycosylated and unglycosylated forms of the proteins was evaluated using tunicamycin, an inhibitor of the oligosaccharide synthesis. It is evident that the smaller forms were unglycosylated forms. The correlation between mRNA (Northern analysis) and protein quantity (Western analysis) for DPRP-1 is shown in Table 4.

**Table 4.** Correlation of mRNA and protein expression of DPRP-1 in human tissues

	Heart	Brain	Placenta	Muscles	Kidney	Prostate	Testis	Ovary
Northern	++	+++	+	+++	++	+++	++++	+
Western	-	++++	-	+	++	+	+++	+++

**Example 4****Immunohistochemical localization of DPRP proteins in human tissues**

Four-micron sections were prepared from a number of different formalin-fixed, paraffin-embedded human tissues. Tissue sections were deparaffined through 4 immersions in xylenes for 5 minutes, followed by a graded alcohol series to distilled water. Steam heat induced epitope recovery (SHIER) was used with several different SHIER solutions with and without enzyme digestion tissue in two different concentrations (Ladner et al, Cancer Res.; 60, p 3493-3503, 2000). The treatments and antibody dilutions employed are outlined below.

- 10           1.     Blocking Reagent for 15 minutes (Normal Goat Serum)
2.     Primary Antibody for 25, 60 min or overnight incubation
3.     Secondary Antibody for 25 minutes (Biotinylated Goat-anti-rabbit IgG)
4.     Endogenous Peroxidase Blocking for 3 x 1.5 minutes
5.     ABC (avidin-biotin complex) / Horse Radish Peroxidase for 25 minutes
- 15           6.     DAB Chromogen for 3 x 5 minutes (Brown reaction product)
7.     Light Hematoxylin Counter Stain 1 minute

Positive controls were run to assure the detection chemistries and antigen pretreatments were working appropriately. Rabbit IgG was run as a negative control. An avidin-biotin based tissue staining system was used for the detection of the DPRP-1 antibody. Horseradish peroxidase was used as a reporter enzyme with DAB as chromogen. After staining, slides were dehydrated through an alcohol series to absolute ethanol followed by xylene rinses. Slides were permanently coverslipped with glass coverslips and permount. Digital images of representative staining, where positive staining was indicated by a dark brown chromogen (DAB-HRP reaction product), were captured using a video camera from Olympus. Hematoxylin counterstain provides a blue nuclear stain to assess cell and tissue morphology.

DPRP-1 rabbit polyclonal antibody labels formalin-fixed, paraffin-embedded human tissues, including normal testis, prostate glands, endometrial glands, tonsils and pancreas. It was also present in endothelial cells of normal ovary, bladder and kidney. Staining was localized in the cytoplasm in epithelial and some stromal cells such as fibroblasts, endothelial cells and lymphocytes. Interestingly in normal testis tested with DPRP-1 antibodies, there was distinctive expression in Leydig cells and multinucleated macrophages found in interstitial tissue, which is the space surrounding the seminiferous tubules. Tonsil B cells were stained with DPRP-1 antibody.

### **Example 5**

#### **Mammalian and Insect Cell Expression of DPRP Proteins and Purification**

Plasmid DNA of pcDNA-DPRP1, pcDNA-MycHis-DPRP1, pcDNA-DPRP-2 or pcDNA-MycHis-DPRP2 was transfected into PEAK (EdgeBioSystems, Gaithersburg MD, USA) or COS-1 (ATCC CRL-1650) using LipofectAmine (Life Technologies, Gaithersburg MD, USA) method recommended by the manufacturer. Transfected cells were maintained in DMEM with 5% FBS at 37°C with 5% CO<sub>2</sub> for 48 hours. Cells were then collected and used for recombinant protein extraction. Cells were harvested 48 hours after transfection, homogenized and then spun at 18,000 x g for 40 min. The supernata were collected as cytosolic fractions. This fraction was loaded on TALON spin column (Clontech), and His-tagged proteins were eluted with 50mM PBS, 150mM imidazole, pH 7. Recombinant proteins were then detected by western blotting with anti-myc antibody and visualized using a ProtoBlot II AP system (Promega). Recombinant affinity purified fusions of the DPRP-1 and DPRP-2 were detected by western blot, and DPRP-1 and DPRP-2 were synthesized as 112kDa and 109kDa forms as predicted.

Naturally occurring or recombinant DPRP proteins were substantially purified by immunoaffinity chromatography using antibodies specific for DPRP-1, DPRP-2 or DPRP-3. An immunoaffinity column was constructed by covalently coupling DPRP antibodies to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin was blocked and washed according to the manufacturer's instructions.

Media or cell extracts containing DPRP proteins were passed over the immunoaffinity column, and the column was washed under conditions that allow the preferential absorbance of DPRPs (e.g., high ionic strength buffers in the presence of detergent). The column was eluted under conditions that disrupt antibody/DPRP binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and purified DPRP was collected.

### **Example 6**

#### **Enzymatic Activity of DPRP proteins and Methods of Screening for Inhibitors**

The kinetic properties of recombinant DPRP-1 and DPRP-2 were determined in a continuous fluorimetric assay. Buffer, pH and temperature dependence optimization led to the following assay conditions: Enzyme assays were performed in 50mM PBS, pH7.4 50 µl (50 µg/ml) of purified enzymes were mixed with 1 µl of different concentration of Ala-Pro-AMC (Enzyme Systems). Plates were then incubated at 37°C for 30 min, and



fluorescence was detected using a Wallac 1420 Fluorimeter with  $\lambda_{ex}40355$  and  $\lambda_{em}535$ . The  $K_m$  values of DPRP-1 and DPRP-2 were similar (208 and 161  $\mu M$  respectively).

Further biochemical characterization reveals that DPRP-1 and DPRP-2 have similar profiles to DPPIV. The two purified proteases and DPPIV were preincubated with inhibitors at room temperature for 30 min. Substrate, Ala-Pro-AMC (100  $\mu M$ ), was then added, and the fluorescence intensity was recorded as 60 readings during a 60 min period. The irreversible serine protease inhibitor AEBSF was the only inhibitor tested that showed strong inhibition of all three enzymes (Table 5). This confirms the structural and domain analysis prediction that these proteins belong to the serine protease superfamily.

**Table 5.** Inhibition of DPRP-1 and DPRP-2 by Protease Inhibitors

Inhibitor	Inhibitor Property	Concentration	Residual activity (% of control)		
			DPRP-1	DPRP-2	DPPIV
AEBSF	serine, irreversible	5mM	29.6	23.9	21.1
Aprotinin	serine, reversible	5 $\mu g/ml$	77.5	63.2	80.2
Pepstatin	aspartic, reversible	2 $\mu g/ml$	97.3	95.0	93.5
DTT	cysteine	2mM	100.1	94.8	98.3
B-Mercaptoethonal	cysteine	100mM	93.2	84.0	98.0
EDTA	metallo, reversible	2mM	91.5	86.0	93.5
Leupeptin	serine, reversible	50 $\mu g/ml$	91.1	90.4	90.7

In addition to Ala-Pro-AMC, additional substrates tested also confirmed that DPRP-1 and DPRP-2 are dipeptidyl peptidases. The data were derived by determining the fluorescence change following a 30-minute incubation of the substrates (125  $\mu M$ ) with enzymes as a percentage of the fluorescence measured at Ala-Pro-AMC and Gly-Pro-AMC were the only good substrates among those tested.

**Table 6.** DPRP-1 and DPRP-2 are dipeptidyl peptidases.

Substrate	% Change in Fluorescence at 30 minutes		
	DPRP-1	DPRP-2	DPPIV
Ala-Pro-AMC	239.0	127.5	379.0
Gly-Pro-AMC	341.5	205.0	444.0
Ala-Pro-pNA	45.5	44.0	29.5
Pro-pNA	-1	-2.5	0.0
Gly-Arg-pNA	-4.5	-0.5	0.0
Lys-Ala-pNA	2.5	0.5	0.5
Ala-Phe-Pro-pNA	-4	-0.5	2.0

Additional natural and non-natural amino acid di-, tri- and tetra-peptides were tested in order to find an optimal substrate for testing each of the DPRP proteins that will also show reduced activity when incubated DPPIV.

The enzyme assay method described here is one of a number of methods that can be utilized to screen for peptide and non-peptide inhibitors of the DPRP enzymes. Libraries of tetrapeptide inhibitors were tested to discover inhibitors of enzyme activity. Candidate inhibitors were prepared as 10-20 mM stock solutions in DMSO and stored at -20°C. Dilutions were made in assay buffer. Inhibition was determined by comparing the changes in fluorescence of the inhibited enzyme to the change in fluorescence of the control (vehicle) enzyme. 100-(f1 units of sample/f1 units of control x 100) gives percent inhibition value. The percent inhibition and the inhibitor concentration at which the enzyme was 50% inhibited ( $IC_{50}$ ) was ascertained by plotting percent inhibition vs. inhibitor concentration on the log scale. As shown in Figure 3, several tetrapeptides amides inhibited enzyme activity, wherein data are expressed as the % of activity in the presence of vehicle (0.02% DMSO) alone. Compounds were added at 1 mM. Most interesting was the apparent differential activity of some tetrapeptides for DPRP-1 and DPRP-2, compared to DPPIV. While all three enzymes were inhibited by Peptide-1, only DPRP-1 and DPRP-2 were significantly inhibited by Peptide-4 and Peptide-5. This demonstrates that selective inhibition of the purified enzymes is achievable.

The assay described in this example can also be used to screen additional synthetic or naturally occurring compound libraries, including macromolecules, for agents that either inhibit or enhance DPRP activity. The DPRP-1 and DPRP-2 polypeptides to be used in the assay can be obtained by, for example, *in vitro* translation, recombinant expression (see Example 5) or biochemical procedures. Methods other than those described here can also be used to screen and identify compounds that inhibit DPRP-1, DPRP-2 or DPRP-3, which methods can include, for example, binding assays such as ELISAs and RIAs.

#### Example 7

##### Effect of DPRP Inhibitors on the Proliferation of Human Cancer Cells In Vitro

In an attempt to assess the effect that several inhibitors of DPRP-1 and DPRP-2 activity may have on the proliferation of human cancer cells, LNCap, PC3 and Du145, mouse testis line MLTC-1 and MDA-MB231 breast cancer cells were plated ( $10^4$  per well) in 96-well tissue culture plates and allowed to grow and attach for 24 hours at 37°C in a CO<sub>2</sub> incubator. Compounds at various dilutions (final dilutions: 0.1 nM – 10  $\mu$ M) were then added to the wells for various incubation periods from 24 hours to 96 hours,

with fresh compound being replaced each day. Addition of the diluent DMSO alone served as the control. Following incubation with these compounds in triplicate, proliferation of the cells was determined using an XTT cell proliferation assay (Roche 1-465-015). The plates were read at 490 and 650nm 5 hours after the XTT mix was added.

- 5 An increase in cell proliferation was observed with three of the inhibitors at concentrations equal to 0.1, 1, 10 and 100 x IC<sub>50</sub>, and the results are shown in FIGS. 4A, 4B and 4C for PC3 cells.

Overall, the DPRPs are expressed in a wide variety of tissues as has been demonstrated by mRNA amplification, western blotting and immunohistochemistry.

- 10 DPRP-1 was most abundant in the testis by Northern blot and western blot. The large number of expressed sequence tags (ESTs) from testis cDNA sources that are homologous to DPRP-1 also confirms abundant expression of DPRP-1 in testis. Example 4 describes the immunohistochemical localization of DPRP-1 protein in human testis using a specific DPRP-1 antibody. DPRP-1 is strongly expressed in epitheloid
- 15 Leydig cells, and Leydig cells are the primary source of testicular androgens (male steroid hormones) in the mammalian male. In the interstitium of the testis, Leydig cells and macrophages are in close association with "digitation" of Leydig cell process extending onto macrophage surface. Multinucleated cells in close proximity to the Leydig cells were also stained with DPRP-1 antibody suggesting that the protease was
- 20 also expressed in macrophages, and macrophages in the testis play an important role in the paracrine regulation of Leydig cells. Cytokines secreted by the testicular macrophages are mitogenic to Leydig cells and play an important role in the differentiation of mesenchymal progenitor cell into mature Leydig cells. A clearer understanding of the proteins and pathways involved in the maturation of the testis is
- 25 important for the discovery of new treatments for precocious puberty. In addition, Leydig cells cause tumors such as sex cord-stromal tumors via sexual steroid production (predominantly testosterone). Testosterone is associated with several neoplasia and diseases such as breast carcinoma and uterine cancers, ovarian carcinoma and androgenic alopecia (hair loss). Further examination of the localization of DPRP
- 30 proteins in other glands in the body (e.g. adrenal glands) that produce testosterone and other androgenic hormones are currently under investigation. The possible association of DPRP-1 with steroid and polypeptide hormone biosynthetic pathways functions is being investigated, and Example 7 is relevant to understanding the role of DPRP proteins in prostate, testis and breast in vitro cell models.

Immunohistochemical analysis also localized DPRP-1 to endometrial glands in the uterus (see Example 4), pancreatic acini, glomeruli of the kidney, plasma cells in the bladder, a subset of B-cells in the tonsils, columnar epithelial cells of the prostate and poorly differentiated prostate squamous metaplasia, Gleason grade 4 prostatic carcinoma, and hyperplastic glands in benign prostatic hyperplasia. Positive staining in breast carcinoma, as well as in seminoma and prostate squamous metaplasia, suggests a general association of DPRP-1 with hormone-sensitive tissues, particularly in cells that become poorly differentiated. The presence of the DPRP-1 in specialized epithelial cells and in inflammatory plasma cells (lymphocytes) is also of interest. Inflammatory breast carcinoma has an abundance of infiltrating lymphocytes and an overall bad prognosis. DPRP-1 and other DPRP proteins appear in medullary carcinomas that typically have a constant infiltrating lymphoplasmacytic component at the periphery of the tumor, which is thought to represent a reaction of the host tissues to the neoplasm. Most of the lymphocytes are T Cells, and most of the plasma cells are of the IgG-producing type. Several antigens are abundant on B cells, a subgroup of breast-cancer cells, and other epithelial cancer cells, and these antigens are targets for a new class of therapeutic monoclonal antibodies with some notable success having been achieved with a humanized monoclonal antibody against the B-cell-specific antigen CD20. Accordingly, monoclonal antibodies to DPRP proteins are felt to be useful to diagnose and treat diseases in which they are involved, including cancer.

The expression of DPRP-1 in specialized epithelial cells of a number of tissues suggests that DPRP-1 and other DPRP proteins may be involved in growth and differentiation thereof. Testing using inhibitors described in Example 6 in *in vitro* models of prostate and testis cancer (Example 7) showed that DPRP-1/DPRP-2 inhibitors caused a 50-60% increase in proliferation of PC3 cells at nM concentrations as shown in FIGS. 4A-4C.

Although the invention has been described in accordance with its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that changes and modifications as would be obvious to those skilled in this art may be made without departing from its scope which is set forth in the claims appended hereto. For example, although the disclosure focuses on DPRP-1 and DPRP-2 in certain instances, DPRP-3 and its fragments are considered to be similarly useful, as are nucleic acids encoding same. Particular features of the invention are emphasized in the claims that follow.

## CLAIMS:

1. Isolated nucleic acid  
which encodes (a) a polypeptide, which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function;  
or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6; or  
which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b) ; or  
which is complementary to any one of the foregoing.
2. The isolated nucleic acid of claim 1 which is DNA or RNA.
3. The isolated nucleic acid of claim 1 which is a DNA transcript that includes the entire length of any one of SEQ ID NOS:2, 4 and 6 or which is complementary to the entire coding region of one of SEQ ID NOS:2, 4 and 6.
4. An antisense oligonucleotide directed against the DNA of claim 3.
5. The isolated nucleic acid of claim 1 which is an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.
6. The isolated nucleic acid of claim 1 which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6.
7. A polypeptide encoded by the nucleic acid of claim 6.
8. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 90% similar to one of SEQ ID NOS:1, 3 and 5.
9. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 95% similar to one of SEQ ID NOS:1, 3 and 5.
10. The isolated nucleic acid of claim 1 which encodes a polypeptide that has at least about 90% identity with one of SEQ ID NOS:1, 3 and 5.
11. A nucleic acid probe according to claim 1 comprising at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 and 6.
12. An isolated recombinant polynucleotide molecule comprising nucleic acid according to claim 1 plus expression-controlling elements linked operably with said nucleic acid to drive expression thereof.
13. An expression vector comprising the nucleic acid of claim 1 encoding a polypeptide having the entire amino acid sequence set forth in any one of SEQ ID NOS:1, 3 and 5 operably linked to a promoter, said expression vector being present in a compatible host cell.

14. A mammalian, insect or bacterial host cell that has been genetically engineered by the insertion of nucleic acid according to claim 1 which codes for at least the mature protein portion of the amino acid sequence of SEQ ID NO:1, 3 or 5.

15. A process for producing a polypeptide which includes the mature protein portion of one of SEQ ID NOS:1, 3 and 5, which process comprises culturing the host cell of claim 11 under conditions sufficient for the production of said polypeptide.

16. The process of claim 15 wherein said polypeptide is expressed at the surface of said cell and further includes the step of recovering the polypeptide or a fragment thereof from the culture.

17. A polypeptide  
which may be optionally glycosylated, and  
which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

18. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

19. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

20. The polypeptide according to claim 14 having the amino acid sequence of the mature protein of one of SEQ ID NOS:1, 3 and 5, or is a fragment thereof which exhibits the same biological function as the respective mature protein.

21. A DPRP antagonist which inhibits the biological function of one of said mature proteins of claim 17, 18 and 19.

22. An antibody that recognizes a polypeptide or a fragment according to claim 17.

23. The antibody of claim 22 which recognizes a polypeptide having an amino acid sequence of SEQ ID NO:1 or 3 or 5.

24. A method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of claim 17, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the

absence of a test compound, and selecting the test compound or compounds that reduce the enzymatic activity.

25. A method for the screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one of the mature proteins of claim 20, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

DPP4 1 .....MKTPTWVLLCGL.....AA...LT  
 DPRP1 1 MAAAMETEQLG...FETADCE...ESQDRPK...EPYVEYSWS...LKKL...DRKYHG...YM  
 DPRP2 1 .....ATTGTP...A...GDAAATDDPAAREOV...KHSWDGL...S...H...SRKYSGL...V  
 DPRP3 1 .....NQTA...VS...HKCQPSKT...KELGS...SPPO...WKGI...AI...LLVILV...CS

DPP4 20 ...ITVPVVLN...CTD...ATADSR...TYLT...D...LKN...TYRLKLY...RWI...DHEYL...KOFN  
 DPRP1 61 AKAPHDF...FVK...NDPDGPHSD...RYL...MSGENREN...LFYSEIPK...NRAAVIMLS...RPLL  
 DPRP2 50 NKAPHDF...QFVO...TDESGPHSH...YYI...MPYGSREN...LLYSEIPK...RKEALLLS...KOML  
 DPRP3 48 ...ITMSVIL...LSP...DELTNSS...ETRLSLED...L...RK...FVLHD...PEARWINDT...V...KSEN

DPP4 75 ...LVFNAYGNSS....FLENSTDEFCH...INDYS...SPDCQ...LLEYNY...KORHSY...T  
 DPRP1 121 ...D...FOAT...YGY...SREEELLRR...RIGTVGTASYDYHOG...SGTFLFOAGSG...HVG...GGP  
 DPRP2 110 ...DHFOATPH...Y...SREFELLRR...RNLGVFGI...SYD...HSE...SGLFLFOASNS...HCRDGGK  
 DPRP3 101 GH...IKLN...ETNAT...LLENTT...EVTF...K...SRHS...SPDLK...LLAY...VKQI...YSYT

DPP4 130 AS...DIYDLNK...R...LITEERI...NNTQWVTWSPVGHKL...NNDI...VVKIEPNLPSY...RT  
 DPRP1 179 QG...TOOPL...P...NL...ETSCPNR...MDPK...CPADPD...A...IHSNDI...SNIY...TREERRLT  
 DPRP2 168 NG...YSP...P...LE...KTQCSGPR...MDPK...CPADPA...F...INNSD...VANLETGEERRLT  
 DPRP3 155 AS...LYN...TREVWE...LNPEVEDSV...QYAAWGVQGQOLI...I...EN...IYQPD...KSSSLRT

DPP4 187 ...G....KE...I...YNG...ITDWVY...EEVFSAYS...LWVSPN...T...LAY....A...Q...N...V  
 DPRP1 235 ...VH...ELANME...DARS...GVATFVLOEEFDRYS...YWWCPK...ETTPS...GGRILRILYE...NDES  
 DPRP2 224 ...CHOGLSNVL...DPKS...GVATFVLOEEFDR...YWWCP...AS...E...SEGL...TLRILYE...VDES  
 DPRP3 215 ...G....KE...I...FNG...IADWLY...EELLHSHI...HWS...ED...ERLAF.....L...IN...LVP

DPP4 235 ...EYSFY...DES...YPKTVRV...PKAGAVNE...T...K...FVVNTDSLSS...TNATSI...ITAPAS  
 DPRP1 294 ...EVEI...IHVTSP...LETR...ADS...RYPKTG...ANPKY...TFK...SE...MID...EG...I...DVIDKEL...QPF  
 DPRP2 284 ...EVEI...IHVPS...PALEERKTDSYR...Y...PKTG...KNPK...AKLAEF...TDSQ...I...STQEKEL...QPF  
 DPRP3 263 ...TVIP...FTGA...YP...KGQ...PYPKAGQVNP...T...KL...FVVNLYG....P...HTLEL...PPDS

DPP4 293 ...LIG...DHY...CDVTW...Q...ERIS...OWLRI...QN.....  
 DPRP1 354 ...LFEGVEYIARAGWTPEGKYAWS...LLDRS...QTRLO...VL...SPELFIPVE...DVMER...ORLIESV  
 DPRP2 344 ...SLFPKVEYIARAGWTRDGKYAWA...LLDRPO...WLO...VL...PPALFIPST...NEEORLASARAV  
 DPRP3 314 FKSR...EYITMVKNV...N...TKTV...R...L...RPN.....

DPP4 322 ...YSV...D...CDY...E...GRWNC...VARO...H...EMS...T...GWVGRFRPSE...PHFTLDGNSFYKIISNE..  
 DPRP1 414 ...EDSVTE...IIYEE...TD...WIN...HDIF...H...FPOS...HEE...E...F...ASECKTGFRHLYKITS...LKE  
 DPRP2 404 ...ERNVQ...YVVE...VTN...WIN...HDIIY...PFPOS...GED...E...CF...RANECKTG...FCHLYK...T...VLKS  
 DPRP3 343 ...IS...T...CETTTG.....ACSK...YEMTS...TWLSQONE...EPVFSRDGS...F...MTVPV...KQG

FIG. 1A



DPP4 379 E.....GRRHICYFOIDK.....CTETKGTWEVVG....TEAITSYLYYISKEYK  
 DPRP1 473 SYKRSSGGLPAPSFKCPIK....EEIATSGEWEVGRHGSNTQVDEVRLVYFEGTK  
 DPRP2 464 QGYDWSEPFSEGEDFKCPIK....EEIATSGEWEVGRHGSNTQVDEVRLVYFEGTK  
 DPRP3 394 GR.....GRRHICYFOIDK.....CTETKGTWEVVG....TEAITSYLYYISKEYK  
  
 DPP4 424 GMPGGNLYKQLSDYTKVTOICELNPERCOYYSVSFSKEKYYSICSGPGPPTTH  
 DPRP1 529 DSPLEHLYVVSYPNPGEVTRLDRCSHSCISQHCDFLSKYSQNP.HCVSYKLS  
 DPRP2 520 DSPLEHLYVVSYPNPGEVTRLDRCSHSCISQHCDFLSKYSQNP.HCVSYKLS  
 DPRP3 445 SSPRGHLYSASTELLNRQCCNFMKEQCYFDASFSPNQHFLFCEGPRVPVSIH  
  
 DPP4 484 SSVNDKGLVLEDNSALDKMLQN..VQPSKKLDEINNETFYQILPPHFDKSKKYP  
 DPRP1 588 SPDDPTCKTKEFWAAGPLPDYTPPEIFSEETGGLTYGMLYKPHDLQPGKKYP  
 DPRP2 579 GPDDPLHQPREFWAEASCPEDYPPPEIFTHRSUVLYGMYKPHALQPGKKYP  
 DPRP3 505 STDNPAKYFLFSNSMLKEAILKKKIGKP..ETTHDDDELPLQSLPDMFDRNOA  
  
 DPP4 542 LELDVYGFCSOKATVET..LNWATYLAENITVASFQGRGSGGQDKIMHAINRRG  
 DPRP1 648 TLFYGGPQVOLVNNFKGKYRLNLTASLGYYVVIDNRRGSCHRGLKFEQAFKYG  
 DPRP2 639 TLFYGGPQVOLVNNFKGKYRLNLTASLGYYVVIDNRRGSCHRGLKFEQAFKYG  
 DPRP3 563 LELINDEEPGGQLVTEET..IDWDSVLMDMNVIVARFDGRGSGGQGLKILQELRRG  
  
 DPP4 600 TFEEDQEFARQF..KMGFYDNKRIAIWGSYGGYMSVLGSGSGVFKCTAVAPVVR  
 DPRP1 708 QVEEDQEFARQF..KMGFYDNKRIAIWGSYGGYMSVLGSGSGVFKCTAVAPVVR  
 DPRP2 699 QVEEDQEFARQF..KMGFYDNKRIAIWGSYGGYMSVLGSGSGVFKCTAVAPVVR  
 DPRP3 621 SVEKDQETAKFLL.KLPIDSKRISIFGKGYGGYMSMLKSDEKFNCSVVPATD  
  
 DPP4 659 WEYDGVYTERYMGFTPELDHYRNSTVSRAENFKQVEYLHGTADNVHFOQAQ  
 DPRP1 768 WEYDGVYTERYMGFTPELDHYRNSTVSRAENFKQVEYLHGTADNVHFOQAQ  
 DPRP2 759 WEYDGVYTERYMGFTPELDHYRNSTVSRAENFKQVEYLHGTADNVHFOQAQ  
 DPRP3 680 LKLYAGGVYTERYMGFTPELDHYRNSTVSRAENFKQVEYLHGTADNVHFOQAQ  
  
 DPP4 719 NSKALDVGVDFQAMWYTDDEHGIASSTAHYIYTHSHFKECFSLP.....  
 DPRP1 828 LLSFLRAGKPYDLOIYPERHSIRVPESGEHYELLLHLOENLGSRIIAALKVI....  
 DPRP2 819 LLSFLRAGKPYDLOIYPERHSIRVPESGEHYELLLHLOENLGSRIIAALKVI....  
 DPRP3 738 LKHLRAGVNYTQYYPDECHNSEK.SKYHLYSTLFFFSCLKEEISVLPQPEPEDE

FIG. 1B

hDPRP1	1	MAAAMETEQLGVEIFETADCEEN.IESQDRPKLEPFYVERYSWSQLKLLADTRKYHGYM
mDPRP1	1	MAAAMETEQLGVEIFETADCEENGESQDRPKLEPFYVERYSWSQLKLLADTRKYHGYM
hDPRP1	60	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTIFYSEIPKTINRAAVLMLSWKPL
mDPRP1	61	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTIFYSEIPKTINRAAVLMLSWKPL
hDPRP1	120	LDLFQATLDYGMYSREEELLRERKRIGTVGIASYDYHQSGTFLFOAGSGIYHKDGGPQ
mDPRP1	121	LDLFQATLDYGMYSREEELLRERKRIGTVGIAAYDYHPGSGTFLFOAGSGIYHKDGGPQ
hDPRP1	180	GFTQQPLRPNLVETSCPNI RMDPKLCPADPDWIAFIHSNDIWISNV TREERTYVHNE
mDPRP1	181	GFTQQPLRPNLVETSCPNI RMDPKLCPADPDWIAFIHSNDIWISNV TREERTYVHNE
hDPRP1	240	LANMEEDARSAGVATFVLQEEFDRYSGYWCPKAETTPSGGKILRILYEENDESEVEI IH
mDPRP1	241	LANMEEDARSAGVATFVLQEEFDRYSGYWCPKAETTPSGGKILRILYEENDESEVEI IH
hDPRP1	300	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEI DAEGRIIDVIDKELQPF EILFEGV
mDPRP1	301	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEI DAAGGIIDVIDKELQPF EILFEGV
hDPRP1	360	EYIARAGWTPEGKYAWSIILDRSQT LQIVLISPELFIPVEDDVMRQR LIESVPDSVTE
mDPRP1	361	EYIARAGWTPEGKHAWSIILDRSQT LQIVLISPELFIPVEDDAMRQR LIESVPDSVTP
hDPRP1	420	LIIYEETTDIWINIHDFHVFQSHHEIEEFIFASECKTGFRHLYKITSILKESKYKRSS
mDPRP1	421	LIIYEETTDIWINIHDFHVFQSHHEIEEFIFASECKTGFRHLYKITSILKESKYKRSS
hDPRP1	480	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIQVDEVR LVYFEGTKDSPLEHHLYV
mDPRP1	481	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIQVDEAR LVYFEGTKDSPLEHHLYVT
hDPRP1	540	SYVNPGEVTRLTDRGYSHSCSRHCDF FISKYSNQKNPHCVSLYKLSSPEDDPTCKTKE
mDPRP1	541	SYANPGEVTRLTDRGYSHSCSRHCDF FISKYSNQKNPHCVSLYKLSSPEDDFVHK TKE
hDPRP1	600	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKYPTVLFYGGPQVQ
mDPRP1	601	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKYPTVLFYGGPQVQ
hDPRP1	660	LVNNRFKGVKYFRINTLASLG YVVVIDNRGSCHRG LKFEGAFKYKMGQIEIDDQVEGLQ
mDPRP1	661	LVNNRFKGVKYFRINTLASLG YVVVIDNRGSCHRG LKFEGAFKYKMGQIEIDDQVEGLQ
hDPRP1	720	YLASRYDFIDLDRVGIHGWSYGGYLSIMALMQRSDFRVAIACAPVTLWIFYDTGYTERY
mDPRP1	721	YLASQYDFIDLDRVGIHGWSYGGYLSIMALMQRSDFRVAIACAPVTLWIFYDTGYTERY
hDPRP1	780	MGHPDQNEQGYLGSVAMQAEKFPSEPNRLLLLHGF LDENVHFAHTSILLSFLVRAGKPY
mDPRP1	781	MGHPDQNEQGYLGSVAMQAEKFPSEPNRLLLLHGF LDENVHFAHTSILLSFLVRAGKPY
hDPRP1	840	DLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI
mDPRP1	841	DLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI

FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

Sequence Listing Summary

## SEQ ID.

1. DPRP1 a.a. sequence
2. DPRP1 DNA sequence
- 5 3. DPRP2 a.a. sequence
4. DPRP2 DNA sequence
5. DPRP-3 a.a. sequence
6. DPRP-3 DNA sequence
7. DPRP-1 transcript 0 a.a. sequence
- 10 8. DPRP-1 transcript 0 DNA sequence
9. DPRP-1 transcript 1 a.a. sequence
10. DPRP-1 transcript 1 DNA sequence
11. DPRP-1 transcript 2 a.a. sequence
12. DPRP-1 transcript 2 DNA sequence
- 15 13. DPRP-1 transcript 3 a.a. sequence
14. DPRP-1 transcript 3 DNA sequence
15. DPRP-1 transcript 4 a.a. sequence
16. DPRP-1 transcript 4 DNA sequence
17. DPRP-1 transcript 5 a.a. sequence
- 20 18. DPRP-1 transcript 5 DNA sequence
19. DPRP-1 transcript 6 a.a. sequence
20. DPRP-1 transcript 6 DNA sequence
21. DPRP-1 transcript 7 a.a. sequence
22. DPRP-1 transcript 7 DNA sequence
- 25 23. DPRP-2 transcript 0 a.a. sequence
24. DPRP-2 transcript 0 DNA sequence
25. DPRP-2 transcript 1 a.a. sequence
26. DPRP-2 transcript 1 DNA sequence
27. DPRP-2 transcript 2 a.a. sequence
- 30 28. DPRP-2 transcript 2 DNA sequence
29. DPRP-2 transcript 3 a.a. sequence
30. DPRP-2 transcript 3 DNA sequence
31. DPRP-2 transcript 4 a.a. sequence
32. DPRP-2 transcript 4 DNA sequence
- 35 33. DPRP-2 transcript 5 a.a. sequence

34. DPRP-2 transcript 5 DNA sequence
35. DPRP-2 transcript 6 a.a. sequence
36. DPRP-2 transcript 6 DNA sequence
37. DPRP-2 transcript 7 a.a. sequence
- 5 38. DPRP-2 transcript 7 DNA sequence
39. DPRP-2 transcript 8 a.a. sequence
40. DPRP-2 transcript 8 DNA sequence
41. DPRP-3 transcript 0 a.a. sequence
42. DPRP-3 transcript 0 DNA. Sequence
- 10 43. DPRP-3 transcript 1 a.a. sequence
44. DPRP-3 transcript 1 DNA sequence
45. DPRP1 forward primer used for cloning
46. DPRP1 reverse primer used for cloning full length gene
47. DPRP1 reverse primer used for cloning fusion gene
- 15 48. DPRP1 forward primer used for expression profiling
49. DPRP1 reverse primer used for expression profiling
50. DPRP2 forward primer used for cloning
51. DPRP2 reverse primer used for cloning full length gene
52. DPRP2 reverse primer used for cloning fusion gene
- 20 53. DPRP2 forward primer used for expression profiling
54. DPRP2 reverse primer used for expression profiling
55. DPRP3 forward primer used for cloning
56. DPRP3 reverse primer used for cloning full length gene
57. DPRP3 forward primer used for cloning fusion gene
- 25 58. DPRP3 reverse primer used for cloning fusion gene
59. DPRP1 peptide antigen sequences
60. DPRP2 peptide antigen sequences
61. DPRP3 peptide antigen sequences

## SEQUENCE LISTING

<110> Qi, Steve  
 Akinsanya, Karen  
 Riviere, Pierre  
 Junien, Jean-Louis

<120> NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

<130> 70669

<150> US 60/240,117

<151> 2000-10-12

<160> 61

<170> Patent In version 3.1

<210> 1

<211> 882

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
          85          90          95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
          100          105          110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
          115          120          125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
          130          135          140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
145          150          155          160
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
          165          170          175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
          180          185          190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
          195          200          205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
          210          215          220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
225          230          235          240
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
          245          250          255

```

4



```
<210> 2
<211> 2671
<212> DNA
<213> Homo sapiens
<400> 2
```

5

```

tgatctacag cctggaaaga aatatacctac tgtgctgttc atatatgggtg gtcctcaggt 1980
gcagttgggtg aataatcgat ttaaaggagt caagtatttc cgcttgaata ccctagcctc 2040
tctaggttat gtggtttag tagatagacaa caggggatcc gtgcaccgag ggcttaaatt 2100
tgaaggcgcc tttaaatata aaatgggtca aatagaaatt gacgatcagg tggaaggact 2160
ccaatatcta gcttctcgat atgatttcat tgacttagat cgtgtgggca tccacggctg 2220
gtcctatgga ggatacctct ccctgatggc attaatgcag aggtcagata tcttcagggt 2280
tgctattgct ggggccccag tcaactctgtg gatcttctat gatacaggat acacggaacg 2340
ttatatgggt caccctgacc agaatagaaca gggctattac ttaggatctg tggccatgca 2400
agcagaaaag ttcccctctg aaccaaactcg tttactgctc ttacatggtt tcctggatga 2460
gaatgtccat tttgcacata ccagtatatt actgagtttt ttagtgaggg ctggaaagcc 2520
atatgattta cagatctatc ctcaggagag acacagcata agagttcctg aatcgggaga 2580
acattatgaa ctgcatcttt tgcactacct tcaagaaaac cttggatcac gtattgctgc 2640
tctaaaagtg atatgagcgg ccgcgagctc c 2671

```

```

<210> 3
<211> 863
<212> PRT
<213> Homo sapiens
<400> 3

```

```

Met Ala Thr Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala
1      5      10      15
Thr Asp Asp Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp
20     25     30
Gly Leu Arg Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile
35     40     45
Val Asn Lys Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu
50     55     60
Ser Gly Pro His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly
65     70     75     80
Ser Arg Glu Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg
85     90     95
Lys Glu Ala Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe
100    105    110
Gln Ala Thr Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu
115    120    125
Arg Glu Arg Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe
130    135    140
His Ser Glu Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe
145    150    155    160
His Cys Arg Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys
165    170    175
Pro Leu Glu Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys
180    185    190
Ile Cys Pro Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp
195    200    205
Leu Trp Val Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe
210    215    220
Cys His Gln Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly
225    230    235    240
Val Ala Thr Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr
245    250    255
Trp Trp Cys Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr
260    265    270
Leu Arg Ile Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile
275    280    285
His Val Pro Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg
290    295    300
Tyr Pro Arg Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala
305    310    315    320

```

Glu	Phe	Gln	Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys
				325					330					335	
Glu	Leu	Val	Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile
			340					345					350		
Ala	Arg	Ala	Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe
		355					360					365	-		
Leu	Asp	Arg	Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala
	370					375				380					
Leu	Phe	Ile	Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala
	385				390					395				400	
Arg	Ala	Val	Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val
			405						410				415		
Thr	Asn	Val	Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln
		420						425					430		
Ser	Glu	Gly	Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys
	435						440					445			
Thr	Gly	Phe	Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln
	450					455					460				
Gly	Tyr	Asp	Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys
	465				470					475				480	
Cys	Pro	Ile	Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val
			485						490				495		
Leu	Ala	Arg	His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu
		500						505					510		
Val	Tyr	Phe	Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr
	515						520					525			
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro
	530					535					540				
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val
	545				550					555				560	
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys
			565					570					575		
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp
		580						585					590		
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro
		595					600					605			
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met
	610					615					620				
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val
	625				630					635				640	
Leu	Phe	Val	Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe
			645						650				655		
Lys	Gly	Ile	Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr
			660					665					670		
Ala	Val	Val	Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg
		675					680					685			
Phe	Glu	Gly	Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp
	690					695					700				
Gln	Val	Glu	Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp
	705				710					715				720	
Leu	Ser	Arg	Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser
			725						730				735		
Leu	Met	Gly	Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Val	Ala	Ile	Ala
		740						745					750		
Gly	Ala	Pro	Val	Thr	Val	Trp	Met	Ala	Tyr	Asp	Thr	Gly	Tyr	Thr	Glu
		755					760					765			

Arg	Tyr	Met	Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly
770						775					780				
Ser	Val	Ala	Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu
785					790					795					800
Leu	Ile	Leu	His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	Phe	His	Thr
			805						810					815	
Asn	Phe	Leu	Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu
		820						825					830		
Gln	Ile	Tyr	Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly
	835					840					845				
Glu	His	Tyr	Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu	
850						855					860				

<210> 4  
 <211> 2617  
 <212> DNA  
 <213> Homo sapiens  
 <400> 4

caagcttacc	atggccacca	ccgggacccc	aacggccgac	cgaggcgacg	cagccgccac	60
agatgaccgc	gccgcccgc	tccaggtgca	gaagcactcg	tgggacgggc	tccggagcat	120
catccacggc	agccgcaagt	actcgggcct	cattgtcaac	aaggcgcccc	acgacttcca	180
gtttgtgcag	aagacggatg	agtctgggccc	ccactcccac	cgctctact	acctgggaat	240
gccatatggc	agccgagaga	actccctcct	ctactctgag	attcccaaga	aggtccggaa	300
agaggctctg	ctgctcctgt	cctggaagca	gatgctggat	catttccagg	ccacgccccca	360
ccatgggggc	tactctcggg	aggaggagct	gctgagggag	cggaaacgcc	tgggggtctt	420
cggcatcacc	tcctacgact	tccacagcga	gattggcctc	ttcctcttcc	aggccaagaa	480
cagcctcttc	cactgtcgcg	acggcgccaa	gaacggcttc	atggtgtccc	ctatgaaacc	540
gctggaaatc	aagaccagct	gctcagggcc	ccgatgggac	cccaaatct	gccctgccga	600
ccctgccttc	ttctccttca	tcaataacag	cgactgtgg	gtggccaaca	tcgagacagg	660
cgaggagcgg	cggctgacct	tctgccacca	aggtttatcc	aatgtcctgg	atgaccccaa	720
gtctgccccg	gtggccacct	tcgatcataca	ggaagagttc	gaccgcttca	ctgggtactg	780
gtggtgcccc	acagcctcct	gggaagggtc	agagggcctc	aagacgctgc	gaatctgtga	840
tgaggaagtc	gactcgatcc	aggtggagggt	gattcacgtc	ccctctcctg	cgctagaaga	900
aaggaagacg	gactcgatcc	ggtaccccag	gacaggcagc	aagaatccca	agattgcctt	960
gaaactggct	gagttccaga	ctgacagcca	gggcaagatc	gtctcgaccc	aggagaagga	1020
gctggtgcag	cccttcagct	cgctgttccc	gaagggtggag	tacatcgcca	gggcccgggtg	1080
gacccgggat	ggcaaatatc	cctggggccat	gttctctggac	cggccccagc	agtggctcca	1140
gctcgtcctc	ctcccccccg	ccctgttcat	cccagacaca	gagaatgagg	agcagcggtc	1200
agcctctgcc	agagctgtcc	ccaggaatgt	ccagccgtat	gtggtgtacg	aggaggtcac	1260
caacgtctgg	atcaatgttc	atgacatctt	ctatcccttc	ccccaatcag	aggagagga	1320
cgagctctgc	tttctccgcg	ccaatgaatg	caagaccggc	ttctgccatt	tgtacaaagt	1380
caccgccgtt	ttaaaatccc	agggtacaga	ttggagtgg	cccttcagcc	ccggggaaga	1440
tgaatttaag	tgccccatta	aggaagagat	tgctctgacc	agcggatgaat	gggaggtttt	1500
ggcgaggcac	ggctccaaga	tctgggtcaa	tgaggagacc	aagctggtgt	acttccaggg	1560
caccaaggac	acgccgctgg	agcaccacct	ctacgtggtc	agctatgagg	cggccggcga	1620
gatcgtacgc	ctcaccacgc	ccggttctc	ccatagctgc	tccatgagcc	agaacttcga	1680
catgttcgtc	agccactaca	gcagcgtgag	cacgccgccc	tgctgacacg	tctacaagct	1740
gagcgccccc	gacgacgacc	ccctgcacaa	gcagccccgc	ttctgggcta	gcatgatgga	1800
ggcagccagc	tgcccccccg	attatgttcc	tccagagatc	ttccatttcc	acacgcgctc	1860
ggatgtgcgg	ctctacggca	tgatctacaa	gccccacgcc	ttgcagccag	ggaagaagca	1920
ccccaccgtc	ctctttgtat	atggaggccc	ccaggtgcag	ctggtgaata	actccttcaa	1980
aggcatcaag	tacttgccgc	tcaacacact	ggctccctcg	ggctacgccg	tggttgtgat	2040
tgacggcagg	ggctcctgtc	agcaggggct	tcggttcgaa	ggggccctga	aaaaccaa	2100
ggggccagggtg	gagatcgagg	accaggtgga	gggcctgcag	ttcgtggccg	agaagtatgg	2160
cttcacgcag	ctgagccgag	ttgccatcca	tggttggtcc	tacgggggct	tcctctcgct	2220
catggggcta	atccacaagc	cccaggtgtt	caaggtggcc	atcgcggtg	ccccggtcac	2280
cgtctggatg	gcctacgaca	cagggtacac	tgagcgctac	atggacgtcc	ctgagaacaa	2340
ccagcacggc	tatgaggcgg	gttccgtggc	cctgcacgtg	gagaagctgc	ccaatgagcc	2400
caaccgcttg	cttatcctcc	acggcttctc	ggacgaaaac	gtgcactttt	tccacacaaa	2460

```

cttcctcgtc tcccaactga tccgagcagg gaaaccttac cagctccaga tctaccccaa 2520
cgagagacac agtattcgct gccccgagtc gggcgagcac tatgaagtca cggtgctgca 2580
ctttctacag gaatacctct gagcggccgc ggatccg 2617

```

```

<210> 5
<211> 796
<212> PRT
<213> Homo sapiens
<400> 5

```

```

Met Asn Gln Thr Ala Ser Val Ser His His Ile Lys Cys Gln Pro Ser
1          5          10          15
Lys Thr Ile Lys Glu Leu Gly Ser Asn Ser Pro Pro Gln Arg Asn Trp
20          25          30
Lys Gly Ile Ala Ile Ala Leu Leu Val Ile Leu Val Val Cys Ser Leu
35          40          45
Ile Thr Met Ser Val Ile Leu Leu Ser Pro Asp Glu Leu Thr Asn Ser
50          55          60
Ser Glu Thr Arg Leu Ser Leu Glu Asp Leu Phe Arg Lys Asp Phe Val
65          70          75          80
Leu His Asp Pro Glu Ala Arg Trp Ile Asn Asp Thr Asp Val Val Tyr
85          90          95
Lys Ser Glu Asn Gly His Val Ile Lys Leu Asn Ile Glu Thr Asn Ala
100         105         110
Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe Val Thr Phe Lys Ala Ser
115         120         125
Arg His Ser Val Ser Pro Asp Leu Lys Tyr Val Leu Leu Ala Tyr Asp
130         135         140
Val Lys Gln Ile Phe His Tyr Ser Tyr Thr Ala Ser Tyr Val Ile Tyr
145         150         155         160
Asn Ile His Thr Arg Glu Val Trp Glu Leu Asn Pro Pro Glu Val Glu
165         170         175
Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly Val Gln Gly Gln Gln Leu
180         185         190
Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr Gln Pro Asp Ile Lys Ser
195         200         205
Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys Glu Glu Ile Ile Phe Asn
210         215         220
Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu Leu His Ser His Ile
225         230         235         240
Ala His Trp Trp Ser Pro Asp Gly Glu Arg Leu Ala Phe Leu Met Ile
245         250         255
Asn Asp Ser Leu Val Pro Thr Met Val Ile Pro Arg Phe Thr Gly Ala
260         265         270
Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr Pro Lys Ala Gly Gln Val
275         280         285
Asn Pro Thr Ile Lys Leu Tyr Val Val Asn Leu Tyr Gly Pro Thr His
290         295         300
Thr Leu Glu Leu Met Pro Pro Asp Ser Phe Lys Ser Arg Glu Tyr Tyr
305         310         315         320
Ile Thr Met Val Lys Trp Val Ser Asn Thr Lys Thr Val Val Arg Trp
325         330         335
Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu Thr Val Cys Glu Thr Thr
340         345         350
Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met Thr Ser Asp Thr Trp Leu
355         360         365
Ser Gln Gln Asn Glu Glu Pro Val Phe Ser Arg Asp Gly Ser Lys Phe
370         375         380
Phe Met Thr Val Pro Val Lys Gln Gly Gly Arg Gly Glu Phe His His
385         390         395         400

```

Ile Ala Met Phe Leu Ile Gln Ser Lys Ser Glu Gln Ile Thr Val Arg  
 405 410 415  
 His Leu Thr Ser Gly Asn Trp Glu Val Ile Lys Ile Leu Ala Tyr Asp  
 420 425 430  
 Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser Thr Glu Ser Ser Pro Arg  
 435 440 445  
 Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu Gly Leu Leu Asn Arg Gln  
 450 455 460  
 Cys Ile Ser Cys Asn Phe Met Lys Glu Gln Cys Thr Tyr Phe Asp Ala  
 465 470 475 480  
 Ser Phe Ser Pro Met Asn Gln His Phe Leu Leu Phe Cys Glu Gly Pro  
 485 490 495  
 Arg Val Pro Val Val Ser Leu His Ser Thr Asp Asn Pro Ala Lys Tyr  
 500 505 510  
 Phe Ile Leu Glu Ser Asn Ser Met Leu Lys Glu Ala Ile Leu Lys Lys  
 515 520 525  
 Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu His Ile Asp Asp Tyr Glu  
 530 535 540  
 Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp Phe Met Asp Arg Asn Gln  
 545 550 555 560  
 Tyr Ala Leu Leu Leu Ile Met Asp Glu Glu Pro Gly Gly Gln Leu Val  
 565 570 575  
 Thr Asp Lys Phe His Ile Asp Trp Asp Ser Val Leu Ile Asp Met Asp  
 580 585 590  
 Asn Val Ile Val Ala Arg Phe Asp Gly Arg Gly Ser Gly Phe Gln Gly  
 595 600 605  
 Leu Lys Ile Leu Gln Glu Ile His Arg Arg Leu Gly Ser Val Glu Val  
 610 615 620  
 Lys Asp Gln Ile Thr Ala Val Lys Phe Leu Leu Lys Leu Pro Tyr Ile  
 625 630 635 640  
 Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys Gly Tyr Gly Gly Tyr Ile  
 645 650 655  
 Ala Ser Met Ile Leu Lys Ser Asp Glu Lys Leu Phe Lys Cys Gly Ser  
 660 665 670  
 Val Val Ala Pro Ile Thr Asp Leu Lys Leu Tyr Ala Ser Ala Phe Ser  
 675 680 685  
 Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu Glu Ser Thr Tyr Gln Ala  
 690 695 700  
 Ala Ser Val Leu His Asn Val His Gly Leu Lys Glu Glu Asn Ile Leu  
 705 710 715 720  
 Ile Ile His Gly Thr Ala Asp Thr Lys Val His Phe Gln His Ser Ala  
 725 730 735  
 Glu Leu Ile Lys His Leu Ile Lys Ala Gly Val Asn Tyr Thr Met Gln  
 740 745 750  
 Val Tyr Pro Asp Glu Gly His Asn Val Ser Glu Lys Ser Lys Tyr His  
 755 760 765  
 Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser Asp Cys Leu Lys Glu Glu  
 770 775 780  
 Ile Ser Val Leu Pro Gln Glu Pro Glu Glu Asp Glu  
 785 790 795

<210> 6  
 <211> 2583  
 <212> DNA  
 <213> Homo sapiens  
 <400> 6

gcctgggatt gtgcactgtc cagggtcctg aaacatgaac caaactgccca gcgtgtccca 60  
 tcacatcaag tgtcaaccct caaaaacaat caaggaactg ggaagtaaca gccctccaca 120  
 gagaaactgg aagggaattg ctattgctct gctggtgatt ttagttgtat gctcactcat 180

```

cactatgtca gtcacacctc taagcccaga tgaactcaca aattcgtcag aaaccagatt 240
gtctttggaa gacctcttta ggaaagactt tgtgcttcac gatccagagg ctcggtggat 300
caatgataca gatgtggtgt ataaaagcga gaatggacat gtcattaaac tgaatataga 360
aacaatgctt accacattat tattggaaaa cacaactttt gtaaccttca aagcatcaag 420
acattcagtt tcaccagatt taaaatatgt ccttctggca tatgatgtca aacagatttt 480
tcattattcg tatactgctt catatgtgat ttacaacata cacactaggg aagtttggga 540
gttaaatacct ccagaagtag aggactccgt cttgcagtac gcggcctggg gtgtccaagg 600
gcagcagctg atttatatatt ttgaaaataa tatctactat caacctgata taaagagcag 660
ttcattgcca ctgacatctt ctggaaaaga agaaataatt ttaaatggga ttgctgactg 720
gttatatgaa gaggaactcc tgcattctca catcgcccac tgggtggtcac cagatggaga 780
aagacttgcc ttctgatga taaatgactc ttgtgtacct accatgggta tccctcggtt 840
tactggagcg ttgtatccca aaggaaagca gtatccgtat cctaaggcag gtcaagtga 900
cccaacaata aaattatatg ttgtaaacct gtatggacca actcacactt tggagctcat 960
gccacctgac agcttttaaat caagagaata ctatatcact atggttaaat gggtaagcaa 1020
taccaagact gtggttaagat ggtaaaaccg acctcagaac atctccatcc tcacagtctg 1080
tgagaccact acaggtgctt gtagtaaaaa atatgagatg acatcagata cgtggctctc 1140
tcagcagaat gaggagcccg tgttttctag agacggcagc aaattcttta tgacagtgcc 1200
tggttaagcaa gggggacgtg gagaatttca ccacatagct atgttcctca tccagagtaa 1260
aagttagcaa attaccgtgc ggcatctgac atcaggaaac tgggaagtga taaagatctt 1320
ggcatacgat gaaactactc aaaaaattta cttcttgagc actgaatctt ctcccagagg 1380
aaggcagctg tacagtgcct ctactgaagg attattgaat cgccaatgca tttcatgtaa 1440
tttcatgaaa gaacaatgta catattttga tgccagtttt agtcccatga atcaacattt 1500
cttattattc tgtgaagggt caaggggtccc agtgggtcagc ctacatagta cggacaaccc 1560
agcaaaatat tttatatattg aaagcaattc tatgctgaag gaagctatcc tgaagaagaa 1620
gataggaaag ccagaaatta aaatccttca tattgacgac tatgaacttc ctttacagtt 1680
gtcccttccc aaagatttta tggaccgaaa ccagtatgct cttctgttaa taatggatga 1740
agaaccagga ggccagctgg ttacagataa gttccatatt gactgggatt ccgtactcat 1800
tgacatggat aatgtcattg tagcaagatt tgatggcaga ggaagtggat tccaggtct 1860
gaaaattttg caggagattc atcgaagatt aggttcagta gaagtaaagg accaaataac 1920
agctgtgaaa tttttgctga aactgcctta cattgactcc aaaagattaa gcatttttgg 1980
aaagggttat ggtggctata ttgcatcaat gatcttaaaa tcagatgaaa agctttttta 2040
atgtggatcc gtggttgccat ctatcacaga cttgaaattg tatgctcag ctttctctga 2100
aagatacctt gggatgccat ctaaggaaga aagcacttac caggcagcca gtgtgtaca 2160
taatgttcat ggcttgaaag aagaaaatat attcaataat catggaaactg ctgacacaaa 2220
agttcatttc caacactcag cagaattaat caagcaccta ataaaagctg gagtgaatta 2280
tactatgcag gtctaccag atgaagggtc taacgtatct gagaagagca agtatcatct 2340
ctacagcaca atcctcaaat tcttcagtga ttgtttgaag gaagaaatat ctgtgctacc 2400
acaggaacca gaagaagatg aataatggac cgtatttata cagaactgaa gggaaatattg 2460
aggctcaatg aaacctgaca aagagactgt aatattgtag ttgctccaga atgtcaaggg 2520
cagcttacgg agatgtcact ggagcagcac gtcagagac agtgaactag catttgaata 2580
cac

```

```

<210> 7
<211> 690
<212> PRT
<213> Homo sapiens
<400> 7

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85          90          95

```

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
 180 185 190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
 195 200 205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
 210 215 220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
 225 230 235 240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
 245 250 255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
 260 265 270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
 275 280 285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
 290 295 300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
 305 310 315 320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
 325 330 335  
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe  
 340 345 350  
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr  
 355 360 365  
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr  
 370 375 380  
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu  
 385 390 395 400  
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser  
 405 410 415  
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn  
 420 425 430  
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile  
 435 440 445  
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr  
 450 455 460  
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly  
 465 470 475 480  
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile  
 485 490 495  
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn  
 500 505 510  
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys  
 515 520 525  
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro  
 530 535 540  
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys  
 545 550 555 560  
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys  
 565 570 575



Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp  
 580 585 590  
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala  
 595 600 605  
 Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser  
 610 615 620  
 Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu  
 625 630 635 640  
 Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Arg  
 645 650 655  
 Leu Leu Leu Leu Gly Pro Gln Ser Leu Cys Gly Ser Ser Met Ile Gln  
 660 665 670  
 Asp Thr Arg Asn Val Ile Trp Val Thr Leu Thr Arg Met Asn Arg Ala  
 675 680 685  
 Ile Thr  
 690

<210> 8  
 <211> 4523  
 <212> DNA  
 <213> Homo sapiens  
 <400> 8

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgct	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtgaggcg	ggcgagcat	gaagcggcgc	aggcccgctc	catagcgcac	gtcgggacgg	180
tccggggcgg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcgagc	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaatc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgtctctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtgga	720
atztatcag	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atttgatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattgggtg	1020
tgtccaaaag	ctgaaacaac	tccagtggtt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgcct	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgccatgatt	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggaataata	tccatgacat	ctttcatggt	tttccccaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataata	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtggatgaat	gggaagttct	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctgggat	atthtgaagg	caccaaagac	1800
tcccccttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatcagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040
cctcttctcg	actatactcc	tccagaaatt	ttctcttttg	aaagtactac	tggtattaca	2100
ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	gaaagaaata	tcctactgtg	2160

```

ctgttcatat atggtggctg gttgctattg ctggggcccc agtcactctg tggatcttct 2220
atgatacagg atacacggaa cgttatatgg gtcaccctga ccagaatgaa cagggtctatt 2280
acttaggatc tgtggccatg caagcagaaa agttcccctc tgaaccaa at cgtttactgc 2340
tcttacatgg tttcctggat gagaatgtcc attttgcaca taccagtata ttactgagtt 2400
ttttagttag ggctggaaag ccatatgatt tacagatcta tcctcaggag agacacagca 2460
taagagttcc tgaatcgga gaacattatg aactgcactt tttgcactac cttcaagaaa 2520
accttggatc acgtattgct gctctaaaag tgatataatt ttgacctgtg tagaactctc 2580
tgggtatacac tggctatttta accaaatgag gaggtttaat caacagaaaa cacagaattg 2640
atcatcacat tttgatacct gccatgtaac atctactcct gaaaataaat gtgggtccat 2700
gcaggggtct acgggtttgtg gtagtaatct aataccttaa ccccatgc tcaaaatcaa 2760
atgatacata ttctgagag acccagcaat accataagaa ttactaaaaa aaaaaaaaaa 2820
aaaaagacat tagcaccatg tattcatact accctatttt cactttta at agtattataa 2880
acttcatgaa cttaattagt gtatttttac agtatacttt tgagtttggt aaaatatgat 2940
gatatttagt attggtttgg ttcagttcca gaatctttga ctagttagag atttgatagc 3000
acttaa atgt aattgaatag cttatgcttc attgcttggg catatccagc atgttatgaa 3060
ctaataacta ttaaacttga ctttaaccagt cattcattaa taatttttca aggataactt 3120
agtggcctcc taaagacact tgttttggca ctgaccagtt tttagccaat ttaactctgta 3180
tctagtataa ataattctca tttttctttg atgatattaa cagagtgggc ttttctttt 3240
gcataaaggc tagtaactgt atatgtagca tggattta at tagtcatgat attgataatt 3300
acaggcagaa aattttta at caaatgatta gagcttaaat atttgcaggc aagttttttt 3360
ttttctttta agaaaaggaa aaagtacaca ttcactagaa ttcttcagaa aatttagtgg 3420
tgccagtttc catttggtat ttccttatta aaatattcta gaattttaag gagattgaag 3480
ggaatcacag tgggggtggg agacctgggt ttggggaatg acagagagaa gaggtggtga 3540
gggcctgatt aaaaactaag cagaagtagt ttaacaaaa atactcatga aaatgtttgg 3600
aaactgaa at ttaaacact gtaatattaa ggaaaccaga atcaataaat cactgtcttg 3660
ccagcacagc tacagagtaa catgattcag gggaggaaaa gttccttaga gttactttta 3720
taattctttt ttttttctct cttaggttta gaaatcttac aaatttaa ac tttatccttt 3780
taaaattatt tgaacataat ttagatattg taagcttaaa atacaaatgt ttatagataa 3840
cctctttacc ataaactaat cctggcaag ccatggctct cttttttttt ttggtgttta 3900
aagcctgtaa acagtttttc tgaatgatca tgaacttttc ttggttttagc actaggattt 3960
agctatgaag agagctcata ggctttcagg tgctaattga gatctgccct gttagagtct 4020
tggggtgcta gattggtcac attgacacca gtggcaggga aggcactat gagtttgatg 4080
ctttttatca cacacttcag tgtttagaaa gttattacca atacttttaa acaactcc 4140
aagaaaattt gctatatctt tttctcatca ctacagagag agtagatttc cccatagaga 4200
gcacagcctc cattagtaag gttggtgact attggttaaga ggtggacttc attgacacca 4260
agtgggaggt agggaaagcc cagaaatggc aggatgatat ggtggttctg tcgttgggaa 4320
aggattggg ttttgctggt tgtatttata ctgtataata gataccacgc tttttcttat 4380
tatctgtata tgtattgctt ttcatgtttg atattttccc atgccaaatg ttgtttatat 4440
atattttcaa tgttaaatta aattgatttg ggtaactttc ttcccaaga aagtattttc 4500
ccccttaagt ataaatctga ctg 4523

```

```

<210> 9
<211> 241
<212> PRT
<213> Homo sapiens
<400> 9

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85          90          95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu

```

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5					10					15	
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
			20					25					30		
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu

	35					40					45					
Leu	Ala	Asp	Thr	Arg	Lys	Tyr	His	Gly	Tyr	Met	Met	Ala	Lys	Ala	Pro	
	50					55					60					
His	Asp	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser	
65					70					75					80	
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr	
				85					90					95		
Leu	Phe	Tyr	Ser	Glu	Ile	Pro	Lys	Thr	Ile	Asn	Arg	Ala	Ala	Val	Leu	
			100					105					110			
Met	Leu	Ser	Trp	Lys	Pro	Leu	Leu	Asp	Leu	Phe	Gln	Ala	Thr	Leu	Asp	
		115				120						125				
Tyr	Gly	Met	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	Lys	Arg	
	130					135					140					
Ile	Gly	Thr	Val	Gly	Ile	Ala	Ser	Tyr	Asp	Tyr	His	Gln	Gly	Ser	Gly	
145					150					155					160	
Thr	Phe	Leu	Phe	Gln	Ala	Gly	Ser	Gly	Ile	Tyr	His	Val	Lys	Asp	Gly	
				165					170					175		
Gly	Pro	Gln	Gly	Phe	Thr	Gln	Gln	Pro	Leu	Arg	Pro	Asn	Leu	Val	Glu	
			180					185					190			
Thr	Ser	Cys	Pro	Asn	Ile	Arg	Met	Asp	Pro	Lys	Leu	Cys	Pro	Ala	Asp	
		195					200					205				
Pro	Asp	Trp	Ile	Ala	Phe	Ile	His	Ser	Asn	Asp	Ile	Trp	Ile	Ser	Asn	
	210					215					220					
Ile	Val	Thr	Arg	Glu	Glu	Arg	Arg	Leu	Thr	Tyr	Val	His	Asn	Glu	Leu	
225					230						235				240	
Ala	Asn	Met	Glu	Glu	Asp	Ala	Arg	Ser	Ala	Gly	Val	Ala	Thr	Phe	Val	
				245					250					255		
Leu	Gln	Glu	Glu	Phe	Asp	Arg	Tyr	Ser	Gly	Tyr	Trp	Trp	Cys	Pro	Lys	
			260					265					270			
Ala	Glu	Thr	Thr	Pro	Ser	Gly	Gly	Lys	Ile	Leu	Arg	Ile	Leu	Tyr	Glu	
		275					280					285				
Glu	Asn	Asp	Glu	Ser	Glu	Val	Glu	Ile	Ile	His	Val	Thr	Ser	Pro	Met	
	290					295					300					
Leu	Glu	Thr	Arg	Arg	Ala	Asp	Ser	Phe	Arg	Tyr	Pro	Lys	Thr	Gly	Thr	
305					310					315					320	
Ala	Asn	Pro	Lys	Val	Thr	Phe	Lys	Met	Ser	Glu	Ile	Met	Ile	Asp	Ala	
				325						330				335		
Glu	Gly	Arg	Ile	Ile	Asp	Val	Ile	Asp	Lys	Glu	Leu	Ile	Gln	Pro	Phe	
			340					345					350			
Glu	Ile	Leu	Phe	Glu	Gly	Val	Glu	Tyr	Ile	Ala	Arg	Ala	Gly	Trp	Thr	
			355				360					365				
Pro	Glu	Gly	Lys	Tyr	Ala	Trp	Ser	Ile	Leu	Leu	Asp	Arg	Ser	Gln	Thr	
	370					375					380					
Arg	Leu	Gln	Ile	Val	Leu	Ile	Ser	Pro	Glu	Leu	Phe	Ile	Pro	Val	Glu	
385					390					395						

515	520	525
Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro		
530	535	540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys		
545	550	555
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys		
565	570	575
Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp		
580	585	590
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala		
595	600	605
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser		
610	615	620
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu		
625	630	635
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Leu		
645	650	655
Leu Arg Cys Ser Trp		
660		

<210> 12  
 <211> 4829  
 <212> DNA  
 <213> Homo sapiens  
 <400> 12

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgct	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtgagggc	ggcgagcat	gaagcgccgc	aggcccgctc	catagcgcac	gtcgggacgg	180
tccgggaggc	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tggtgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggtcatatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggaacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaagggaag	ggaacatttc	tgtttcaagc	cggtagtggg	720
atztatcag	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagtgtgtc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttatata	tagcaacgat	atgtggatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattgggtg	1020
tgtccaaaag	ctgaaacaac	tcccagtggg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacagg	acagcaaatc	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaa	atgcttggtc	cactctacta	gategctccc	agactcgcct	acagatagt	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgctgtatcc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttcccaaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacagg	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaatataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagttct	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctggtat	attttgaagg	caccaaagac	1800
tcccctttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatcagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040

```

cctcttctctg actatactcc tccagaaatt ttctcttttg aaagtactac tggattttaca 2100
ttgtatggga tgctctacaa gcctcatgat ctacagcctg gaaagaaata tcctactgtg 2160
ctgttcatat atggtggtct cctcaggtgc agttggtgaa taatcggttt aaaggagtca 2220
agtatttccg cttgaatacc ctacgctctc taggttatgt ggttgtagtg atagacaaca 2280
ggggatcctg tcaccgaggg cttaaatttg aaggcgctt taaatataaa atgggtcaaa 2340
tagaaattga cgatcaggtg gaaggactcc aatatctagc ttctcgatat gatttcattg 2400
acttagatcg tgtgggcac cagggctggt cctatggagg atacctctcc ctgatggcat 2460
taatgcagag gtcagatata ttcagggttg ctattgctgg ggccccagtc actctgtgga 2520
tcttctatga tacaggatac acggaacggt atatgggtca ccctgaccag aatgaacagg 2580
gctattactt aggatctgtg gccatgcaag cagaaaagtt cccctctgaa ccaaactcgt 2640
tactgctctt acatgggttt ctggatgaga atgtccattt tgcacatacc agtatattac 2700
tgagtttttt agtgagggct ggaaagccat atgatttaca gatctatcct caggagagac 2760
acagcataag agttcctgaa tcgggagAAC attatgaact gcactctttg cactaccttc 2820
aagaaaacct tggatcacgt attgctgctc taaaagtgat ataattttga cctgtgtaga 2880
actctctggt atacactggc tatttaacca aatgaggagg tttaatcaac agaaaacaca 2940
gaattgatca tcacattttg atacctgcca tgtaacatct actcctgaaa ataatgtgg 3000
tgccatgcag gggctctacgg tttgtggtag taatctaata ccttaacccc acatgctcaa 3060
aatcaaatga tacatattcc tgagagaccc agcaatacca taagaattac taaaaaaaaa 3120
aaaaaaaaaa agacattagc accatgtatt catactaccc tatttttact tttaatagta 3180
ttataaactt catgaactta attagtgtat ttttaccagta tacttttgag tttgttaaaa 3240
tatgatgata ttagttagtg gtttggttca gttccagaat ctttgactag ttacagattt 3300
gatagcactt aaatgtaatt gaatagctta tgcttcattg cttgggcata tccagcatgt 3360
tatgaactaa taactattaa acttgactta accagtcatt cattaataat ttttcaagga 3420
taacttagtg gcctcctaaa gacacttgtt ttggcactga ccagttttta gccaatttta 3480
tctgtatcta gtataaataa ttctcatttt tctttgatga tattaacaga gtgggctttt 3540
ccttttgcac aaaggctagt aactgtatat gtagcatgga tttaattagt catgatattg 3600
ataattacag gcagaaaatt tttaatcaaa tgattagagc ttaaatattt gcaggcaagt 3660
tttttttttt cctttaagaa aaggaaaaag tacacattca ctagaattct tcagaaaatt 3720
tagtggtgcc agtttccatt tggattttcc ttattaaaat attctagaat tttaaggaga 3780
ttgaagggaa tcacagtggg gtggggagac ctgggttttg ggaatgacag agagaagagg 3840
tggtgagggc ctgattaaaa actaagcaga agtagtttta acaaaaatac tcatgaaaat 3900
gtttggaaac tgaaatttaa acaactgtaa tattaaggaa accagaatca ataatcact 3960
gtcttgccag cacagctaca gagtaacatg attcagggga ggaaaagttc cttagagtta 4020
cttttataat tctttttttt tttcctctta ggtttagaaa tcttaciaat ttaaacttta 4080
tccttttaaa attattgaa cataatttag atattgtaag cttaaaatac aaatgtttat 4140
agataaccto tttaccataa actaatccct ggcaagccat ggctctcttt ttttttttg 4200
tgtttaagc ctgtaaacag tttttctgaa tgatcatgaa cttttcttggt tttagcacta 4260
ggatttagct atgaagagag ctcataggct ttcaggtgct aattgagatc tgccctgtta 4320
gagctctggg gtgctagatt ggtcacattg acaccagtgg cagggaaggc atctatgagt 4380
ttgatgcttt ttatcacaca cttcagtgtt tagaaagtta ttaccaatac ttttaacaa 4440
cactccaaga aaatttgcta tatttctttc tcatcactac agagagagta gatttcccca 4500
tagagagcac agcctccatt agtaaggttg gtgactattg gtaagagggt gacttcattg 4560
acaccaagtg ggagtaggg aaagcccaga aatggcagga tgatatggtg gttctgtcgt 4620
tgggaaaggt attgggtttt gctggttgta tttatactgt ataatagata ccacgctttt 4680
tcttattatc tgtatatgta ttgcttttca tgtttgatat tttcccatgc caagatttgt 4740
ttatatatat tttcaatgtt aaattaaatt gatttgggta actttcttcc ccaagaaagt 4800
attttccccc ttaagtataa atctgactg 4829

```

```

<210> 13
<211> 358
<212> PRT
<213> Homo sapiens
<400> 13

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1           5           10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35          40          45

```

Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
 50 55 60  
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
 65 70 75 80  
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr  
 85 90 95  
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
 180 185 190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
 195 200 205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
 210 215 220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
 225 230 235 240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
 245 250 255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
 260 265 270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
 275 280 285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
 290 295 300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
 305 310 315 320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
 325 330 335  
 Glu Gly Arg Ser Lys Leu Met Lys Ser Glu Gly Trp Tyr Ile Leu Lys  
 340 345 350  
 Ala Pro Lys Thr Pro Leu  
 355

<210> 14  
 <211> 4309  
 <212> DNA  
 <213> Homo sapiens  
 <400> 14

aagtgctaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtggaggg	ggcgagcat	gaagcggcgc	aggcccgcctc	catagcgcac	gtcgggacgg	180
tccgggcccgg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtggtg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tggtgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggtacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggaacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtccttaa	tgctctcttg	gaagcctctt	tggatccttt	tcagggaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaagggaag	ggaacatttc	tgtttcaagc	cggtagtggg	720
atztatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780

ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	ctttttatata	tagcaacgat	atttggatat	ctaacatcgt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaadc	ctaaagtcac	ttttaagatg	1200
tcagaaaata	tgattgatgc	tgaaggaaga	tccaagttga	tgaagtcaga	aggctgggtat	1260
atthttgaagg	caccaaagac	tcccccttag	agcatcacct	gtacgtagtc	agttacgtaa	1320
atcctggaga	ggtgacaagg	ctgactgacc	gtggctactc	acattcttgc	tgcatcagtc	1380
agcactgtga	cttctttata	agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	1440
tttacaagct	atcaagtcct	gaagatgacc	caacttgcaa	aacaaaggaa	ttttgggcca	1500
ccattttgga	ttcagcaggt	cctcttctcg	actatactcc	tccagaaatt	ttctcttttg	1560
aaagtactac	tggattttaca	ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	1620
gaaagaaata	tcctactgtg	ctgttcatat	atggtgggtc	cctcaggtgc	agttggtgaa	1680
taatcggttt	aaaggagtca	agtatttccg	cttgaatacc	ctagcctctc	taggttatgt	1740
ggttgtagtg	atagacaaca	ggggatcctg	tcaccgaggg	cttaaatthg	aaggcgcctt	1800
taaatataaa	atgggtcaaa	tagaaattga	cgtacaggtg	gaaggactcc	aatatctagc	1860
ttctcgatat	gatttcattg	acttagatcg	tgtgggcatc	cacggctggg	cctatggagg	1920
atacctctcc	ctgatggcat	taatgcagag	gtcagatata	ttcaggggtg	ctattgctgg	1980
ggccccagtc	actctgtgga	tcttctatga	tacaggatac	acggaacggt	atatgggtca	2040
ccctgaccag	aatgaacagg	gctattactt	aggatctgtg	gccatgcaag	cagaaaagtt	2100
cccctctgaa	ccaaatcgtt	tactgtctct	acatgggtttc	ctggatgaga	atgtccattt	2160
tgcacatacc	agtatattac	tgagtttttt	agtgagggct	ggaaagccat	atgatttaca	2220
gatctatcct	caggagagac	acagcataag	agttcctgaa	tcgggagAAC	attatgaact	2280
gcactctttg	cactaccttc	aagaaaacct	tggatcacgt	attgtctgtc	taaaagtgat	2340
ataattttga	cctgtgtaga	actctctggg	atacactggc	tatttaacca	aatgaggagg	2400
tttaatcaac	agaaaacaca	gaattgatca	tcacattttg	atacctgcca	tgtaacatct	2460
actcctgaaa	ataaatgtgg	tgccatgcag	gggtctacgg	tttgtggtag	taatctaata	2520
ccttaacccc	acatgctcaa	aatcaaatga	tacatattcc	tgagagaccc	agcaatacca	2580
taagaattac	taaaaaaaaa	aaaaaaaaaa	agacattagc	accatgtatt	catactaccc	2640
tattttcact	tttaatagta	ttataaaactt	catgaactta	attagtgtat	ttttacagta	2700
tacttttgag	tttggttaaaa	tatgatgata	tatgtgattg	gtttgggttca	gttccagaat	2760
ctttgactag	ttacagattt	gatagcactt	aaatgtaatt	gaatagctta	tgcttcattg	2820
cttgggcata	tccagcatgt	tatgaactaa	taactattaa	acttgactta	accagtcatt	2880
cattaataat	ttttcaagga	taacttagtg	gcctcctaaa	gacacttggt	ttggcactga	2940
ccagttttta	gccaattttaa	tctgtatcta	gtataaataa	ttctcatttt	tctttgatga	3000
tattaacaga	gtgggctttt	ccttttgcag	aaaggctagt	aactgtatat	gtagcatgga	3060
tttaattagt	catgatattg	ataattacag	gcagaaaatt	tttaatcaaa	tgattagagc	3120
ttaaataatt	gcaggcaagt	tttttttttt	cctttaagaa	aaggaaaaag	tacacattca	3180
ctagaattct	tcagaaaatt	tagtgggtgcc	agtttccatt	tggtatttcc	ttattaaaat	3240
attctagaat	tttaaggaga	ttgaagggaa	tcacagtggt	gtggggagac	ctgggttttg	3300
ggaatgacag	agagaagagg	tggtgagggc	ctgattaaaa	actaagcaga	agtagtttta	3360
acaaaaatac	tcatgaaaat	gttttggaac	tgaaatttta	acaactgtaa	tattaaggaa	3420
accagaatca	ataaatcact	gtcttgccag	cacagctaca	gagtaacatg	attcagggga	3480
ggaaaagttc	cttagagtta	ctttttataat	tctttttttt	tttctcttta	ggtttagaaa	3540
tcttacaaat	ttaaacttta	tccttttttaa	attattttgaa	cataatttag	atattgtaag	3600
cttaaaaatac	aaatgtttat	agataacctc	tttaccataa	actaatccct	ggcaagccat	3660
ggctctcttt	tttttttttg	tgtttaaaagc	ctgtaaacag	tttttctgaa	tgatcatgaa	3720
cttttcttgg	tttagcacta	ggatttagct	atgaagagag	ctcataggct	ttcaggtgct	3780
aattgagatc	tgccctgtta	gagtcctggg	gtgctagatt	ggcacattg	acaccagtgg	3840
cagggaaaggc	atctatgagt	ttgatgcttt	ttatcacaca	cttcagtgtt	tagaaaagtt	3900
ttaccaatac	ttttaaacaa	cactccaaga	aaatttgcta	tatttctttc	tcatcactac	3960
agagagagta	gatttcccca	tagagagcac	agcctccatt	agtaagggtg	gtgactattg	4020
gtaagaggtg	gacttcattg	acaccaagtg	ggaggtaggg	aaagcccaga	aatggcagga	4080
tgataggtg	gttctgtcgt	tgggaaagg	attgggtttt	gctgtttgta	tttatactgt	4140
ataatagata	ccacgctttt	tcttattatc	tgtatatgta	ttgcttttca	tgtttgatat	4200
tttcccatgc	caagatttgt	ttatatatat	tttcaatgtt	aaattaaatt	gatttgggta	4260
actttcttcc	ccaagaaagt	atthttcccc	tttaagtata	atctgactg		4309



<210> 15  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens  
 <400> 15

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1           5           10           15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
          20           25           30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
          35           40           45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
          50           55           60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
          65           70           75           80
Asp Arg Ile Tyr Tyr Leu Gly Asn Lys Ser Leu Ile Asp His Asp Arg
          85           90           95
Phe Ser Lys Ser Lys Met Pro Glu Ile Ala Ser Ser
          100           105

```

<210> 16  
 <211> 620  
 <212> DNA  
 <213> Homo sapiens  
 <400> 16

```

aagtgcataa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg      60
cgttcgccgc ctgggttgct accggcgccg ccgccgagga agccactgca accaggaccg      120
gagtggaggc ggcgcagcat gaagcggcgc aggcccgctc catagcgcac gtcgggacgg      180
tccgggcccgg gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag      240
ctgggtgttg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg      300
cctaaattgg agccttttta tgttgagcgg tattcctgga gtcagcttaa aaagctgctt      360
gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt      420
gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tggtaacaag      480
tcattaattg atcatgatcg tttttcaaaa tcgaagatgc cagaaattgc ttcttcctaa      540
agctagcttg aaatgccttt ctttagatgg tctgattagg aaaacaaaca ataaaacat      600
tagtttgctt ccactcaaca

```

<210> 17  
 <211> 194  
 <212> PRT  
 <213> Homo sapiens  
 <400> 17

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
 1 5 10 15  
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
 20 25 30  
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
 35 40 45  
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro  
 50 55 60  
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser  
 65 70 75 80  
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr  
 85 90 95  
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Pro Leu Arg Pro Asn Leu Val Glu Thr  
 180 185 190  
 Cys Ala

<210> 18  
 <211> 832  
 <212> DNA  
 <213> Homo sapiens  
 <400> 18

aagtgtctaaa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg 60  
 cgttcgccgc ctgggttgct accggcgccg ccgcccaggga agccactgca accaggaccg 120  
 gagtggaggc ggcgcagcat gaagcggcgc aggcccgctc catagcgcac gtcgggacgg 180  
 tccgggcccgg gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag 240  
 ctgggtggtg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg 300  
 cctaaattgg agccttttta tgttgagcgg tattcctgga gtcagcttaa aaagctgctt 360  
 gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt 420  
 gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tgccatgtct 480  
 ggtgagaaca gagaaaatac actgttttat tctgaaattc caaaactat caatagagca 540  
 gcagtcttaa tgctctcttg gaagcctctt ttggatcttt ttcaggcaac actggactat 600  
 ggaatgtatt ctcgagaaga agaactatta agagaaagaa aacgcattgg aacagtcgga 660  
 attgcttctt acgattatca ccaaggaagt ggaacatttc tgtttcaagc cggtagtgga 720  
 atttatcacg taaaagatgg agggccacaa ggatttacgc wacaaccttt aaggcccaat 780  
 ctagtggaaa ctasttgtsc caracytgca tgacccaatc agatcctgta ga 832

<210> 19  
 <211> 658  
 <212> PRT  
 <213> Homo sapiens  
 <400> 19

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu  
 1 5 10 15  
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu  
 20 25 30  
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu  
 35 40 45  
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro

	50					55					60					
His 65	Asp	Phe	Met	Phe	Val 70	Lys	Arg	Asn	Asp	Pro 75	Asp	Gly	Pro	His	Ser 80	
Asp	Arg	Ile	Tyr	Tyr 85	Leu	Ala	Met	Ser	Gly 90	Glu	Asn	Arg	Glu	Asn 95	Thr	
Leu	Phe	Tyr	Ser 100	Glu	Ile	Pro	Lys	Thr 105	Ile	Asn	Arg	Ala	Ala 110	Val	Leu	
Met	Leu	Ser 115	Trp	Lys	Pro	Leu	Leu 120	Asp	Leu	Phe	Gln	Ala 125	Thr	Leu	Asp	
Tyr	Gly 130	Met	Tyr	Ser	Arg	Glu	Glu 135	Glu	Leu	Leu	Arg	Glu 140	Arg	Lys	Arg	
Ile 145	Gly	Thr	Val	Gly	Ile 150	Ala	Ser	Tyr	Asp	Tyr 155	His	Gln	Gly	Ser	Gly 160	
Thr	Phe	Leu	Phe 165	Gln	Ala	Gly	Ser	Gly	Ile 170	Tyr	His	Val	Lys	Asp 175	Gly	
Gly	Pro	Gln	Gly 180	Phe	Thr	Gln	Gln 185	Pro	Leu	Arg	Pro	Asn	Leu 190	Val	Glu	
Thr	Ser 195	Cys	Pro	Asn	Ile	Arg	Met 200	Asp	Pro	Lys	Leu	Cys 205	Pro	Ala	Asp	
Pro	Asp 210	Trp	Ile	Ala	Phe	Ile	His 215	Ser	Asn	Asp	Ile 220	Trp	Ile	Ser	Asn	
Ile 225	Val	Thr	Arg	Glu	Glu 230	Arg	Arg	Leu	Thr	Tyr 235	Val	His	Asn	Glu	Leu 240	
Ala	Asn	Met	Glu 245	Glu	Asp	Ala	Arg	Ser	Ala 250	Gly	Val	Ala	Thr	Phe 255	Val	
Leu	Gln	Glu 260	Glu	Phe	Asp	Arg	Tyr	Ser 265	Gly	Tyr	Trp	Trp	Cys 270	Pro	Lys	
Ala	Glu 275	Thr	Thr	Pro	Ser	Gly 280	Gly	Lys	Ile	Leu	Arg	Ile 285	Leu	Tyr	Glu	
Glu	Asn 290	Asp	Glu	Ser	Glu 295	Val	Glu	Ile	Ile	His	Val 300	Thr	Ser	Pro	Met	
Leu 305	Glu	Thr	Arg	Arg	Ala 310	Asp	Ser	Phe	Arg	Tyr 315	Pro	Lys	Thr	Gly	Thr 320	
Ala	Asn	Pro	Lys 325	Val	Thr	Phe	Lys	Met	Ser 330	Glu	Ile	Met	Ile	Asp 335	Ala	
Glu	Gly	Arg	Ile 340	Ile	Asp	Val	Ile	Asp 345	Lys	Glu	Leu	Ile	Gln 350	Pro	Phe	
Glu	Ile 355	Leu	Phe	Glu	Gly 360	Val	Glu	Tyr	Ile	Ala	Arg	Ala 365	Gly	Trp	Thr	
Pro	Glu 370	Gly	Lys	Tyr	Ala 375	Trp	Ser	Ile	Leu	Leu	Asp 380	Arg	Ser	Gln	Thr	
Arg 385	Leu	Gln	Ile	Val	Leu 390	Ile	Ser	Pro	Glu	Leu	Phe 395	Ile	Pro	Val	Glu 400	
Asp	Asp	Val	Met 405	Glu	Arg	Gln	Arg	Leu	Ile 410	Glu	Ser	Val	Pro	Asp 415	Ser	
Val	Thr 420	Pro	Leu	Ile	Ile	Tyr	Glu	Glu 425	Thr	Thr	Asp	Ile	Trp 430	Ile	Asn	
Ile	His 435	Asp	Ile	Phe	His	Val	Phe 440	Pro	Gln	Ser	His	Glu 445	Glu	Glu	Ile	
Glu	Phe 450	Ile	Phe	Ala	Ser	Glu 455	Cys	Lys	Thr	Gly	Phe	Arg	His	Leu	Tyr	
Lys 465	Ile	Thr	Ser	Ile	Leu 470	Lys	Glu	Ser	Lys	Tyr 475	Lys	Arg	Ser	Ser	Gly 480	
Gly	Leu	Pro	Ala 485	Pro	Ser	Asp	Phe	Lys	Cys 490	Pro	Ile	Lys	Glu 495	Glu	Ile	
Ala	Ile	Thr	Ser 500	Gly	Glu	Trp	Glu	Val 505	Leu	Gly	Arg	His	Gly 510	Ser	Asn	
Ile	Gln 515	Val	Asp	Glu	Val	Arg	Arg 520	Leu	Val	Tyr	Phe	Glu 525	Gly	Thr	Lys	
Asp	Ser	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser	Tyr	Val	Asn	Pro	

530	535	540
Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys		
545	550	555
Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys		
	565	570
Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp		
	580	585
Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala		
	595	600
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser		
	610	615
Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu		
	625	630
Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Arg		
	645	650
		655

Val Lys

<210> 20  
 <211> 4676  
 <212> DNA  
 <213> Homo sapiens  
 <400> 20

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cggtccgcgc	ctgggttgtc	accggcgccg	ccgccgagga	agccactgca	accaggaccg	120
gagtgagggc	ggcgagcat	gaagcgccgc	aggcccgcctc	catagcgcac	gtcgggacgg	180
tccggggcggg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtgga	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atttgatat	ctaactcgt	aaccagagaa	900
gaaaggagac	tactttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattgggtg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgtttgga	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaatc	ctaaagtac	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgctc	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcttgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tgataaata	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaatataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtgggtgaat	gggaagttct	tgccgggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctggtat	atgttgagg	caccaaagac	1800
tccccttttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcatcagtc	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagtagacc	caacttgcaa	aacaaaggaa	ttttgggcca	ccattttgga	ttcagcaggt	2040
cctcttctcg	actatactcc	tccagaaatt	ttctcttttg	aaagtactac	tggtattaca	2100
ttgtatggga	tgctctacaa	gcctcatgat	ctacagcctg	gaaagaaata	tcctactgtg	2160
ctgttcatat	atgggtggtc	ggtcaaatag	aaattgacga	tcaggtggaa	ggactccaat	2220

```

atctagcttc tcgatatgat ttcattgact tagatcgtgt gggcatccac ggctggctct 2280
atggaggata cctctccctg atggcattaa tgcagagggtc agatatcttc aggggttgcta 2340
ttgctggggc cccagtcact ctgtggatct tctatgatac aggatacacg gaacgttata 2400
tgggtcacc caccagaat gaacagggtc attacttagg atctgtggcc atgcaagcag 2460
aaaagttccc ctctgaacca aatcgtttac tgcctttaca tggtttctcg gatgagaatg 2520
tccattttgc acataccagt atattactga gttttttagt gagggtctgga aagccatatg 2580
atttacagat ctatcctcag gagagacaca gcataagagt tcctgaatcg ggagaacatt 2640
atgaactgca tcttttgcac taccttcaag aaaaccttgg atcacgtatt gctgctctaa 2700
aagtgatata attttgacct gtgtagaact ctctggtata cactggctat ttaaccaa 2760
gaggaggttt aatcaacaga aaacacagaa ttgatcatca catttttgata cctgccatgt 2820
aacatctact cctgaaaata aatgtggtgc catgcagggg tctacgggtt gtggtagtaa 2880
tctaatacct taaccccaca tgcctaaaat caaatgatac atattcctga gagaccagc 2940
aataccataa gaattactaa aaaaaaaaaa aaaaaaaaga cattagcacc atgtattcat 3000
actaccctat tttcactttt aatagtatta taaacttcat gaacttaatt agtgtatttt 3060
tacagtatac ttttgagttt gttaaaatat gatgatatta gtgattgggt tgggttcagtt 3120
ccagaatctt tgactagtta cagatttgat agcacttaaa tgtaattgaa tagcttatgc 3180
ttcattgctt gggcatatcc agcatgttat gaactaataa ctattaaact tgacttaacc 3240
agtcattcat taataatttt tcaaggataa cttagtggcc tcctaaagac acttgttttg 3300
gcactgacca gtttttagcc aatttaatct gtatctagta taaataattc tcatttttct 3360
ttgatgatat taacagagtg ggcttttctt ttgcataaa ggctagtaac tgtatgta 3420
gcattggatt aattagtcac gatattgata attacaggca gaaaattttt aatcaaatga 3480
ttagagctta aatatttgca ggcaagtttt ttttttctt ttaagaaaag gaaaaagtac 3540
acattcacta gaattcttca gaaaatttag tgggtccagt ttccatttgg tatttctt 3600
ttaaataatt ctagaatttt aaggagattg aagggaatca cagtgggtg gggagacctg 3660
ggtttgggga atgacagaga gaagaggtgg tgagggcctg attaaaaact aagcagaagt 3720
agttttaaca aaaataactca tgaaaatgtt tggaaaactga aatttaaaac actgtaatat 3780
taaggaaacc agaatacaata aatcactgtc ttgccagcac agctacagag taacatgatt 3840
caggggagga aaagttcctt agagttactt ttataattct tttttttttt cctcttaggt 3900
ttagaaatct taaaaattta aactttatcc ttttaaaatt atttgaacat aatttagata 3960
ttgtaagctt aaaatacaaa tgtttataga taacctctt accataaact aatccctggc 4020
aagccatggc tctctttttt tttttggtgt ttaaagcctg taaacagttt ttctgaatga 4080
tcatgaactt ttcttggttt agcactagga tttagctatg aagagagctc ataggctttc 4140
aggtgcta at tgagatctgc cctgttagag tcttgggtg ctagattggt cacattgaca 4200
ccagtggcag ggaaggcatc tatgagtttg atgcttttta tcacacactt cagtgtttag 4260
aaagttatta ccaatacttt taaacaacac tccaagaaaa tttgctatat ttctttctca 4320
tcactacaga gagagtagat ttcccatag agagcacagc ctccattagt aaggttggtg 4380
actattggta agaggtggac ttcatgaca ccaagtggga ggtagggaaa gccagaaat 4440
ggcaggatga tatggtggtt ctgtcggttg gaaaggtatt gggttttgct gtttgattt 4500
atactgtata atagatacca cgctttttct tattatctgt atatgtattg cttttcatgt 4560
ttgatatttt cccatgccaa gatttgttta tatatatatt caatgttaaa ttaaattgat 4620
ttgggtaact ttcttcccca agaaagtatt ttccccctta agtataaatc tgactg 4676

```

```

<210> 21
<211> 613
<212> PRT
<213> Homo sapiens
<400> 21

```

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1          5          10          15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20          25          30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35          40          45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50          55          60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65          70          75          80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85          90          95

```

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu  
 100 105 110  
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp  
 115 120 125  
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg  
 130 135 140  
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly  
 145 150 155 160  
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly  
 165 170 175  
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu  
 180 185 190  
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp  
 195 200 205  
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn  
 210 215 220  
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu  
 225 230 235 240  
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val  
 245 250 255  
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys  
 260 265 270  
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu  
 275 280 285  
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met  
 290 295 300  
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr  
 305 310 315 320  
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala  
 325 330 335  
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe  
 340 345 350  
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr  
 355 360 365  
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr  
 370 375 380  
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu  
 385 390 395 400  
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser  
 405 410 415  
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn  
 420 425 430  
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile  
 435 440 445  
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr  
 450 455 460  
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly  
 465 470 475 480  
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile  
 485 490 495  
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn  
 500 505 510  
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys  
 515 520 525  
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro  
 530 535 540  
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys  
 545 550 555 560  
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys  
 565 570 575

Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp  
                   580                  585                  590  
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Val  
                   595                  600                  605  
 Leu Arg Cys Ser Trp  
                   610

<210> 22  
 <211> 4685  
 <212> DNA  
 <213> Homo sapiens  
 <400> 22

aagtgcataaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cggttcgccc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggaccg	120
gagtgagggc	ggcgcagcat	gaagcggcgc	aggcccgcctc	catagcgcac	gtcgggacgg	180
tccggggcggg	gccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcccgc	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaattgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctcttg	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtagtggg	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgat	atttggatat	ctaaccatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtggt	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacaatccc	ctatgttggg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaaata	ctaaagtcac	ttttaagatg	1200
tcagaaataa	tgaattgatg	tgaagggaag	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttg	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgcct	acagatagtg	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgatcc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttcccaaaa	gtcacgaaga	ggaaattgag	1560
tttatttttg	cctctgaatg	caaaacaggt	ttccgctcatt	tatacaaaat	tacatctatt	1620
ttaaaggaaa	gcaaatataa	acgatccagt	gggtgggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtggtgaaat	gggaagttct	tggccggcat	1740
ggatctaata	tccaagttga	tgaagtcaga	aggctgggat	attttgaagg	caccaaagac	1800
tccccttttag	agcatcacct	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattcttgc	tgcacagtcg	agcactgtga	cttctttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcct	1980
gaagatgacc	caacttgcaa	aacaaggaa	ttttgggcca	ccatttttgg	ttcagtcctc	2040
agggtgcagtt	ggtgaataat	cggtttaaag	gagtcagata	tttccgcttg	aataccctag	2100
cctctctagg	ttatgtggtt	gtagtgatag	acaacagggg	atcctgtcac	cgagggcctta	2160
aatttgaagg	cgcttttaaa	tataaaatgg	gtcaaataga	aattgacgat	cagggtggaag	2220
gactccaata	tctagcttct	cgatatgatt	tcattgactt	agatcgtgtg	ggcatccacg	2280
gctggctcta	tggaggatac	ctctccctga	tggcattaat	gcagaggatc	gatattctca	2340
gggttgctat	tgtctggggc	ccagtcactc	tgtggatctt	ctatgatata	ggatacacgg	2400
aacgttatat	gggtcaccct	gaccagaatg	aacagggcta	ttacttagga	tctgtggcca	2460
tgcaagcaga	aaagttcccc	tctgaaccaa	atcgcttact	gctcttacat	ggtttcctgg	2520
atgagataat	ccattttgca	cataccagta	tattactgag	tttttttagt	agggctggaa	2580
agccatatga	tttacagatc	tatcctcagg	agagacacag	cataagagtt	cctgaatcgg	2640
gagaacatta	tgaactgcat	cttttgcact	accttcaaga	aaaccttggg	tcacgtattg	2700
ctgctctaaa	agtgatataa	ttttgacctg	tgtagaactc	tctggtatac	actggctatt	2760
taaccaaattg	aggagggtta	atcaacagaa	aacacagaat	tgatcatcac	attttgatac	2820

```

ctgccatgta acatctactc ctgaaaataa atgtgggtgcc atgcaggggt ctacggtttg 2880
tggtagtaat ctaatacctt aacccccacat gctcaaaatc aaatgataca tattcctgag 2940
agaccagca ataccataag aattactaaa aaaaaaaaaa aaaaaaagac attagcacca 3000
tgtattcata ctacctattt ttcactttta atagtattat aaacttcatg aacttaatta 3060
gtgtattttt acagtatact tttgagtttg ttaaaatatg atgatattag tgattggttt 3120
ggttcagttc cagaatcttt gactagttac agatttgata gcacttaaat gtaattgaat 3180
agcttatgct tcattgcttg ggcataacca gcatgttatg aactaataac tattaacttt 3240
gacttaacca gtcattcatt aataattttt caaggataac ttagtggcct cctaaagaca 3300
cttggttttg cactgaccag tttttagcca atttaactct tatctagtat aaataattct 3360
catttttctt tgatgatatt aacagagtgg gcttttcctt ttgcataaag gctagtaact 3420
gtatatgtag catggattta attagtcatt atattgataa ttacaggcag aaaattttta 3480
atcaaagtag tagagcttaa atatttgcag gcaagttttt ttttttcctt taagaaaaag 3540
aaaaagtaca cattcactag aattcttcag aaaatttagt ggtgccagtt tccatttggt 3600
atttccttat taaaatattc tagaatttta aggagattga agggaatcac agtggggtgg 3660
ggagacctgg gtttggggaa tgacagagag aagaggtggg gagggcctga ttaaaaacta 3720
agcagaagta gttttaacaa aaatactcat gaaaatgttt ggaaactgaa atttaacaa 3780
ctgtaatat aaggaaacca gaatcaataa atcactgtct tgccagcaca gctacagagt 3840
aacatgattc aggggaggaa agtttcctta gagttacttt tataattctt ttttttttc 3900
ctcttaggtt tagaaatctt acaaatttaa actttatcct tttaaaatta tttgaacata 3960
atttagatat tgtaagctta aaatacaaat gtttatagat aacctcttta ccataaacta 4020
atccctggca agccatggct ctcttttttt ttttggtgtt taaagcctgt aaacagtttt 4080
tctgaatgat catgaacttt tcttggttta gcactaggat ttagctatga agagagctca 4140
taggctttca ggtgctaatt gagatctgcc ctgttagagt cttggggtgc tagattggtc 4200
acattgacac cagtggcagg gaaggcatct atgagtttga tgctttttat cacacacttc 4260
agtgtttaga aagttattac caatactttt aaacaacact ccaagaaaat ttgctatatt 4320
tctttctcat cactacagag agagtagatt tcccataga gagcacagcc tccattagta 4380
agggtggtag ctattggtaa gaggtggact tcattgacac caagtgggag gtagggaaag 4440
cccagaaatg gcaggatgat atggtggttc tgtcgttggg aaaggtattg gggtttgctg 4500
tttgatttta tactgtataa tagataccac gctttttctt attatctgta tatgtattgc 4560
ttttcatgtt tgatattttc ccatgccaag atttgtttat atatattttc aatgtttaat 4620
taaattgatt tgggtaactt tcttcccaa gaaagtattt tcccccttaa gtataaatct 4680
gactg 4685

```

```

<210> 23
<211> 892
<212> PRT
<213> Homo sapiens
<400> 23

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
130         135         140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145         150         155         160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu

```



29

645 650 655  
 Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val  
 660 665 670  
 Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile  
 675 680 685  
 Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val  
 690 695 700  
 Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly  
 705 710 715 720  
 Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu  
 725 730 735  
 Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg  
 740 745 750  
 Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly  
 755 760 765  
 Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro  
 770 775 780  
 Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met  
 785 790 795 800  
 Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala  
 805 810 815  
 Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu  
 820 825 830  
 His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu  
 835 840 845  
 Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr  
 850 855 860  
 Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr  
 865 870 875 880  
 Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu  
 885 890

<210> 24  
 <211> 4302  
 <212> DNA  
 <213> Homo sapiens  
 <400> 24

caggcgccg	cctgggtcgc	tcaacttcgc	gggtcaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccacttc	cggggtcgca	gtccccgggc	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgccctcct	gaggtcagct	gagcgggtta	tgcggaaggt	taagaaactg	300
cgctggaca	aggagaacac	cggaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cgatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgccccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcgcc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcactgg	gtactgggtg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtgcgatg	agtcggaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgccctgaaa	1320

ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgaccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggtaggca	aatacgcttg	ggcatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgcgcct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tgggtgactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcgagatc	1980
gtacgcctca	ccacgcccgg	cttctcccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcag	ccgccctgcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgaccccc	gcacaagcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatcttcc	atttccacac	gcgctcggat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccagggaa	gaagcaccac	2280
accgtcctct	ttgtatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgcggctcaa	cacactggcc	tccctgggct	acgccgtggg	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggtctcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
cagggtggaga	tcgaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggcttc	2520
atcgacctga	gccgagttgc	catccatggc	tggctctacg	ggggcttctc	ctcgctcatg	2580
gggctaattc	acaagcccca	ggtgttcaag	gtggccatcg	cgggtgcccc	ggtcaccgtc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcgggttc	cgtggccctg	cacgtggaga	agctgcccaa	tgagcccaac	2760
cgttgcttta	tcctccacgg	cttcctggac	gaaaacgtgc	actttttcca	cacaaacttc	2820
ctcgtctccc	aactgatccg	agcagggaaa	ccttaccagc	tccagatcta	ccccacagag	2880
agacacagta	ttcgctgccc	cgagtccggc	gagcactatg	aagtcacgtt	gttgcaactt	2940
ctacaggaat	acctctgagc	ctgccaccg	ggagccgcca	catcacagca	caagtggctg	3000
cagcctccgc	ggggaaccag	gcgggagggg	ctgagtggcc	cgcgggcccc	agtgaggcac	3060
tttgtcccgc	ccagcgctgg	ccagccccga	ggagccgctg	ccttcaccgc	cccgcgcct	3120
tttatccttt	tttaaacgct	cttgggtttt	atgtccgctg	cttcttggtt	gccgagacag	3180
agagatgggt	gtctcggggc	agccctcct	ctccccgct	tctgggagga	ggaggtcaca	3240
cgctgatggg	cactggagag	gccagaagag	actcagagga	gcgggctgcc	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cggccagcca	ccgtccccag	cacccaagca	3360
tgcaattgcc	tgtccccccc	ggccagcctc	cccaacttga	tgtttgtgtt	ttgtttgggg	3420
ggatattttt	cataattatt	taaaagacag	gccgggcgcg	gtggctcacg	tctgtaatcc	3480
cagcactttg	ggaggctgag	gcgggcggat	cacctgaggt	tgggagttca	agaccagcct	3540
ggccaacatg	gggaaacccc	gtctctacta	aaaatacaaa	aaattagccg	ggtgtggtgg	3600
cgcgtgccta	taatcccagc	tactcgggag	gctgaggcag	gagaatcgct	tgaacccggg	3660
aggtggaggt	tgcggtgagc	caagatcgca	ccattgcact	ccagcctggg	caacaagagc	3720
gaaactctgt	ctcaaaaata	ataaaaaata	aaagacagaa	agcaaggggt	gcctaaatct	3780
agacttgggg	tccacaccgg	gcagcggggg	tgcaaccagc	cacctggtag	gctccatttc	3840
ttcccaagcc	cgagcagagg	gtcatgcggg	ccccacagga	gaagcggcca	gggcccgcgg	3900
ggggcaccac	ctgtggacag	ccctcctgtc	cccaagcttt	caggcaggca	ctgaaacgca	3960
ccgaacttcc	acgtctctgt	ggtcagtggc	ggctgtcccc	tccccagccc	agccgcccag	4020
ccacatgtgt	ctgcctgacc	cgtacacacc	aggggttccg	gggttgggag	ctgaaccatc	4080
cccacctcag	ggttatattt	ccctctcccc	ttccctcccc	gccaagagct	ctgccagggg	4140
cgggcaaaaa	aaaaagtaaa	aagaaaagaa	aaaaaaaaaa	aagaaacaaa	ccacctctac	4200
atattatgga	aagaaaatat	ttttgtcgat	tcttattctt	ttataattat	gcgtggaaga	4260
agtagacaca	ttaaaccgatt	ccagttggaa	acatgtcacc	tg		4302

&lt;210&gt; 25

&lt;211&gt; 518

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1				5				10				15			
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr

	20							25						30					
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp																			
	35							40						45					
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg				
	50				55						60								
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys				
65				70						75					80				
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro				
				85					90					95					
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu				
			100					105					110						
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala				
		115					120					125							
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr				
		130				135					140								
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg				
145					150						155				160				
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu				
				165						170				175					
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg				
			180					185					190						
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu				
		195					200					205							
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro				
		210				215					220								
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val				
225					230					235					240				
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg		Leu	Thr	Phe	Cys	His	Gln				
				245						250				255					
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr				
			260					265					270						
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys				
		275					280					285							
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile				
	290					295					300								
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro				
305					310						315				320				
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg				
				325						330				335					
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln				
			340					345					350						
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val				
		355				360						365							
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala				
		370				375					380								
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg				

500  
Ala Val Asp Ser Ser Arg  
515

505

510

<210> 26  
<211> 2411  
<212> DNA  
<213> Homo sapiens  
<400> 26

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccacttc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggg	gccgctggac	ccgggacgac	ctgcccagtc	cggccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcgggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaaagttg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcctcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcc	600
tatggcagcc	gagagaactc	cctcctctac	ctctgagattc	ccaagaaggt	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggggtctact	ctcgggagga	ggagctgctg	agggagcggg	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgctc	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcgcc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttactagg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgcttgaaga	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgccctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggttct	gccatttcta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgcgcct	tcagccccgg	ggaagggtgag	1800
cagagcctga	cgaatgctgt	cgactcatcg	cgtagtcac	gtgtggttca	atatgctgtt	1860
tgttcattgg	tcggcccccc	cactcagcca	gcacaccctg	cgggagaagg	aacagggatc	1920
ggcaggaagc	cagccttccc	cagtgcctgc	atgatctggc	agggcttaga	gcacccaact	1980
gttggcttat	tcaggcagca	gatttactga	gcacctcccc	tgtgccaggc	ccttagcaca	2040
accaggggtt	ggccacctac	ggccccaggg	tcaaatccgg	cccaccacct	gtgttcataa	2100
ataaagtttt	attggcactg	agccacagcc	acttgtttac	agagactgtc	tgtggtcgct	2160
tttgtgctgc	agcagcagaa	ctgggtagtc	ccagcagaaa	ctgttgtgca	aggccaagat	2220
ttactgtcta	gcccttttga	gaaacatttg	ccagctcctg	ctgtaggtag	ctgtgatgga	2280
attgttcact	gtaaataaag	aaaaaggaaa	atccctgctc	ttgggacctt	ctagtggagg	2340
aggcagattt	ccagaaacag	ttagaggtgc	tgctctggt	gtgctgtggg	tggcagatgc	2400
agatcctagt	c					2411

<210> 27  
<211> 892  
<212> PRT  
<213> Homo sapiens  
<400> 27

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser  
1 5 10 15

Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr  
 20 25 30  
 Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp  
 35 40 45  
 Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg  
 50 55 60  
 Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys  
 65 70 75 80  
 Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro  
 85 90 95  
 His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu  
 100 105 110  
 Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala  
 115 120 125  
 Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr  
 130 135 140  
 Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg  
 145 150 155 160  
 Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu  
 165 170 175  
 Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg  
 180 185 190  
 Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu  
 195 200 205  
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro  
 210 215 220  
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val  
 225 230 235 240  
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln  
 245 250 255  
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr  
 260 265 270  
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
 275 280 285  
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
 290 295 300  
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
 305 310 315 320  
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
 325 330 335  
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
 340 345 350  
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
 355 360 365  
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
 370 375 380  
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
 385 390 395 400  
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile  
 405 410 415  
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
 420 425 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
 435 440 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
 450 455 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
 465 470 475 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
 485 490 495

Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile	500	505	510
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg	515	520	525
His	Gly	Ser	Lys	Ile	Trp	Val	Asn	Glu	Glu	Thr	Lys	Leu	Val	Tyr	Phe	530	535	540
Gln	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser	545	550	555
Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro	Gly	Phe	Ser	565	570	575
His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val	Ser	His	Tyr	580	585	590
Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys	Leu	Ser	Gly	595	600	605
Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp	Ala	Ser	Met	610	615	620
Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro	Glu	Ile	Phe	625	630	635
His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met	Ile	Tyr	Lys	645	650	655
Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val	Leu	Phe	Val	660	665	670
Tyr	Gly	Gly	Pro	Gln	Val	Gln	Leu	Val	Asn	Asn	Ser	Phe	Lys	Gly	Ile	675	680	685
Lys	Tyr	Leu	Arg	Leu	Asn	Thr	Leu	Ala	Ser	Leu	Gly	Tyr	Ala	Val	Val	690	695	700
Val	Ile	Asp	Gly	Arg	Gly	Ser	Cys	Gln	Arg	Gly	Leu	Arg	Phe	Glu	Gly	705	710	715
Ala	Leu	Lys	Asn	Gln	Met	Gly	Gln	Val	Glu	Ile	Glu	Asp	Gln	Val	Glu	725	730	735
Gly	Leu	Gln	Phe	Val	Ala	Glu	Lys	Tyr	Gly	Phe	Ile	Asp	Leu	Ser	Arg	740	745	750
Val	Ala	Ile	His	Gly	Trp	Ser	Tyr	Gly	Gly	Phe	Leu	Ser	Leu	Met	Gly	755	760	765
Leu	Ile	His	Lys	Pro	Gln	Val	Phe	Lys	Val	Ala	Ile	Ala	Gly	Ala	Pro	770	775	780
Val	Thr	Val	Trp	Met	Ala	Tyr	Asp	Thr	Gly	Tyr	Thr	Glu	Arg	Tyr	Met	785	790	795
Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly	Ser	Val	Ala	805	810	815
Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu	Leu	Ile	Leu	820	825	830
His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	Phe	His	Thr	Asn	Phe	Leu	835	840	845
Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu	Gln	Ile	Tyr	850	855	860

Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr  
 865 870 875 880  
 Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu  
 885 890

<210> 28  
 <211> 4219  
 <212> DNA  
 <213> Homo sapiens  
 <400> 28

caggcgcgcg	cctgggtcgc	tcaacttccg	ggtaaagggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcgggtgtcg	tccccgcgtc	ccgccacttc	cggggtcgca	gtccccggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaagggt	taagaaactg	300
cgctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gacccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccgccg	cccgtttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	ggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgccca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagggt	ccggaagag	660
gctctgtctg	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcagcg	cggcaagaac	ggcttcattg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccg	atggacccca	aaatctgccc	tgcccacctt	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaagggt	ttatccaatg	tcttggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttactctg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgctttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgaccaggga	gaaggagctg	1380
gtgcagccct	tccagctcgt	gttcccgaag	gtggagtaca	tgcgccgggc	cggggtggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gcggttttaa	aatcccaggg	ctacgattgg	agtgcgccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccaagc	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggccaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggctagct	atgaggcggc	cggcgagatc	1980
gtacgcctca	ccacgcccgg	cttctcccat	agctgtcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcag	ccgccctgcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgacccccct	gcacaagcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatcttcc	atttccacac	gcgctcggat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccaggga	gaagcacccc	2280
accgtcctct	ttgtatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgcggctcaa	cacactggcc	tccctgggct	acgccgtggg	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggcttcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggc	ctgcagttcg	tggcagagaa	gtatggcttc	2520
atcgacctga	gccgagttgc	catccatggc	tggtcctacg	ggggcttccct	ctcgtcatg	2580
gggctaatacc	acaagcccca	ggtgttcaag	gtggccatcg	cggggtgcccc	ggtcacccgc	2640
tggatggcct	acgacacagg	gtacactgag	cgctccatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcgggttc	cgtggccctg	cacgtggaga	agctgcccaa	tgagcccaac	2760
cgcttgctta	tcttccacgg	cttctgggac	gaaaacgtgc	actttttcca	cacaaacttc	2820
ctcgtctccc	aactgatccg	agcagggaaa	ccttaccagc	tccagatcta	ccccaacgag	2880
agacacagta	ttcgtgcccc	cgagtcgggc	gagcactatg	aagtcacgtt	gctgcacttt	2940



```

ctacaggaat acctctgagc ctgcccaccg ggagccgcca catcacagca caagtggctg 3000
cagcctccgc ggggaaccag gcgggagggg ctgagtgagg cgcgggccccc agtgaggcac 3060
tttgtccgc ccagcgctgg ccagcccga ggagccgctg ccttcaccgc cccgacgcct 3120
tttatccttt tttaaacgct cttgggtttt atgtccgctg cttcttggtt gccgagacag 3180
agagatggtg gtctcggggc agccctcct cctcccgct tctgggagga ggaggtcaca 3240
cgctgatggg cactggagag gccagaagag actcagagga gcgggctgcc ttccgcctgg 3300
ggctccctgt gacctctcag tcccctggcc cgccagcca ccgtccccag caccgaagca 3360
tgcaattgcc tgtccccccc ggccagcctc cccaacttga tgtttgtgtt ttgtttgggg 3420
ggatattttt cataattatt taaaagacag gccgggcgcg gtggctcacg tctgtaatcc 3480
cagcactttg ggaggtgag gcgggaggat cacctgaggt tgggagttca agaccagcct 3540
ggccaacatg gggaaacccc gtctctacta aaaatacaaa aaattagccg ggtgtggtgg 3600
cgcggtgccta taatcccagc tactcgggag gctgaggcag gagaatcgct tgaaccgggg 3660
aggtggaggt tgcggtgagc caagatcgca ccattgcact ccagcctggg caacaagagc 3720
gaaactctgt ctcaaaataa ataaaaata aaagacagaa agcaaggggt gcctaaatct 3780
agacttgggg tccacaccgg gcagcggggg tgcaaccag cacctggtag gctccatttc 3840
ttccaagcc cgactttcag gcaggcactg aaacgcaccg aacttccag ctctgtggt 3900
cagtggcggc tgtcccctcc ccagcccagc cgccagcca catgtgtctg cctgaccctg 3960
acacaccagg ggttcggggg ttgggagctg aaccatcccc acctcagggt tatattccc 4020
tctcccttc cctccccgcc aagagctctg ccaggggagg gcaaaaaaa aagtaaaaag 4080
aaaaaagaaa aaaaaaaaag aaacaaacca cctctacata ttatggaaag aaaatatatt 4140
tgctgattct tattctttta taattatgcg tggaagaagt agacacatta aacgattcca 4200
gttggaaca tgtcacctg 4219

```

```

<210> 29
<211> 832
<212> PRT
<213> Homo sapiens
<400> 29

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
130         135         140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145         150         155         160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
165         170         175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
180         185         190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
195         200         205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
210         215         220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
225         230         235         240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln

```

38

```
<210> 30
<211> 4159
<212> DNA
<213> Homo sapiens
<400> 30
```

39

```

ggcaggggct cctgtcagcg agggcttcgg ttccaagggg ccctgaaaaa ccaaattgggc 2460
caggtggaga tccaggacca ggtggagggc ctgcagttcg tggccgagaa gtatggcttc 2520
atcgacctga gccgagttgc catccatggc tggctctacg ggggcttcct ctcgctcatg 2580
gggctaattcc acaagcccca ggtgttcaag gcccaccgc ttgcttatcc tccacggctt 2640
cctggacgaa aacgtgcact tttccacac aaacttcctc gtctcccaac tgatccgagc 2700
agggaaacct taccagctcc agatctaccc caacgagaga cacagtattc gctgccccga 2760
gtcgggagag cactatgaag tcacgttgct gcactttcta caggaatacc tctgagcctg 2820
cccaccggga gccgccacat cacagcaca gtggctgcag cctccgcggg gaaccaggcg 2880
ggagggactg agtggcccg cggcccccagt gaggcacttt gtcccggcca gcgtggcca 2940
gccccgagga gccgctgcct tcaccgcccc gacgcctttt atcctttttt aaacgctctt 3000
gggttttatg tccgctgctt cttgggtgcc gagacagaga gatggtggtc tcggggcagc 3060
ccctcctctc cccgccttct gggaggagga ggtcacacgc tgatgggcac tggagaggcc 3120
agaagagact cagaggagcg ggctgccttc cgctggggc tccctgtgac ctctcagtcc 3180
cctggcccg ccagccaccg tccccagcac ccaagcatgc aattgcctgt ccccccggc 3240
cagcctcccc aacttgatgt ttgtgttttg ttgggggga tatttttcat aattatttaa 3300
aagacaggcc gggcgcggtg gctcacgtct gtaatcccag cactttggga ggctgaggcg 3360
ggcggatcac ctgaggttg gagttcaaga ccagcctggc caacatgggg aaaccccgtc 3420
tctactaaaa atacaaaaaa ttagccgggt gtggtggcg gtgcctataa tcccagctac 3480
tcgggaggtc gaggcaggag aatcgcttga accggggagg tggaggttgc ggtgagccaa 3540
gatcgaccca ttgcactcca gcctgggcaa caagagcgaa actctgtctc aaaataaata 3600
aaaaataaaa gacagaaagc aaggggtgcc taaatctaga cttgggggtc acaccgggca 3660
gcggggttgc aacccagcac ctggtaggct ccatttcttc ccaagccga gcagagggtc 3720
atgcggggcc cacaggagaa gcggccaggg ccgcggggg gcaccacctg tggacagccc 3780
tcctgtcccc aagctttcag gcaggcactg aaacgcaccg aacttccacg ctctgtggt 3840
cagtggcggc tgtcccctcc ccagcccagc cgcccagcca catgtgtctg cctgaccctg 3900
acacaccagg ggttccgggg ttgggagctg aaccatcccc acctcagggt tatatttccc 3960
tctccccttc cctcccgcgc aagagctctg ccagggggcg gcaaaaaaaa aagtaaaaag 4020
aaaagaaaaa aaaaaaaaag aaacaaacca cctctacata ttatggaaag aaaatatatt 4080
tgtcgattct tattctttta taattatgcg tggaagaagt agacacatta aacgattcca 4140
gttgaaaca tgtcacctg 4159

```

<210> 31  
<211> 832  
<212> PRT  
<213> Homo sapiens  
<400> 31

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
130         135         140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145         150         155         160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
165         170         175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg

```

41

	660		665		670
Tyr Gly Gly	Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile				
	675		680		685
Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val					
	690		695		700
Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly					
	705		710		715
Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu					
	725		730		735
Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg					
	740		745		750
Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly					
	755		760		765
Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu Ala Tyr Pro					
	770		775		780
Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His Lys Leu Pro					
	785		790		795
Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala Pro Asp Leu					
	805		810		815
Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly Arg Ala Leu					
	820		825		830

<210> 32  
 <211> 4076  
 <212> DNA  
 <213> Homo sapiens  
 <400> 32

caggcgcgcg	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggtctgtc	tccccgcgtc	ccgccacttc	cggggtcgca	gtccccggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cggccgcgcg	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagagatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgtttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaaagag	660
gctctgtgtc	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggggtctact	ctcgggagga	ggagctgctg	agggagcggg	aacgcctggg	ggcttccggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcttgatga	ccccagtct	1080
gcgggtgtgg	ccaccttctg	catacaggaa	gagttcgacc	gcttactggt	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgcttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920

```

aaggacacgc cgctggagca ccacctctac gtggtcagct atgaggcggc cggcgagatc 1980
gtacgcctca ccacgcccgg cttctcccat agctgctcca tgagccagaa cttcgacatg 2040
ttcgtcagcg actacagcag cgtgagcag ccgccttgcg tgcacgtcta caagctgagc 2100
ggccccgacg acgaccccct gcacaagcag ccccgcttct gggctagcat gatggaggca 2160
gccagctgcc ccccgatta tgttctcca gagatcttcc atttccacac gcgctcgat 2220
gtgcggtctc acggcatgat ctacaagccc cacgccttgc agccaggga gaagaccccc 2280
accgtcctct ttgtatatgg agggccccag gtgcagctgg tgaataactc cttcaaaggc 2340
atcaagtact tgcggctcaa cacactggcc tccctgggct acgccgtggt tgtgattgac 2400
ggcaggggct cctgtcagcg agggcttcgg ttcgaagggg cctgaaaaa ccaaatgggc 2460
caggtggaga tgcaggacca ggtggagggc ctgcagttcg tggccgagaa gtatggcttc 2520
atcgacctga gccgagttgc catccatggc tggctctacg ggggcttctc ctcgctcatg 2580
gggctaatacc acaagcccca ggtgttcaag gcccaaccgc ttgcttatcc tccacggctt 2640
cctggacgaa aacgtgcaact ttttccacac aaacttctc gtctcccaac tgatccgagc 2700
agggaaacct taccagctcc agatctaccc caacgagaga cacagtattc gctgccccga 2760
gtcgggagcg cactatgaag tcacgttgc gcactttcta caggaatacc tctgagcctg 2820
cccaccggga gccgccacat cacagcacaa gtggctgcag cctccgctgg gaaccaggcg 2880
ggagggactg agtggcccg cggccccagt gaggcacttt gtcccgccca gcgctggcca 2940
gccccgagga gccgctgcct tcaccgcccc gacgcctttt atcctttttt aaacgctctt 3000
gggtttttatg tccgctgctt cttggttgcc gagacagaga gatggtggtc tcgggccagc 3060
ccctcctctc cccgcttct gggaggagga ggtcacacgc tgatgggcac tggagaggcc 3120
agaagagact cagaggagcg ggctgccttc cgcctggggc tccctgtgac ctctcagtcc 3180
cctggcccg ccagccaccg tccccagcac ccaagcatgc aattgcctgt ccccccggc 3240
cagcctcccc aacttgatgt ttgtgtttt tttgggggga tatttttcat aattatttaa 3300
aagacaggcc gggcgcggtg gctcacgtct gtaatcccag cactttggga ggctgaggcg 3360
ggcggatcac ctgaggttg gagttcaaga ccagcctggc caacatgggg aaaccccgtc 3420
tctactaaaa atacaaaaaa ttagccgggt gtggtggcgc gtgcctataa tccagctac 3480
tcgggaggtc gaggcaggag aatcgcttga accgggagg tggaggttgc tggagccaa 3540
gatcgacca ttgcactcca gcctgggcaa caagagcgaa actctgtctc aaaataaata 3600
aaaaataaaa gacagaaagc aaggggtgcc taaatctaga cttgggggtc acaccgggca 3660
gcggggttgc aaccagcac ctggtaggct ccatttcttc ccaagccga ctttcaggca 3720
ggcactgaaa cgcaccgaac ttccacgctc tgctggtcag tggcggtgt cccctccca 3780
gcccagccgc ccagccacat gtgtctgcct gaccgtaca caccaggggt tccggggttg 3840
ggagctgaac catccccacc tcagggttat atttccctct ccccttccct ccccgccaag 3900
agctctgcca ggggcgggca aaaaaaaaag taaaaagaaa agaaaaaaa agaaaaagaaa 3960
caaacacct ctacatatta tggaagaaa atatttttgt cgattcttat tcttttataa 4020
ttatgcgtgg aagaagtaga cacattaac gattccagtt ggaaacatgt cacctg 4076

```

<210> 33  
 <211> 879  
 <212> PRT  
 <213> Homo sapiens  
 <400> 33

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr

```

130	135	140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg		
145	150	155
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu		160
	165	170
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg		175
	180	185
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		190
	195	200
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		205
	210	215
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		220
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		240
	245	250
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		255
	260	265
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		270
	275	280
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		285
	290	295
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		300
305	310	315
Ser Pro Ala Leu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		320
	325	330
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		335
	340	345
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		350
	355	360
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		365
	370	375
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		380
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		400
	405	410
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		415
	420	425
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		430
	435	440
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		445
	450	455
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		460
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		480
	485	490
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		495
	500	505
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		510
	515	520
His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr		525
	530	535
Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro		540
545	550	555
		560



Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
 565 570 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
 580 585 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
 595 600 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
 610 615 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
 625 630 635 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
 645 650 655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala  
 755 760 765  
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu  
 770 775 780  
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly  
 785 790 795 800  
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu  
 805 810 815  
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr  
 820 825 830  
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu  
 835 840 845  
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly  
 850 855 860  
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu  
 865 870 875

<210> 34  
 <211> 4263  
 <212> DNA  
 <213> Homo sapiens  
 <400> 34

caggccgcgc cctgggtcgc tcaacttcgc ggtcaaaggt gcctgagccg gcgggtcccc 60  
 tgtgtccgcc gcggctgtcg tccccgcctc ccgccacttc cggggtcgca gtccccggca 120  
 tggagccgcg accgtgaggc gccgctggac ccgggacgac ctgcccagtc cggccgccgc 180  
 cccacgtccc ggtctgtgtc ccacgcctgc agctggaatg gaggtctctt ggacccttta 240  
 gaaggcacc cctgccctcct gaggtcagct gagcggttaa tgcggaaggt taagaaactg 300  
 cgcctggaca aggagaacac cggaagttgg agaagcttct cgctgaattc cgagggggct 360  
 gagaggatgg ccaccaccgg gaccccaacg gccgaccgag gcgacgcagc cgccacagat 420  
 gacccggccg cccgcttcca ggtgcagaag cactcgtggg acgggctccg gagcatcatc 480  
 cagggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacga cttccagttt 540  
 gtgcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaatgccca 600  
 tatggcagcc gagagaactc cctcctctac tctgagattc ccaagaaggt ccggaaagag 660  
 gctctgtctg tcctgtcctg gaagcagatg ctggatcatt tccaggccac gccccaccat 720  
 ggggtctact ctccgggagga ggagctgctg agggagcgga aacgcctggg ggtcttcggc 780

atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccagge	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcctggatga	ccccagtct	1080
gcggtgtgg	ccaccttctg	catcacaggaa	gagttcgacc	gcttactggt	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgcttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgaccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggtagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttct	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtacc	1740
gccgttttaa	aatcccaggg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	ctgtgtcagc	1920
tatgaggcgg	cggcgagat	cgtacgcctc	accagcccg	gcttctccca	tagctgtctc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgcctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgacaagca	gccccgttc	2100
tgggctagca	tgatggaggc	agccagctgc	cccccgatt	atgttctctc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtgcggctc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcacc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	tgcggctca	acacactggc	ctccctgggc	2340
tacgccgtgg	ttgtgattga	cggcaggggc	tcctgtcagc	gagggcttcg	gttcgaagg	2400
gccctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggagg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccaggttg	ccatccatgg	ctggctctac	2520
gggggcttcc	tctcgctcat	ggggctaata	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gcgctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gagcggggtt	ccgtggccct	gcacgtggag	2700
aagctgcccc	atgagcccaa	ccgcttgctt	atcctccacg	gcttctctga	cgaaaacgtg	2760
cactttttcc	acacaaactt	cctcgctctc	caactgatcc	gagcagggaa	acctaccag	2820
ctccagatct	accccaacga	gagacacagt	attcgctgcc	ccgagtcggg	cgagcactat	2880
gaagtcacgt	tgtctgactt	tctacaggaa	tacctctgag	cctgcccacc	gggagccgcc	2940
acatcacagc	acaagtggct	gcagcctccg	cggggaacca	ggcgggagg	actgagtggc	3000
ccgcgggccc	cagtgaggca	ctttgtcccg	ccagcgcgtg	gccagccccg	aggagccgct	3060
gccttcaccg	ccccgacgcc	ttttatcctt	ttttaaacgc	tcttgggttt	tatgtccgct	3120
gcttcttggg	tgccgagaca	gagagatggg	ggtctcgggc	cagccctctc	tctccccgcc	3180
ttctgggagg	aggaggtcac	acgctgatgg	gcactggaga	ggccagaaga	gactcagagg	3240
agcgggctgc	cttcgcctcg	gggctccctg	tgacctctca	gtccctggc	cgggccagcc	3300
accgtcccca	gcacccaagc	atgcaattgc	ctgtcccccc	cggccagcct	ccccacttg	3360
atgttttgtg	tttgtttggg	gggatatttt	tcataattat	ttaaaagaca	ggccggggcg	3420
ggtggctcac	gtctgtaata	ccagcacttt	gggaggctga	ggcgggcgga	tcacctgagg	3480
ttgggagttc	aagaccagcc	tgccaacat	ggggaaaccc	cgtctctact	aaaaatacaa	3540
aaaattagcc	gggtgtgggt	gcgcgtgcct	ataatcccag	ctactcgga	ggctgaggca	3600
ggagaatcgc	ttgaacccgg	gaggtggagg	ttgcggtgag	ccaagatcgc	accattgcac	3660
tccagcctgg	gcaacaagag	cgaaactctg	tctcaaaaata	aataaaaaat	aaaagacaga	3720
aagcaagggg	tgcttaaatc	tagacttggg	gtccacaccg	ggcagcgggg	ttgcaaccca	3780
gcacctggta	ggctccattt	cttcccaagc	ccgagcagag	ggtcatgcgg	gccccacagg	3840
agaagcggcc	agggcccgcg	gggggcacca	cctgtggaca	gccctcctgt	ccccagctt	3900
tcaggcaggc	actgaaacgc	accgaacttc	cacgctctgc	tggtcagtg	cggctgtccc	3960
ctccccagcc	cagccgcccc	gccacatgtg	tctgcctgac	ccgtacacac	caggggttcc	4020
ggggttggga	gctgaaccat	ccccacctca	gggttatatt	tcctctctcc	cttccctccc	4080
cgccaagagc	tctgccagg	gcgggcaaaa	aaaaaaagta	aaagaaaaaa	aaaaaaataa	4140
aaagaaacaa	accacctcta	catattatgg	aaagaaaata	tttttgtcga	ttcttattct	4200
tttataatta	tgcggtggaag	aagtagacac	attaaacgat	tccagttgga	aacatgtcac	4260
ctg						4263

<210> 35  
 <211> 879  
 <212> PRT  
 <213> Homo sapiens  
 <400> 35

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
          20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
          35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
          50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
          85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
          100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
          115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
          130         135         140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145         150         155         160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
          165         170         175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
          180         185         190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
          195         200         205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
          210         215         220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
225         230         235         240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
          245         250         255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
          260         265         270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
          275         280         285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
          290         295         300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
305         310         315         320
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
          325         330         335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
          340         345         350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
          355         360         365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
          370         375         380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
385         390         395         400
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile
          405         410         415

```

Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
 420 425 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
 435 440 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
 450 455 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
 465 470 475 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
 485 490 495  
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
 500 505 510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
 515 520 525  
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
 530 535 540  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
 545 550 555 560  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
 565 570 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
 580 585 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
 595 600 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
 610 615 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
 625 630 635 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
 645 650 655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala  
 755 760 765  
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu  
 770 775 780  
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly  
 785 790 795 800  
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu  
 805 810 815  
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr  
 820 825 830  
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu  
 835 840 845  
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly  
 850 855 860  
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu  
 865 870 875

<210> 36  
 <211> 4180  
 <212> DNA  
 <213> Homo sapiens  
 <400> 36

caggccgcgc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgctc	ccgccacttc	cggggtcgca	gtccccggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggtctctc	ggacccttta	240
gaaggcacc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggtatg	ccaccaccgg	gaccccaacg	ggcgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgttcca	ggtgcagaag	cactcgtggg	acgggtccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaaggt	ccggaagag	660
gctctgtctg	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggcttact	ctcgggagga	ggagctgctg	agggagcggg	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cgcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggccccgg	atggacccca	aaatctgccc	tgccgacct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaatg	tcttgatga	ccccagctct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactg	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcatg	agtcgaggt	ggaggtcatt	cacgtcccct	ctcctgcgct	agaagaaagg	1260
aagacggatt	cgtatcggta	ccccaggaca	ggcagcaaga	atcccaagat	tgccctgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgacccagga	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaa	gtggagtaca	tcgccagggc	cgggtggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgcacct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttgccg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgtggagc	accacctcta	cgtggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgccc	gcttctccca	tagctgctcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgcctgc	2040
gtgcagctct	acaagctgag	cggccccgac	gacgaccccc	tgcaacaagca	gccccgcttc	2100
tgggctagca	tgatggaggc	agccagctgc	cccccgatt	atgttcctcc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtgcggctc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcacc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgccgtgg	ttgtgattga	cggcaggggc	tctgtcagc	gagggcttcg	gttcgaaggg	2400
gccctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggtcctac	2520
gggggttccc	tctcgctcat	ggggctaate	cacaagcccc	aggtgttcaa	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	ggtacactga	gcgctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gagggcgggt	ccgtggccct	gcacgtggag	2700
aagctgccc	atgagcccaa	ccgcttgctt	atcctccacg	gcttcctgga	cgaaaacgtg	2760
cactttttcc	acacaaactt	cctcgtctcc	caactgatcc	gagcagggaa	accttaccag	2820
ctccagatct	acccaacga	gagacacagt	attcgctgcc	ccgagtcggg	cgagcactat	2880
gaagtacagt	tgtctgactt	tctacaggaa	tacctctgag	cctgccacc	gggagccgcc	2940
acatcacagc	acaagtggct	gcagcctccg	cggggaacca	ggcgggaggg	actgagtggc	3000
ccggggccc	cagtggagca	ctttgtcccg	cccagcgctg	gccagccccg	aggagccgct	3060
gccttcaccg	ccccgaacgc	ttttatcctt	ttttaaacgc	tcttgggttt	tatgtccgct	3120
gcttcttggt	tgccgagaca	gagagatgg	ggtctcgggc	cagccctcc	tctccccgcc	3180

```

ttctgggagg aggaggtcac acgctgatgg gcactggaga ggccagaaga gactcagagg 3240
agcggggtgc cttccgcctg gggctccctg tgacctctca gtcccctggc ccggccagcc 3300
accgtcccca gcaccaagc atgcaattgc ctgtccccc cggccagcct ccccaacttg 3360
atgttttgtt tttgtttggg gggatatttt tcataattat ttaaaagaca ggccgggagc 3420
ggtgggtcac gtctgtaatc ccagcacttt gggaggctga ggccggcgga tcacctgagg 3480
ttgggagttc aagaccagcc tggccaacat ggggaaaccc cgtctctact aaaaatacaa 3540
aaaattagcc ggggtgtggtg gcgcgtgcct ataatcccag ctactcggga ggctgaggca 3600
ggagaatcgc ttgaaccggg gaggtggagg ttgcggtgag ccaagatcgc accattgcac 3660
tccagcctgg gcaacaagag cgaaactctg tctcaaaata aataaaaaat aaaagacaga 3720
aagcaagggg tgcttaaatc tagacttggg gtccacaccg ggcagcgggg ttgcaacca 3780
gcacctggta ggctccattt cttcccaagc ccgactttca ggcaggcact gaaacgcacc 3840
gaacttccac gctctgctgg tcagtggcgg ctgtcccctc cccagcccag ccgccagcc 3900
acatgtgtct gcctgaccg tacacaccag gggttccggg gttgggagct gaaccaatccc 3960
cacctcaggg ttatatattc ctctcccctt cctcccgcgc caagagctct gccaggggcg 4020
ggcaaaaaaa aaagtaaaaa gaaaagaaaa aaaaaaaaaa gaaacaaacc acctctacat 4080
attatggaaa gaaaatattt ttgtcgattc ttattctttt ataattatgc gtggaagaag 4140
tagacacatt aaacgattcc agttggaaac atgtcacctg 4180

```

<210> 37  
 <211> 819  
 <212> PRT  
 <213> Homo sapiens  
 <400> 37

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1      5      10      15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
      20      25      30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
      35      40      45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
      50      55      60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65      70      75      80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
      85      90      95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
      100     105     110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
      115     120     125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
      130     135     140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145     150     155     160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
      165     170     175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
      180     185     190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
      195     200     205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
      210     215     220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
225     230     235     240
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
      245     250     255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
      260     265     270

```

Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys  
 275 280 285  
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile  
 290 295 300  
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro  
 305 310 315 320  
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg  
 325 330 335  
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln  
 340 345 350  
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val  
 355 360 365  
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala  
 370 375 380  
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg  
 385 390 395 400  
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile  
 405 410 415  
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val  
 420 425 430  
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val  
 435 440 445  
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly  
 450 455 460  
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe  
 465 470 475 480  
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp  
 485 490 495  
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile  
 500 505 510  
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg  
 515 520 525  
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr  
 530 535 540  
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro  
 545 550 555 560  
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val  
 565 570 575  
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys  
 580 585 590  
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp  
 595 600 605  
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro  
 610 615 620  
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met  
 625 630 635 640  
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val  
 645 650 655  
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
 660 665 670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
 675 680 685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
 690 695 700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705 710 715 720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
 725 730 735

Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
 740 745 750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu  
 755 760 765  
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His  
 770 775 780  
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala  
 785 790 795 800  
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly  
 805 810 815  
 Arg Ala Leu

<210> 38  
 <211> 4120  
 <212> DNA  
 <213> Homo sapiens  
 <400> 38

caggccgccc	cctgggtcgc	tcaacttcgc	gggtcaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcgggtgtgc	tccccgcgc	ccgccacttc	cggggtcgca	gtccccggca	120
tggagccgcg	accgtgaggg	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgccctcct	gaggtcagct	gagcggttaa	tgcggaagg	taagaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcctcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtgcagaaga	cggatgagtc	tgggccccac	tcccaccgcc	tctactacct	gggaatgcc	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaagag	660
gctctgtctg	tctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggggtctact	ctcgggagga	ggagctgctg	agggagcgga	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttcaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cggcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtct	agggcccccg	atggacccca	aaatctgccc	tgccgacct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcgcc	tgacctctg	ccaccaagg	ttatccaatg	tcttgatga	ccccagttct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttactggt	gtactggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtgcgat	agtccgaggt	ggaggtcatt	caggtcccc	ctcctgcgct	agaagaaagg	1260
aagacggact	cgtatcggtg	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatcgtct	cgaccaggga	gaaggagctg	1380
gtgcagccct	tccagctcgt	gttcccgaag	gtggagtaca	tgcgacgggc	cggtgggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgta	caaagtcacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	ggttttggcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtgggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgcccc	gcttctccca	tagctgtccc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgccttgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgaccccc	tgacacaagca	gccccgcttc	2100
tgggctagca	tgatggaggg	agccagctgc	ccccggatt	atgttctctc	agagatcttc	2160
catttccaca	cgcgctcggg	tgtgcggctc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcacc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgcgctgg	ttgtgattga	cggcaggggc	tctgtcagc	gagggcttcg	gttcgaagg	2400
gccctgaaaa	accaaagg	ccaggtggag	atcaggagcc	aggtggaggg	cctgcagttc	2460



```

gtggccgaga agtatggctt catcgacctg agccgagttg ccatccatgg ctggtcctac 2520
gggggcttcc tctcgctcat ggggctaata cacaagcccc aggtgttcaa ggcccaaccg 2580
cttgcttata ctccacggct tcctggacga aaacgtgcac tttttccaca caaacttcct 2640
cgtctcccaa ctgatccgag cagggaaacc ttaccagctc cagatctacc ccaacgagag 2700
acacagtatt cgctgccccg agtcggggcg gcactatgaa gtcacgttgc tgcactttct 2760
acaggaatac ctctgagcct gcccaccggg agccgccaca tcacagcaca agtggtgca 2820
gcctccgagg ggaaccaggc gggagggact gagtggcccc cgggccccag tgaggcactt 2880
tgtcccggcc agcgtgggcc agccccgagg agcgcgtgcc ttcaccgccc cgacgccttt 2940
tatccttttt taaacgctct tgggttttat gtccgctgct tcttggttgc cgagacagag 3000
agatggtggt ctcgggccag cccctcctct cccgccttc tgggaggagg aggtcacacg 3060
ctgaggggca ctggagaggc cagaagagac tcagaggagc gggctgcctt ccgcctgggg 3120
ctcctgtga cctctcagtc ccttgcccgc gccagccacc gtcccagca cccaagcatg 3180
caattgcctg tcccccccg ccagcctccc caacttgatg tttgtgtttt gtttgggggg 3240
atatttttca taattattta aaagacaggc cgggcgcggt ggctcacgtc tghtaatcca 3300
gcactttggg aggtgagggc gggcggatca cctgaggttg ggagttcaag accagcctgg 3360
ccaacatggg gaaaccccg ctctactaaa aatacaaaaa attagccggg tgtggtggcg 3420
cgtgcctata atcccagcta ctcgggaggc tgaggcagga gaatcgcttg aaccggggag 3480
gtggaggttg cggtagacca agatcgacc attgcactcc agcctgggca acaagagcga 3540
aactctgtct caaaataaat aaaaaataaa agacagaaag caaggggtgc cttaatctag 3600
acttggggtc cacaccgggc agcgggggtg caaccagca cctggtaggc tccatttctt 3660
cccaagcccg agcagagggt catgcgggcc ccacaggaga agcggccagg gccgcggggg 3720
ggcaccacct gtggacagcc ctctgtccc caagctttca ggcaggcact gaaacgcacc 3780
gaacttccac gctctgctgg tcagtggcgg ctgtccctc cccagcccag ccgcccagcc 3840
acatgtgtct gcctgaccgg tacacaccag gggttccggg gttgggagct gaaccatccc 3900
cacctcaggg ttatatattcc ctctcccctt ccctcccgc caagagctct gccagggggc 3960
ggcaaaaaaa aaagtaaaaa gaaaagaaaa aaaaaaaaaa gaaacaaacc acctctacat 4020
attatggaaa gaaaatattt ttgtcgattc ttattctttt ataattatgc gtggaagaag 4080
tagacacatt aaacgattcc agttggaac atgtcacctg 4120

```

```

<210> 39
<211> 819
<212> PRT
<213> Homo sapiens
<400> 39

```

```

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
1          5          10          15
Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
20          25          30
Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
35          40          45
Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
50          55          60
Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
65          70          75          80
Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
85          90          95
His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
100         105         110
Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
115         120         125
Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
130         135         140
Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg
145         150         155         160
Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
165         170         175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
180         185         190

```

Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu
		195					200					205			
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro
	210					215					220				
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val
225					230					235					240
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln
				245					250					255	
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr
			260					265					270		
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys
	275						280					285			
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile
	290					295					300				
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro
305					310					315					320
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg
				325					330					335	
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln
			340					345					350		
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val
	355						360					365			
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala
	370					375					380				
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg
385					390					395					400
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile
				405					410					415	
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val
			420					425					430		
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val
	435						440					445			
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Glu	Gly
	450					455					460				
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe
465					470					475					480
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp
				485					490					495	
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Asp	Glu	Phe	Lys	Cys	Pro	Ile
			500					505					510		
Lys	Glu	Glu	Ile	Ala	Leu	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Ala	Arg
	515							520				525			
His	Gly	Ser	Lys	Gly	Thr	Lys	Asp	Thr	Pro	Leu	Glu	His	His	Leu	Tyr
	530					535					540				
Val	Val	Ser	Tyr	Glu	Ala	Ala	Gly	Glu	Ile	Val	Arg	Leu	Thr	Thr	Pro
545					550					555					560
Gly	Phe	Ser	His	Ser	Cys	Ser	Met	Ser	Gln	Asn	Phe	Asp	Met	Phe	Val
				565					570					575	
Ser	His	Tyr	Ser	Ser	Val	Ser	Thr	Pro	Pro	Cys	Val	His	Val	Tyr	Lys
			580					585					590		
Leu	Ser	Gly	Pro	Asp	Asp	Asp	Pro	Leu	His	Lys	Gln	Pro	Arg	Phe	Trp
	595						600					605			
Ala	Ser	Met	Met	Glu	Ala	Ala	Ser	Cys	Pro	Pro	Asp	Tyr	Val	Pro	Pro
	610					615					620				
Glu	Ile	Phe	His	Phe	His	Thr	Arg	Ser	Asp	Val	Arg	Leu	Tyr	Gly	Met
625					630					635					640
Ile	Tyr	Lys	Pro	His	Ala	Leu	Gln	Pro	Gly	Lys	Lys	His	Pro	Thr	Val
				645					650					655	

Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe  
                   660                  665                  670  
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr  
                   675                  680                  685  
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg  
                   690                  695                  700  
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp  
 705                  710                  715                  720  
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp  
                   725                  730                  735  
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser  
                   740                  745                  750  
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu  
                   755                  760                  765  
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His  
                   770                  775                  780  
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala  
 785                  790                  795                  800  
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly  
                   805                  810                  815  
 Arg Ala Leu

<210> 40  
 <211> 4037  
 <212> DNA  
 <213> Homo sapiens  
 <400> 40

caggccgcgc cctgggtcgc tcaacttccg ggtcaaaggt gcctgagccg gcgggtcccc 60  
 tgtgtccgcc gcggtgtcgc tccccgcgc ccgccacttc cggggtcgca gtccccggca 120  
 tggagccgcg accgtgaggc gccgtggac ccgggacgac ctgccagtc cggccgcgc 180  
 cccacgtccc ggtctgtgtc ccacgcctgc agctggaatg gaggtctctt ggacccttta 240  
 gaaggcacc ctcgctcctt gaggtcagct gagcggttaa tgcggaaggt taagaaactg 300  
 cgcctggaca aggagaacac cggaagtgg agaagcttct cgctgaattc cgagggggct 360  
 gagaggatgg ccaccaccgg gacccaacg gccgaccgag gcgacgcagc cgccacagat 420  
 gacccggccg cccgcttcca ggtgcagaag cactcgtggg acgggtccg gagcatcatc 480  
 cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacga cttccagttt 540  
 gtgcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaatgcc 600  
 tatggcagcc gagagaactc cctcctctac tctgagattc ccaagaaggt ccggaagag 660  
 gctctgtctc tcctgtcctg gaagcagatg ctggatcatt tccaggccac gccccacct 720  
 ggggtctact ctcgggagga ggagctgtg agggagcggg aacgcctggg ggtcttcggc 780  
 atcacctcct acgacttcca cagcgagagt ggcctcttcc tcttcaggc cagcaacagc 840  
 ctcttccact gccgcgacgg cgcaagaac ggcttcatgg tgtccctat gaaaccgctg 900  
 gaaatcaaga cccagtgtc agggccccg atggaccca aaatctgccc tgccgacct 960  
 gccttcttct ccttcatcaa taacagcgac ctgtgggtgg ccaacatcga gacaggcgag 1020  
 gagcggcggc tgaccttctg ccaccaaggt ttatccaatg tcctggatga cccaagtct 1080  
 gcgggtgtgg ccaccttcgt catacaggaa gagttcgacc gcttactggt gtactggtgg 1140  
 tgccccacag ctcctggga aggttcagag gccctcaaga cgctgcgaat cctgtatgag 1200  
 gaagtcgatg agtccgaggt ggaggtcatt cacgtcccct ctcctgcgct agaagaaagg 1260  
 aagacggact cgtatcggtg cccaggaca ggcagcaaga atcccaagat tgccttgaaa 1320  
 ctggctgagt tccagactga cagccagggc aagatcgtct cgaccagga gaaggagctg 1380  
 gtgcagccct tcagctcgct gttcccgaag gtggagtaca tcgccagggc cgggtggacc 1440  
 cgggatggca aatacgctg ggccatgttc ctggaccggc ccagcagtg gctccagctc 1500  
 gtcctcctcc ccccgccct gttcatccc agcacagaga atgaggagca gcggctagcc 1560  
 tctgccagag ctgtccccag gaatgtccag ccgtatgtgg tgtacagga ggtcaccaac 1620  
 gtctggatca atgttcag catcttctat cccttcccc aatcagagg agagaccagag 1680  
 ctctgttttc tccgcgcaa tgaatgcaag accggcttct gccatttcta caaagtcacc 1740  
 gccgttttaa aatcccagg ctacgattgg agtgagccct tcagccccg ggaagatgaa 1800  
 ttttaagtgc ccattaagga agagattgct ctgaccagcg gtgaatggga ggttttgccg 1860

```

aggcacggct ccaagggcac caaggacacg ccgctggagc accacctcta cgtgggtcagc 1920
tatgaggcgg cgggcgagat cgtacgcctc accacgcccg gcttctccca tagctgtctc 1980
atgagccaga atttcgacat gttcgtcagc cactacagca gcgtgagcac gcccgccctgc 2040
gtgcacgtct acaagctgag cggcccccgc gcagacccc tgacacaagca gcccgcttc 2100
tgggttagca tgatggaggc agccagctgc cccccggatt atgttcctcc agagatcttc 2160
catttccaca cgcgctcgga tgtgcggctc tacggcatga tctacaagcc ccacgccttg 2220
cagccaggga agaagcacc caccgtctc tttgtatatg gagggcccca ggtgcagctg 2280
gtgaataact ccttcaaagg catcaagtac ttgcggtcca acacactggc ctccctgggc 2340
tacgccgtgg ttgtgattga cggcaggggc tcctgtcagc gagggcttcg gttcgaaggg 2400
gccctgaaaa accaaatggg ccaggtggag atcgaggacc aggtggaggg cctgcagttc 2460
gtggccgaga agtatggctt catcgacctg agccagttg ccatccatgg ctggtcctac 2520
gggggcttcc tctcgctcat ggggctaata cacaagcccc aggtgttcaa ggccaaccg 2580
cttgcttata ctccacggct tcctggacga aaacgtgcac tttttccaca caaacttcct 2640
cgtctcccaa ctgatccgag cagggaaacc ttaccagctc cagatctacc ccaacgagag 2700
acacagtatt cgctgccccg agtcgggcga gcactatgaa gtcacgttgc tgcactttct 2760
acaggataac ctctgagcct gccaccggg agccgccaca tcacagcaca agtggctgca 2820
gcctccgcgg ggaaccaggc gggagggact gagtggcccg cgggcccagc tgaggcactt 2880
tgtcccgccc agcgctggcc agccccgagg agccgctgcc ttcaccgccc cgacgccttt 2940
tatccttttt taaacgctct tgggttttat gtcgctgct tcttggttg cgagacagag 3000
agatggtggt ctccggccag cccctcctct ccccgcttc tgggaggagg aggtcacacg 3060
ctgatgggca ctggagaggc cagaagagac tcagaggagc gggctgcctt ccgcctgggg 3120
ctccctgtga cctctcagtc ccctggcccg gccagccacc gtccccagca cccaagcatg 3180
caattgcttg tcccccccg ccagcctccc caacttgatg tttgtgtttt gtttggggg 3240
atatttttca taattattta aaagacaggc cgggcgcggt ggctcacgtc tgtaatccca 3300
gcactttggg aggtgaggc gggcggatca cctgaggttg ggagttcaag accagcctgg 3360
ccaacatggg gaaaccccg ctctactaaa aatacaaaaa attagccggg tgtggtggcg 3420
cgtgcctata atcccagcta ctcgggaggc tgaggcagga gaatcgcttg aaccgggag 3480
gtggagggtg cgggtgagcca agatcgacc attgcactcc agcctgggca acaagagcga 3540
aactctgtct caaaataaat aaaaaataaa agacagaaag caaggggtgc cttaatctag 3600
acttggggtc cacaccggg agcgggggtg caaccagca cctggtaggc tccatttctt 3660
cccaagcccg actttcaggc aggcactgaa acgcaccgaa cttccacgct ctgctgggtca 3720
gtggcggtg tccccctccc agcccagccg cccagccaca tgtgtctgcc tgaccggtac 3780
acaccagggg ttccggggtt gggagctgaa ccatccccac ctcaggggta tatttccctc 3840
tccccctccc tccccgcaa gagctctgcc aggggcgggc aaaaaaaaaa gtaaaaagaa 3900
aagaaaaaaa aaaaaaagaa acaaacacc tctacatatt atggaaagaa aatatttttg 3960
tcgattctta ttcttttata attatgcgtg gaagaagtag acacattaaa cgattccagt 4020
tggaacatg tcacctg 4037

```

```

<210> 41
<211> 706
<212> PRT
<213> Homo sapiens
<400> 41

```

```

Asp Thr Asp Val Val Tyr Lys Ser Glu Asn Gly His Val Ile Lys Leu
1          5          10          15
Asn Ile Glu Thr Asn Ala Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe
20          25          30
Val Thr Phe Lys Ala Ser Arg His Ser Val Ser Pro Asp Leu Lys Tyr
35          40          45
Val Leu Leu Ala Tyr Asp Val Lys Gln Ile Phe His Tyr Ser Tyr Thr
50          55          60
Ala Ser Tyr Val Ile Tyr Asn Ile His Thr Arg Glu Val Trp Glu Leu
65          70          75          80
Asn Pro Pro Glu Val Glu Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly
85          90          95
Val Gln Gly Gln Gln Leu Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr
100          105          110

```

Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys  
 115 120 125  
 Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu  
 130 135 140  
 Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg  
 145 150 155 160  
 Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile  
 165 170 175  
 Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr  
 180 185 190  
 Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn  
 195 200 205  
 Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe  
 210 215 220  
 Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr  
 225 230 235 240  
 Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu  
 245 250 255  
 Thr Val Cys Glu Thr Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met  
 260 265 270  
 Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser  
 275 280 285  
 Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly  
 290 295 300  
 Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser  
 305 310 315 320  
 Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile  
 325 330 335  
 Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser  
 340 345 350  
 Thr Glu Ser Ser Pro Arg Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu  
 355 360 365  
 Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu Gln  
 370 375 380  
 Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe Leu  
 385 390 395 400  
 Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser Thr  
 405 410 415  
 Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu Lys  
 420 425 430  
 Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu  
 435 440 445  
 His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp  
 450 455 460  
 Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Leu Ile Met Asp Glu Glu  
 465 470 475 480  
 Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp Ser  
 485 490 495  
 Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly Arg  
 500 505 510  
 Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg Arg  
 515 520 525  
 Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe Leu  
 530 535 540  
 Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys  
 545 550 555 560  
 Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu Lys  
 565 570 575

Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys Leu  
 580 585 590  
 Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu  
 595 600 605  
 Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly Leu  
 610 615 620  
 Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys Val  
 625 630 635 640  
 His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala Gly  
 645 650 655  
 Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val Ser  
 660 665 670  
 Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser  
 675 680 685  
 Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu Glu  
 690 695 700  
 Asp Glu  
 705

<210> 42  
 <211> 4541  
 <212> DNA  
 <213> Homo sapiens  
 <400> 42

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tgctcattaaa	60
ctgaatatag	aaacaaatgc	taccacatta	ttattggaaa	acacaacttt	tgtaaccttc	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc	180
aaacagattt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg	240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgacagta	cgcggcctgg	300
ggtgtccaag	ggcagcagct	gatttatatt	tttgaaaata	atatctacta	tcaacctgat	360
ataaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaaaataat	ttttaatggg	420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccca	ctgggtggta	480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	ctttggtacc	caccatgggt	540
atccctcggg	ttactggagc	gttgatatcc	aaaggaaaagc	agtatccgta	tcctaaggca	600
ggtcaagtga	acccaacaat	aaaattatat	gttgtaaaac	tgtatggacc	aactcacact	660
ttggagctca	tgccacctga	cagctttaaa	tcaagagaat	actatatcac	tatggttaaa	720
tgggtaagca	ataccaagac	tgtggttaaga	tgggtaaacc	gacctcagaa	catctccatc	780
ctcacagtct	gtgagaccac	tacaggtgct	tgtagtaaaa	aatatgagat	gacatcagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgttttcta	gagacggcag	caaattcctt	900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	tatgttcctc	960
atccagagta	aaagtgaagca	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg	1020
ataaagatct	tggcatacga	tgaactact	caaaaaattt	actttctgag	cactgaatct	1080
tctcccagag	gaaggcagct	gtacagtgtc	tctactgaag	gattattgaa	tcgccaatgc	1140
atttcatgta	atttcatgaa	agaacaatgt	acatatcttg	atgccagttt	tagtcccattg	1200
aatcaacatt	tcttattatt	ctgtgaagg	ccaagggctc	cagtggtcag	cctacatagt	1260
acggacaacc	cagcaaaaata	ttttatattg	gaaagcaatt	ctatgctgaa	ggaagctatc	1320
ctgaagaaga	agataggaaa	gccagaaatt	aaaatccttc	atattgacga	ctatgaactt	1380
cctttacagt	tgtcccttcc	caaagatttt	atggaccgaa	accagtatgc	tcttctgtta	1440
ataatggatg	aagaaccagg	aggccagctg	gttacagata	agttccatat	tgactgggat	1500
tccgtactca	ttgacatgga	taatgtcatt	gtagcaagat	ttgatggcag	aggaagtggga	1560
ttccagggtc	tgaaaatttt	gcaggagatt	catcgaagat	taggttcagt	agaagtaaa	1620
gaccaaataa	cagctgtgaa	atttttgctg	aaactgcctt	acattgactc	caaaagatta	1680
agcatttttg	gaaaggggta	tgggtggctat	attgcatcaa	tgatcttaaa	atcagatgaa	1740
aagcttttta	aatgtggatc	cgtgggttga	cctatcacag	acttgaatt	gtatgcctca	1800
gctttctctg	aaagatacct	tgggatgcca	tctaaggaag	aaagcactta	ccaggcagcc	1860
agtgtgctac	ataatgttca	tggcttgaaa	gaagaaaata	tattaataat	tcattggaact	1920
gctgacacaa	aagttcattt	ccaacactca	gcagaattaa	tcaagcacct	aataaaagct	1980
ggagtgaatt	atactatgca	ggtctaccca	gatgaaggct	ataacgtatc	tgagaagagc	2040

```

aagtatcatc tctacagcac aatcctcaaa ttcttcagtg attgtttgaa ggaagaaata 2100
tctgtgctac cacaggaacc agaagaagat gaataatgga ccgtatttat acagaactga 2160
agggaatatt gaggtcfaat gaaacctgac aaagagactg taatattgta gttgctccag 2220
aatgtcaagg gcagcttacg gagatgtcac tggagcagca cgctcagaga cagtgaacta 2280
gcatttgaat acacaagtcc aagtctactg tgttgctagg ggtgcagaac ccgtttcttt 2340
gtatgagaga ggtcaaaggg ttggtttcct gggagaaatt agttttgcat taaagtagga 2400
gtagtgcacg ttttcttctg ttatccccct gtttgttctg taactagttg ctctcatttt 2460
aatttcactg gccaccatca tctttgcata taatgcacaa tctatcatct gtcctacagt 2520
ccctgatctt tcatggctga gctgcaatct aacactttac tgtaccttta taataagtgc 2580
aattctttca ttgtctatta ttatgcttaa gaaaatattc agttaataaa aaacagagta 2640
ttttatgtaa tttctgtttt taaaagaca ttattaaatg ggtcaaagga catatagaaa 2700
tgtggatttc agcaccttcc aaagtccagc cagttatcag tagatacaat atctttaaat 2760
gaacacacga gtgtatgtct cacaatatat atacacaagt gtgcatatac agttaatgaa 2820
actatcttta aatgttattc atgctataaa gagtaaactg ttgatgaatt agaagagatg 2880
ctcttttcca agctataatg gatgctttgt ttaatgagcc aaatatgatg aaacattttt 2940
tccaattcaa attctagcta ttgctttcct ataaatgttt ggggtgtgtt tgggtattgtt 3000
tttagtggtt aatagttttc cagttgcatt taattttttg aatatgatac cttgtcacat 3060
gtaaattaga tacttaataa ttaaattata gtttctgata aagaaatttt gttaacaatg 3120
caatgccatt gagtgctatt ttgctctttt ggtggagaag gcttttttca aaactcttgg 3180
tccttttact tctttctctc agtgcagaat caattctcat tttcatcgta aaagcaata 3240
gctggattat ttcatttgcc agtttctatt tagtattcca tgcctgcccc attcatctgt 3300
tactgtttaa tttcaattct tctggtgaga attagaaatg aaatattttt tattcattgg 3360
ccaaaaagtt cacagacagc agtgtttgct atttactttg aattgaaggc acaaaatgca 3420
tcaattcctg tgctgtgttg acttgacagta gtaagtaact gagagcataa aataaacctg 3480
actgtatgaa gtcaatttaa gtgatgagaa catttaactt tggtgactaa agtcagaata 3540
tcttctcact tcacttaagg gatcttccag aagatatcta aaagtctgta ataagcttag 3600
aagttcagat aaatctaggc aggatactgc atttttgttg ttttaaaaaa gtccttagga 3660
cagactgaat tatcataact tatggcatca ggaggaaact ttaaaatata aaggaatcac 3720
tcagtcaccc tcctgttttg ttgaaggatc aaccccaaat tctgggtatt tgagtacatg 3780
tgaatcatgg atttggtatt caactttttc cctggatgct ttggaatcgt gtcttccatg 3840
ctccactggg ttcaatttaa aataggagag gctttctctt ctgaaagatc catttttaggt 3900
ctttttcaag aatagtgaac acatttttta acaaaataag ttgtaatttt aaaaggaaaag 3960
ttttgcctat tttattaaga tggaaatttc tttttaggct aatttgaaat ccaactgaag 4020
ctttttaacc aatattttaa atttgaacca ctagagtttt ttatgatgca aatgattatg 4080
ttgtctgaaa ggtgtggttt tattgaatgt ctatttgagt atcattttaa aagtatttgc 4140
cttttactgt catcatttct cttgttttat tattattatc aatgtttatc tatttttcaa 4200
ttaatttaat acagtttcta atgtgaaaga catttttctg gaacccggtt tccccataaa 4260
cactaaagag acctcaagtg aaagcatatt gcttagtagg aaggtagaaa atgttaatcc 4320
ctgcgattct ttgagtttta atgacagggg cattttcagt aaaggaaatg ctcaccaaca 4380
catagtcacc aactattaaa ggaatcatgt gattggattt tcccctgtat acatgtaccc 4440
ttggtcataa tcccactatt tcatacatat ttatgcattg ctagattttc ctaggactcc 4500
aatagcatgc tttccaagtg ttattattcc cttaatgtta a 4541

```

```

<210> 43
<211> 691
<212> PRT
<213> Homo sapiens
<400> 43

```

```

Asp Thr Asp Val Val Tyr Lys Ser Glu Asn Gly His Val Ile Lys Leu
1           5           10          15
Asn Ile Glu Thr Asn Ala Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe
                20          25          30
Val Thr Phe Lys Ala Ser Arg His Ser Val Ser Pro Asp Leu Lys Tyr
                35          40          45
Val Leu Leu Ala Tyr Asp Val Lys Gln Ile Phe His Tyr Ser Tyr Thr
                50          55          60
Ala Ser Tyr Val Ile Tyr Asn Ile His Thr Arg Glu Val Trp Glu Leu
65                70                75                80

```

```

Asn Pro Pro Glu Val Glu Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly
      85      90      95
Val Gln Gly Gln Gln Leu Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr
      100      105      110
Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys
      115      120      125
Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu
      130      135      140
Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg
      145      150      155      160
Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile
      165      170      175
Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr
      180      185      190
Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn
      195      200      205
Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe
      210      215      220
Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr
      225      230      235      240
Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu
      245      250      255
Thr Val Cys Glu Thr Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met
      260      265      270
Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser
      275      280      285
Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly
      290      295      300
Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser
      305      310      315      320
Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile
      325      330      335
Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Ser Ala Ser Thr
      340      345      350
Glu Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu
      355      360      365
Gln Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe
      370      375      380
Leu Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser
      385      390      395      400
Thr Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu
      405      410      415
Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile
      420      425      430
Leu His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys
      435      440      445
Asp Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Leu Ile Met Asp Glu
      450      455      460
Glu Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp
      465      470      475      480
Ser Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly
      485      490      495
Arg Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg
      500      505      510
Arg Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe
      515      520      525
Leu Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly
      530      535      540

```



Lys Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu  
 545 550 555 560  
 Lys Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys  
 565 570 575  
 Leu Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys  
 580 585 590  
 Glu Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly  
 595 600 605  
 Leu Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys  
 610 615 620  
 Val His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala  
 625 630 635 640  
 Gly Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val  
 645 650 655  
 Ser Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe  
 660 665 670  
 Ser Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu  
 675 680 685  
 Glu Asp Glu  
 690

<210> 44  
 <211> 4496  
 <212> DNA  
 <213> Homo sapiens  
 <400> 44

gkctykgtkg	wtsmagatac	agatgtggtg	tataaaagcg	agaatggaca	tgctcattaaa	60
ctgaatatag	aaacaaatgc	taccacatta	ttattggaaa	acacaacttt	tgtaaccttc	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaatatg	tccttctggc	atatgatgtc	180
aaacagattt	ttcattattc	gtatactgct	tcatatgtga	tttacaacat	acacactagg	240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgcaagta	cgcggcctgg	300
ggtgtccaag	ggcagcagct	gattttatatt	tttgaaaata	atatctacta	tcaacctgat	360
ataaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaaataat	ttttaatggg	420
attgttgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccca	ctggtggtca	480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	ctttggtacc	caccatgggt	540
atccctcggt	ttactggagc	gttgtatccc	aaaggaaaagc	agtatccgta	tcctaaggca	600
ggtcaagtga	acccaacaat	aaaattatat	gttgtaaacc	tgtatggacc	aactcacact	660
ttggagctca	tgccacctga	cagctttaaa	tcaagagaat	actatatcac	tatgggttaa	720
tgggtaagca	ataccaagac	tgtggtaaga	tggttaaaacc	gacctcagaa	catctccatc	780
ctcacagtct	gtgagaccac	tacaggtgct	tgtagtaaaa	aatatgagat	gacatcagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgttttcta	gagacggcag	caaattcctt	900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	tatgttcctc	960
atccagagta	aaagtgagca	aattaccgtg	cggcatctga	catcaggaaa	ctgggaagtg	1020
ataaagatct	tggcatacga	tgaaactact	caaaaaatca	gtgcttctac	tgaaggatta	1080
ttgaatcgcc	aatgcatttc	atgtaatttc	atgaaagaac	aatgtacata	ttttgatgcc	1140
agtttttagtc	ccatgaatca	acattttctta	ttattctgtg	aagggtccaag	gggtcccagt	1200
gtcagcctac	atagtacgga	caaccacagca	aaatatttta	tattggaaaag	caattctatg	1260
ctgaagggaag	ctatcctgaa	gaagaagata	ggaaagccag	aaattaaaaat	ccttcatatt	1320
gacgactatg	aacttccttt	acagttgtcc	cttcccaaag	attttatgga	ccgaaaccag	1380
tatgctcttc	tgtaataaat	ggatgaagaa	ccaggaggcc	agctggttac	agataagttc	1440
catattgact	gggattccgt	actcattgac	atggataatg	tcattgtagc	aagatttgat	1500
ggcagaggaa	gtggattcca	gggtctgaaa	attttgcagg	agattcatcg	aagatttaggt	1560
tcagtagaag	taaaggacca	aataacagct	gtgaaatttt	tgctgaaact	gccttacatt	1620
gactccaaaa	gattaagcat	ttttggaaaag	ggttatgggtg	gctatatattg	atcaatgatc	1680
ttaaaatcag	atgaaaagct	ttttaaatgt	ggatccgtgg	ttgcacctat	cacagacttg	1740
aaattgtatg	cctcagcttt	ctctgaaaga	taccttggga	tgccatctaa	ggaagaaagc	1800
acttaccagg	cagccagtg	gctacataat	gttcatggct	tgaaagaaga	aaatatatta	1860
ataattcatg	gaactgctga	cacaaaagtt	catttccaac	actcagcaga	attaatcaag	1920

```

cacctaataa aagctggagt gaattatact atgcaggtct acccagatga aggtcataac 1980
gtatctgaga agagcaagta tcatctctac agcacaatcc tcaaattctt cagtgattgt 2040
ttgaaggaag aaatatctgt gctaccacag gaaccagaag aagatgaata atggaccgta 2100
tttatacaga actgaagggg atattgaggc tcaatgaaac ctgacaaaga gactgtaata 2160
ttgtagttgc tccagaatgt caagggcagc ttacggagat gtcactggag cagcacgctc 2220
agagacagtg aactagcatt tgaatacaca agtccaagtc tactgtgttg ctaggggtgc 2280
agaacccggt tctttgtatg agagaggtca aagggttggg ttcctggggg aaattagttt 2340
tgcattaaag taggagtagt gcatgttttc ttctgttatc cccctgtttg ttctgtaact 2400
agttgctctc attttaattt cactggccac catcatcttt gcatataatg cacaatctat 2460
catctgtcct acagtccttg atctttcatg gctgagctgc aatctaacac tttactgtac 2520
ctttataata agtgcaattc tttcattgtc tattattatg cttaagaaaa tattcagtta 2580
ataaaaaaca gagtatttta tgtaatttct gtttttaaaa agacattatt aaatgggtca 2640
aaggacatat agaaatgtgg atttcagcac ctcccaaagt tcagccagtt atcagtagat 2700
acaatatctt taaatgaaca cagcagtgta tctctcaca tatatataca caagtgtgca 2760
tatacagtta atgaaactat ctttaaatgt tattcatgct ataaagagta aacgtttgat 2820
gaattagaag agatgctctt ttccaagcta taatggatgc tttgtttaat gagccaaata 2880
tgatgaacaa ttttttccaa ttcaaattct agctattgct ttcctataaa tgtttgggtt 2940
gtgtttggta ttgttttagg tggttaatag ttttccagtt gcatttaatt ttttgaatat 3000
gataccttgt cacatgtaaa ttagatactt aaatattaaa ttatagtttc tgataaagaa 3060
attttgttaa caatgcaatg ccactgagtg ctattttgct cttttgggtg agaaggcttt 3120
tttcaaaact cttggtcctt ttacttcttt ctctcagtc agaataaatt ctcttttca 3180
tcgtaaaagc aaatagctgg attatttcat ttgccagttt ctatttagta ttccatgcct 3240
gcccaattca tctgttactg ttttaatttc attcttctgg tgagaattag aaatgaaata 3300
ttttttattc attggccaaa aagttcacag acagcagtg ttgctattta ctttgaattg 3360
aaggcacaaa atgcatcaat tcctgtgctg tgttgacttg cagtagtaag taactgagag 3420
cataaaaaaa acctgactgt atgaagtcaa ttaagtgat gagaacattt aactttggtg 3480
actaaagtca gaatatcttc tcacttcact taagggatct tccagaagat atctaaaagt 3540
ctgtaataag cttagaagtt cagataaatc taggcaggat actgcatttt tgtgggttta 3600
aaaaagtcct taggacagac tgaattatca taacttatgg catcaggagg aaactttaaa 3660
atatcaagga atcactcagt caccctcctg ttttgttgaa ggatcaacc caaattctgg 3720
gtatttgagt acatgtgaat catggatttg gtattcaact ttttccctgg atgctttgga 3780
atcgtgtcct ccatgctcca ctgggttcaa tttaaaatag gagaggcttt ctcttctgaa 3840
agatccattt taggtctttt tcaagaatag tgaacacatt ttttaacaaa ataagttgta 3900
attttaaaag gaaagttttg cctattttat taagatggaa atttcttttt aggctaattt 3960
gaaatccaac tgaagctttt taaccaatat tttaaatttg aaccactaga gttttttatg 4020
atgcaaatga ttatgtgtc tgaaaggtgt ggtttttatt aatgtctatt tgagtatcat 4080
ttaaaaagta tttgcctttt actgtcatca tttctcttgt tttattatta ttatcaatgt 4140
ttatctattt ttcaattaat ttaatacagt ttctaatttg aaagacattt ttctggaacc 4200
cgttttccc ttaaacta aagagacctc aagtgaagc atattgctta gtagggaagg 4260
agaaaatggt aatccctgcg attctttgag ttttaatgac agggtcattt tcagtaaagg 4320
aatgctcac caacacatag tcaccaacta ttaaaggaat catgtgattg gattttcccc 4380
tgtatacatg tacccttggg cataatccca ctatttcata catatttatg cattgctaga 4440
ttttcctagg actccaatag catgctttcc aagtgttatt attcccttaa tgttaa 4496

```

```

<210> 45
<211> 29
<212> DNA
<213> Homo sapiens
<400> 45

```

```

cgggtaccatg gcagcagcaa tggaaacag 29

```

```

<210> 46
<211> 39
<212> DNA
<213> Homo sapiens
<400> 46

```

```

ggagctcgcg gccgctcata tcacttttag agcagcaat 39

```

<210> 47  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 47

caagctttat cactttttaga gcagcaa

27

<210> 48  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 48

cacattcttg ctgcatcagt ca

22

<210> 49  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 49

ttgggtcatc ttcaggactt ga

22

<210> 50  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 50

caagcttacc atggccacca ccgggac

27

<210> 51  
<211> 37  
<212> DNA  
<213> Homo sapiens  
<400> 51

cggatccgcg gccgctcaga ggtattcctg tagaaag

37

<210> 52  
<211> 27  
<212> DNA  
<213> Homo sapiens  
<400> 52

cggatccagg tattcctgta gaaagtg

27

<210> 53  
<211> 20  
<212> DNA  
<213> Homo sapiens  
<400> 53

tacgccgtgg ttgtgattga

20

<210> 54  
<211> 20  
<212> DNA

<213> Homo sapiens  
<400> 54

ccatacttct cggccacgaa 20

<210> 55  
<211> 19  
<212> DNA  
<213> Homo sapiens  
<400> 55

gcctgggatt gtgcactgt 19

<210> 56  
<211> 29  
<212> DNA  
<213> Homo sapiens  
<400> 56

gtgtattcaa atgctagttc actgtctct 29

<210> 57  
<211> 22  
<212> DNA  
<213> Homo sapiens  
<400> 57

agctagcact gtccagggtc ct 22

<210> 58  
<211> 25  
<212> DNA  
<213> Homo sapiens  
<400> 58

agggcccttc atcttcttct ggttc 25

<210> 59  
<211> 19  
<212> PRT  
<213> Homo sapiens  
<400> 59

Val Glu Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro  
1 5 10 15  
Asp Ser Val

<210> 60  
<211> 19  
<212> PRT  
<213> Homo sapiens  
<400> 60

Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val Pro  
1 5 10 15  
Arg Asn Val

<210> 61  
<211> 15

<212> PRT  
<213> Homo sapiens  
<400> 61

Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys  
1 5 10 15

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**